You are on page 1of 334

Human Papillomavirus

and
Related Diseases Report

WORLD
Version posted at www.hpvcentre.net on 27 July 2017

- ii -

Copyright and Permissions

©ICO Information Centre on HPV and Cancer (HPV Information Centre), 2017.

All rights reserved. HPV Information Centre publications can be obtained from the HPV Informa-
tion Centre Secretariat, Institut Català d’Oncologia, Avda. Gran Via de l’Hospitalet, 199-203 08908
L’Hospitalet del Llobregat (Barcelona), Spain. E-mail: hpvcentre@iconcologia.net. Requests for per-
mission to reproduce or translate HPV Information Centre publications - whether for sale or for non-
commercial distribution- should be addressed to the HPV Information Centre Secretariat, at the above
address.

The designations employed and the presentation of the material in this publication do not imply the
expression of any opinion whatsoever on the part the HPV Information Centre concerning the legal
status of any country, territory, city or area or of its authorities, or concerning the delimitation of its
frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may
not yet be full agreement. The mention of specific companies or of certain manufacturers products does
not imply that they are endorsed or recommended the HPV Information Centre in preference to others
of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary
products are distinguished by initial capital letters. All reasonable precautions have been taken by the
HPV Information Centre to verify the information contained in this publication. However, the published
material is being distributed without warranty of any kind, either expressed or implied. The respon-
sibility for the interpretation and use of the material lies with the reader. In no event shall the HPV
Information Centre be liable for damages arising from its use.

The development of this report has been supported by grants from the European Comission (7th Frame-
work Programme grant HEALTH-F3-2010-242061, HEALTH-F2-2011-282562, HPV AHEAD).

Recommended citation:

Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé
S. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and
Related Diseases in the World. Summary Report 27 July 2017. [Date Accessed]

ICO HPV Information Centre

- iii -

Abbreviations

Table 1: Abbreviations
Abbreviation Full term
HPV Human papillomavirus
PREHDICT Project Health economic modelling of prevention strategies for HPV-related diseases in
European countries
HPV Information Centre ICO Information Centre on HPV and Cervical Cancer
GW Genital warts
RRP Recurrent respiratory papillomatosis
SIL Squamous intraepithelial lesions
LSIL Low-grade cervical lesions
HSIL High-grade cervical lesions
ICC Invasive cervical cancer
CIS Carcinoma in situ
CIN Cervical intraepithelial neoplasia
AIN2/3 Anal intraepithelial neoplasia of grade 2 and/or 3
VIN 2/3 Vulvar intraepithelial neoplasia of grade 2 and/or 3
VaIN 2/3 Vaginal intraepithelial neoplasia of grade 2 and/or 3
PeIN 2/3 Penile intraepithelial neoplasia of grade 2 and/or 3
95% CI 95% confidence interval
N Number of cases tested
HPV Prev HPV prevalence
ASR Age-standardised rate
MSM Men who have sex with men
Non MSM Heterosexual men
SCC Squamous cell carcinomas
STI Sexually transmitted infections
HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency syndrome
TS Type specific
EIA Enzyme immunoassay
RLBM Reverse line blotting method
RFLP Restriction fragment length polymorphism
RHA Reverse hybridisation assay
RLH Reverse line hybridisation
LiPA Line probe assay
SBH Southern blot hybridisation
ISH In situ hybridisation
MABA Micro array-based assay
LBA Line blot assay
HC2 Hybrid Capture 2
SAT Suspension array technology
PCR Polymerase chain reaction
SPF Short primer fragment
q-PCR Quantitative polymerase chain reaction
RLBH Reverse line blot hybridisation
RT-PCR Real-time polymerase chain reaction
DBH Dot blot hybridisation
HR High risk
DSA Direct sequence analysis
MAA Microchip array assay

ICO HPV Information Centre

- iv -

Executive summary
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is
growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and
penis) as well as head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cer-
vical cancer cases worldwide. HPV vaccines that prevent HPV 16 and 18 infections are now available
and have the potential to reduce the incidence of cervical and other anogenital cancers.

This report provides key information for Less developed regions on: cervical cancer; other anogeni-
tal cancers and head and neck cancers; HPV-related statistics; factors contributing to cervical cancer;
cervical cancer screening practises; HPV vaccine introduction; and other relevant immunization indi-
cators. The report is intended to strengthen the guidance for health policy implementation of primary
and secondary cervical cancer prevention strategies in the region.

The World has a population of 2,784 million women aged 15 years and older who are at risk of de-
veloping cervical cancer. Current estimates indicate that every year 527,624 women are diagnosed with
cervical cancer and 265,672 die from the disease. Cervical cancer ranks* as the fourth most frequent
cancer among women in the World.
* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st). Ranking is based on crude incidence rates (actual number of

cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

Table 2: Key statistics

More developed regions
Less developed regions
World

Population
Women at risk for cervical cancer (Female population aged >=15 yrs) in millions 2,784.9 2,240.4 544.4
Burden of cervical cancer
Annual number of new cervical cancer cases 527,624 444,546 83,078
Standardized incidence rates per 100,000 population 14.0 15.7 9.9
Annual number of cervical cancer deaths 265,672 230,158 35,514
Standardized mortality rates per 100,000 population 6.8 8.3 3.3
Burden of cervical HPV infection
Prevalence (%) of HPV 16 and/or HPV 18 among women with:
Normal cytology 4.1 4.4 3.9
Low-grade cervical lesions (LSIL/CIN-1) 25.8 25.1 25.9
High-grade cervical lesions (HSIL/ CIN-2 / CIN-3 / CIS) 51.9 46.7 54.1
Cervical cancer 69.4 69.5 71.8
Please see the specific sections for more information.

ICO HPV Information Centre

LIST OF CONTENTS -v-

Contents
Abbreviations iii

Executive summary iv

1 Introduction 1

2 Demographic and socioeconomic factors 3

3 Burden of HPV related cancers 8
3.1 Cervical cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
3.1.1 Incidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
3.1.2 Mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.1.3 Comparison of incidence and mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.2 Anogenital cancers other than the cervix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2.1 Anal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2.2 Vulvar cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.3 Vaginal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.2.4 Penile cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.3 Head and neck cancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
3.3.1 Pharyngeal cancer (excluding nasopharynx) . . . . . . . . . . . . . . . . . . . . . . . . 101

4 HPV related statistics 107
4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or
invasive cervical cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.1.1 HPV prevalence in women with normal cervical cytology . . . . . . . . . . . . . . . . 108
4.1.2 HPV type distribution among women with normal cervical cytology, precancerous
cervical lesions and cervical cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
4.1.3 Terminology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
4.2 HPV burden in anogenital cancers other than the cervix . . . . . . . . . . . . . . . . . . . . . 179
4.2.1 Anal cancer and precancerous anal lesions . . . . . . . . . . . . . . . . . . . . . . . . . 179
4.2.2 Vulvar cancer and precancerous vulvar lesions . . . . . . . . . . . . . . . . . . . . . . . 189
4.2.3 Vaginal cancer and precancerous vaginal lesions . . . . . . . . . . . . . . . . . . . . . 200
4.2.4 Penile cancer and precancerous penile lesions . . . . . . . . . . . . . . . . . . . . . . . 207
4.3 HPV burden in men . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
4.4 HPV burden in the head and neck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
4.4.1 Burden of oral HPV infection in healthy population . . . . . . . . . . . . . . . . . . . . 232
4.4.2 HPV burden in head and neck cancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235

5 Factors contributing to cervical cancer 262

6 Sexual behaviour and reproductive health indicators 266

7 HPV preventive strategies 267
7.1 Cervical cancer screening practices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267
7.2 HPV vaccination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278
7.2.1 HPV vaccine licensure and introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 278

8 Protective factors for cervical cancer 283

9 References 288

10 Glossary 322

ICO HPV Information Centre

LIST OF FIGURES - vi -

List of Figures
1 World geographical regions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 Population pyramids by World, developing and developed regions, estimates for 2017 . . . . . . . . . . . . . . . . 3
3 Population trends in four selected age groups by World, developing and developed regions for 2017 . . . . . . . . 4
4 Age-standardised incidence rates of cervical cancer in the World (estimates for 2012) . . . . . . . . . . . . . . . . 8
5 Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Africa (estimates for
2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in the Americas (esti-
mates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
7 Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Asia (estimates for
2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
8 Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Europe (estimates
for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
9 Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Oceania (estimates
for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
10 Ranking of cervical cancer versus other cancers among all women and women aged 15-44 years, according to
incidence rates in the World (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
11 World age-standardised incidence rates by World and sub regions (estimates for 2012) . . . . . . . . . . . . . . . . 17
12 Comparison of the ten most frequent cancers in all women by World, developing and developed regions (estimates
for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
13 Comparison of the ten most frequent cancers in all women by World and continents (estimates for 2012) . . . . 19
14 Comparison of the ten most frequent cancers in women aged 15-44 years by World developing and developed
regions (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
15 Comparison of the ten most frequent cancers in women aged 15-44 years by World and continents (estimates for
2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
16 Age-specific incidence of cervical cancer by World, developing and developed regions and five continents . . . . . 22
17 Annual number of new cases of cervical cancer by age group in developing and developed regions and five
continents World (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
18 Annual number of cases and age-specific incidence rates of cervical cancer in the World and its regions (estimates
for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
19 Annual number of cases and age-specific incidence rates of cervical cancer in the World and its regions (estimates
for 2012) (Continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
20 Age-standardised mortality rates of cervical cancer in the World (estimates for 2012) . . . . . . . . . . . . . . . . 28
21 Ranking of cervical cancer versus other cancers among all women and women aged 15-44 years, according to
mortality rates in the World (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
22 World age-standardised mortality rates of cervical cancer by World and sub regions World (estimates for 2012) . 31
23 Comparison of the ten most frequent cancer deaths in all women in the World compared to developing and
developed regions (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
24 Comparison of the ten most frequent cancer deaths in all women in the World compared to the continents
(estimations for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
25 Comparison of the ten most frequent cancer deaths in women aged 15-44 years by World, developing and devel-
oped regions (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
26 Comparison of the ten most frequent cancer deaths in women aged 15-44 years by World and continents (esti-
mates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
27 Age-specific mortality of cervical cancer by World and continents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
28 Annual number of deaths of cervical cancer by age group by developing and developed regions and continents
(estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
29 Annual number of deaths and age-specific mortality rates of cervical cancer in the World and its regions (esti-
mates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
30 Annual number of deaths and age-specific mortality rates of cervical cancer in the World and its regions (esti-
mates for 2012) (Continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
31 Age-specific incidence and mortality rates of cervical cancer in the World and its regions (estimates for 2012) . 41
32 Age-standardised incidence rates of other anogenital cancer in the World (estimates for 2012) . . . . . . . . . . . 42
33 Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Africa (esti-
mates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
34 Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in the Americas
(estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
35 Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Asia (esti-
mates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
36 Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Europe
(estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
37 Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Oceania
(estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
38 Age-standardised incidence rates of head and neck cancer in the World (estimates for 2012) . . . . . . . . . . . . 91

ICO HPV Information Centre

. 122 57 Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) . . . . . Includes ICD-10 codes: C09-10. . . . . . . . . . . . . . . . . . . 151 78 Prevalence of HPV 16 among women with low-grade cervical lesions in Asia by country and study (continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 74 Prevalence of HPV 16 among women with low-grade cervical lesions in Africa by country and study . . . . . 108 48 Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in the World and its regions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 44 Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) by sex and age group in the World. . . . . . . . . Includes ICD-10 codes: C09-10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153 80 Prevalence of HPV 16 among women with low-grade cervical lesions in Europe by country and study (continued) 154 81 Prevalence of HPV 16 among women with low-grade cervical lesions in Oceania by country and study . 96 42 Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Europe (esti- mates for 2012) . . . . . . . . . 135 64 Prevalence of HPV among women with normal cervical cytology in Europe by country and study (continued) . . . . 133 63 Prevalence of HPV among women with normal cervical cytology in Europe by country and study (continued) . 144 71 Prevalence of HPV 16 among women with normal cervical cytology in Europe by country and study . . . . . . . . . . . . 152 79 Prevalence of HPV 16 among women with low-grade cervical lesions in Europe by country and study . . . . . . . . . . . . . . . . . . . 140 67 Prevalence of HPV 16 among women with normal cervical cytology in the Americas by country and study . . . . . . . . . . . . . 157 84 Prevalence of HPV 16 among women with high-grade cervical lesions in the Americas by country and study (continued) . . . . . . . . . . . 112 51 Prevalence of HPV among women with normal cervical cytology in the Americas by country and study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C12-14 (estimates for 2012) . . . . . . . . . . . . 124 58 Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) . . . . . . . . . . . . . . . . 128 60 Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) . . . . . . . . . . . . . . 103 45 Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) in males by age group in the World and its regions. . . . . . . . . . . . . . . . . . . 145 72 Prevalence of HPV 16 among women with normal cervical cytology in Europe by country and study (continued) 146 73 Prevalence of HPV 16 among women with normal cervical cytology in Oceania by country and study . . . . . .C12-14 (estimates for 2012) . . . . . . . . . . . . . . . . . . 98 43 Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Oceania (esti- mates for 2012) . . . . . . . 156 83 Prevalence of HPV 16 among women with high-grade cervical lesions in the Americas by country and study . . . . . . . 155 82 Prevalence of HPV 16 among women with high-grade cervical lesions in Africa by country and study . . . . . . . . . . 92 40 Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in the Americas (estimates for 2012) . . . . . . 148 75 Prevalence of HPV 16 among women with low-grade cervical lesions in the Americas by country and study . . . . . . . . . . . . . . . . . . . 150 77 Prevalence of HPV 16 among women with low-grade cervical lesions in Asia by country and study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 56 Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137 65 Prevalence of HPV among women with normal cervical cytology in Oceania by country and study . . . . . 142 69 Prevalence of HPV 16 among women with normal cervical cytology in Asia by country and study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 85 Prevalence of HPV 16 among women with high-grade cervical lesions in Asia by country and study . 131 62 Prevalence of HPV among women with normal cervical cytology in Europe by country and study (continued) . . . . . . . . .vii - 39 Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Africa (esti- mates for 2012) . . . . . . . 138 66 Prevalence of HPV 16 among women with normal cervical cytology in Africa by country and study . . . . . . . . . . 109 49 Prevalence of HPV among women with normal cervical cytology in Africa by country and study . 126 59 Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) . . . . . . 130 61 Prevalence of HPV among women with normal cervical cytology in Europe by country and study . . . 104 46 Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) in females by age group in the World and its regions. . . . . . . . . . . . . . . . . . . . . . . . . . 113 52 Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued)115 53 Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued)117 54 Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued)119 55 Prevalence of HPV among women with normal cervical cytology in Asia by country and study . . . . . . . . . . . . . . . . . . . . 149 76 Prevalence of HPV 16 among women with low-grade cervical lesions in the Americas by country and study (continued) . . . . . . .C12-14 (estimates for 2012) . . . . . . . . . . . . . . . . . 163 90 Prevalence of HPV 16 among women with invasive cervical cancer in Africa by country and study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 68 Prevalence of HPV 16 among women with normal cervical cytology in the Americas by country and study (con- tinued) . 110 50 Prevalence of HPV among women with normal cervical cytology in Africa by country and study (continued) . . . . . . . . . . . . . . . . . . . . . . . . . 161 88 Prevalence of HPV 16 among women with high-grade cervical lesions in Europe by country and study (continued) 162 89 Prevalence of HPV 16 among women with high-grade cervical lesions in Oceania by country and study . . . . . . Includes ICD-10 codes: C09-10. . . . . . . . 105 47 Prevalence of HPV among women with normal cervical cytology in the World . . . . . . . . . . . . . . . . . . . . . 164 91 Prevalence of HPV 16 among women with invasive cervical cancer in the Americas by country and study . . 94 41 Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Asia (estimates for 2012) . 165 ICO HPV Information Centre . . . . . . . . 143 70 Prevalence of HPV 16 among women with normal cervical cytology in Asia by country and study (continued) .LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 86 Prevalence of HPV 16 among women with high-grade cervical lesions in Asia by country and study (continued) 160 87 Prevalence of HPV 16 among women with high-grade cervical lesions in Europe by country and study . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . developing and developed regions . . . . . . . . . . . . . . . . . . . . . . 199 122 Comparison of the ten most frequent HPV types in vaginal cancer cases in Africa and the World . . . . . . . . 187 110 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Europe and the World . . 263 144 World prevalence of hormonal contraceptive use . 197 118 Comparison of the ten most frequent HPV types in VIN 2/3 cases in the Americas and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 142 Female smoking prevalence . . . . . . . . . . . . . . . . . . . . 198 121 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Oceania and the World . . . . . . . . . . 264 145 World HIV prevalence . . . . . 196 117 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Africa and the World . . . . 187 111 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Oceania and the World . . . . . . . . . . . . . . . . . . . . . . . 212 136 Comparison of the ten most frequent HPV types in penile cancer cases in Oceania and the World . . . . . . . . . . . . 184 104 Comparison of the ten most frequent HPV types in anal cancer cases in Asia and the World . . . 203 126 Comparison of the ten most frequent HPV types in vaginal cancer cases in Oceania and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206 132 Comparison of the ten most frequent HPV types in penile cancer cases in Africa and the World . 175 102 Comparison of the ten most frequent HPV types in anal cancer cases in Africa and the World . . . . . 169 96 Prevalence of HPV 16 among women with invasive cervical cancer in Europe by country and study . . . . . . . . . . .LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . 171 98 Prevalence of HPV 16 among women with invasive cervical cancer in Europe by country and study (continued) . 267 148 Worldwide status of HPV vaccination programmes . 173 100 Comparison of the ten most frequent HPV oncogenic types among women with and without cervical lesions by World compared to developing and developed regions . . . . . 213 137 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Africa and the World . . . 167 94 Prevalence of HPV 16 among women with invasive cervical cancer in Asia by country and study (continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 141 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Oceania and the World . . . . . . . . . . . . . . . . . . . . . . . 172 99 Prevalence of HPV 16 among women with invasive cervical cancer in Oceania by country and study . . . . . . . . 174 101 Comparison of the ten most frequent HPV types among women with invasive cervical cancer by histology by World. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184 105 Comparison of the ten most frequent HPV types in anal cancer cases in Europe and the World . . . . . . . . 185 106 Comparison of the ten most frequent HPV types in anal cancer cases in Oceania and the World . . . . . . . . . . . . . . . . 197 119 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Asia and the World . 186 108 Comparison of the ten most frequent HPV types in AIN 2/3 cases in the Americas and the World . . . . . . 196 116 Comparison of the ten most frequent HPV types in vulvar cancer cases in Oceania and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166 93 Prevalence of HPV 16 among women with invasive cervical cancer in Asia by country and study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183 103 Comparison of the ten most frequent HPV types in anal cancer cases in the Americas and the World . . . 195 114 Comparison of the ten most frequent HPV types in vulvar cancer cases in Asia and the World . . . . . . . . 266 147 Worldwide status of cervical cancer screening programmes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214 140 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Europe and the World . . . . . . . . . . . . . . . . . . . . . . . . 265 146 Percentage of 15-year-old girls who report sexual intercourse . . . . . . . . . . . . . . . . . . . . . . . 185 107 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Africa and the World . . . . . . . . . . . . . . . . . . 205 130 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Europe and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214 139 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Asia and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204 128 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in the Americas and the World . . . . . . . . . . . . . . . . . . . 186 109 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Asia and the World . 170 97 Prevalence of HPV 16 among women with invasive cervical cancer in Europe by country and study (continued) . . . . . . . . . . . 285 ICO HPV Information Centre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 125 Comparison of the ten most frequent HPV types in vaginal cancer cases in Europe and the World . . . . . . . . . . . . 202 124 Comparison of the ten most frequent HPV types in vaginal cancer cases in Asia and the World . . 194 113 Comparison of the ten most frequent HPV types in vulvar cancer cases in the Americas and the World . . 278 149 Worldwide prevalence of male circumcision . . . . . . . . . . . . . . . . . . . . . . . . . . 195 115 Comparison of the ten most frequent HPV types in vulvar cancer cases in Europe and the World . . . . . 198 120 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Europe and the World . . . . . . . . . . 204 127 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Africa and the World . . . . . . . . . . . . . . . . . . . 202 123 Comparison of the ten most frequent HPV types in vaginal cancer cases in the Americas and the World . . . . . . . . . . . . . . 205 129 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Asia and the World . . . . . . 262 143 Total fertility rates . . . 283 150 Worldwide prevalence of condom use . . . . . . . . . . . . . . 211 133 Comparison of the ten most frequent HPV types in penile cancer cases in the Americas and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . .viii - 92 Prevalence of HPV 16 among women with invasive cervical cancer in the Americas by country and study (con- tinued) . . . 211 134 Comparison of the ten most frequent HPV types in penile cancer cases in Asia and the World . . . . . . . . 213 138 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in the Americas and the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212 135 Comparison of the ten most frequent HPV types in penile cancer cases in Europe and the World . . . . . . . . . . . . . . . 206 131 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Oceania and the World . . . . . . . . . . . . . . . 168 95 Prevalence of HPV 16 among women with invasive cervical cancer in Asia by country and study (continued) . . . . . . . . 188 112 Comparison of the ten most frequent HPV types in vulvar cancer cases in Africa and the World . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 9 Incidence of vaginal cancer by cancer registry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .LIST OF TABLES . . . 268 31 HPV vaccination policies for the female population in the World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235 28 Studies on HPV prevalence among cases of oropharyngeal cancer . in the World and its regions. . . . . . . . . . . . . . . . . . . . . . . . . . 279 32 References of studies included . . . . . . . 217 25 Studies on anogenital HPV prevalence among men from special subgroups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Includes ICD-10 codes: C09-10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210 24 Studies on anogenital HPV prevalence among men . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .ix - List of Tables 1 Abbreviations . . . . . . 207 23 Studies on HPV prevalence among PeIN 2/3 cases . . . . 232 27 Studies on HPV prevalence among cases of oral cavity cancer . 52 8 Incidence of vulvar cancer by cancer registry . . . . . . . . . . . . . . . . 246 29 Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322 ICO HPV Information Centre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2017 . . . . . . . . in the World and its regions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C12-14 (estimates for 2012). . . . . 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 30 Cervical cancer screening policies . . . . . . . . . . . . . 221 26 Studies on oral HPV prevalence among healthy populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192 20 Studies on HPV prevalence among vaginal cancer cases . . . . 201 22 Studies on HPV prevalence among penile cancer cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 17 Studies on HPV prevalence among AIN 2/3 cases (male and female) . . . . . . . . . . . . . . . . . . . . . . . . . . 73 10 Incidence of penile cancer by cancer registry . . . . . . . . . 139 14 Type-specific HPV prevalence in women with normal cervical cytology. . . . . . . . precancerous cervical lesions and invasive cervical cancer by World region and sub-regions . . . . . . . 288 33 Glossary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101 12 Cancer mortality of pharynx (excluding nasopharynx) by sex. . . . . . . . . . . . . . . . 189 19 Studies on HPV prevalence among VIN 2/3 cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4 World sociodemographic indicators. . . . . . . . . . . . . . . . . . . . . . . . . 15 6 Cervical cancer mortality by World region and sub regions (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200 21 Studies on HPV prevalence among VaIN 2/3 cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Includes ICD-10 codes: C09-10. . . . . . . . . . . . . . . 82 11 Cancer incidence of pharynx (excluding nasopharynx) by sex. . . . . . . . . . . . . . . . . . precancerous cervical lesions and invasive cervical cancer . . . . . . . . . . . . 177 16 Studies on HPV prevalence among anal cancer cases (male and female) . . . . . . . . . . . . . . . . . . . . . . . . . 29 7 Incidence of anal cancer by cancer registry and sex . . . . . . . . . . . . C12-14 (estimates for 2012). . . . . . . . . . . . . . . . . . . . . . . 6 5 Incidence of cervical cancer by World region and sub regions (estimates for 2012) . . . . . . . . . . . . . . . . . . . . . . 101 13 Prevalence of HPV 16/18 in women with normal cervical cytology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181 18 Studies on HPV prevalence among vulvar cancer cases . iv 3 World population estimates (in millions). . . . . . 176 15 Type-specific HPV prevalence among invasive cervical cancer cases by histology . . . . . . . . . iii 2 Key statistics . . . . . . . . . . . . . . . . . . . . . . . . .

Section 6. The report is structured into the following sections: Section 2. vulva. Data include rel- evant cancer statistic estimates. This section summarizes the sociodemo- graphic profile of the World. Demographic and socioeconomic factors. This section presents preventive strategies that include ba- sic characteristics and performance of cervical cancer screening status. This section summarizes reports on prevalence of HPV and HPV type-specific distribution in women with normal cytology. HPV preventive strategies.Standard Country and Area Codes Classifications. This section describes the current burden of invasive cervical cancer and other HPV-related cancers in the World with estimates of prevalence. Section 3. parity. Section 5. Europe and Oceania (Figure 1). socioeconomic factors. HPV related statistics. the burden of HPV in other anogenital cancers (anus. oral contraceptive use and co-infection with HIV. women with precancerous lesions and inva- sive cervical cancer. Section 7. risk factors. vagina. burden of HPV infection in women and men. Sexual behaviour and reproductive health indicators. the World is divided into five regions: Africa. and cervical screening and immunization practices. Asia. and penis) are presented. The HPV Information Centre aims to compile and centralize updated data and statistics on HPV and HPV-related cancers. This report aims to summarize the data available to fully evaluate the burden of disease in the World and to facilitate stakeholders and relevant bodies of decision makers to formulate recommendations on the prevention of cervical cancer and other HPV-related cancers. incidence and mortality rates. epidemiological determinants of cervical cancer such as demographics. In addition. Factors contributing to cervical cancer. Burden of HPV related cancers. the Americas.1 INTRODUCTION -1- 1 Introduction Figure 1: World geographical regions Northern Europe Eastern Europe Northern America Central Asia Western Europe Southern Europe Eastern Asia Northern Africa Western Asia Southern Asia Caribbean Central America Western Africa South−Eastern Asia Micronesia Eastern Africa Middle Africa Melanesia Polynesia South America Australia and New Zealand Southern Africa Data sources: United Nations Statistics Division. This section describes factors that can modify the natural history of HPV and cervical carcinogenesis such as smoking. This section presents sex- ual behaviour and reproductive health indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers. For analytical purposes. Section 4. status of HPV vaccine licensure ICO HPV Information Centre .

Section 8. and recommendations for national immunization programmes. ICO HPV Information Centre . Protective factors for cervical cancer.1 INTRODUCTION -2- introduction. This section presents the prevalence of male circumcision and condom use.

219 75−79 33.521 279.157.175 42.279.930 29.118 65−69 112.830.928.761.628 240.096.851.422.805 20−24 37. Please refer to original source for methods of estimation.720.491.075 40−44 42.628 240.587.019.918.546 42.053.084 327.115 10−14 34.967.849 20−24 268.398.168 55−59 176.668 36.544 35−39 216.785 209.608.164 37.480.268.234.194.256.035 30−34 43.568 57.2 DEMOGRAPHIC AND SOCIOECONOMIC FACTORS -3- 2 Demographic and socioeconomic factors Figure 2: Population pyramids by World.306.487 40.829.356 253.528.031 5−9 299.893.457.938.584.518 197.697.804.681 251. developing and developed regions.869 298.235.323 60−64 110.860 45−49 191.931 15−19 34.786.610 33.775.683 45−49 234.381.919.180 33.117.284 35−39 42.962.227 More developed regions Males Females 80+ 22.853. ICO HPV Information Centre .354.349 288.806 34.342.089 283.136 188.060 Less developed regions Males Females 80+ 30.565.773.845.504.654 20−24 306.962.457 15−19 305.038.519 30−34 292.746.931.665 298.327 313.275.984 25.un.033 82.989. 2017]. Data sources: United Nations.484 30−34 249.526 65−69 80.110 42.130.473. [Accessed on March 21.709 75−79 18.039 Under 5 35.533 165.330 39.086 55−59 42.928 75−79 51. Population Division (2015).603 5−9 335.278.518.815.833 Population by sex and age group Data accessed on 27 Mar 2017.314 64.923.729.755.366. DVD Edition.317.847.828 35−39 258.640.644 257. Department of Economic and Social Affairs.713 60−64 37.498 87.633 123.809.823 45−49 42.238.259 264.187 70−74 24.545 10−14 319.554 32.216.082 55−59 134.916.358 156.904 294.483.003.432.751.572 5−9 35.127.430 10−14 284.620.334.526 15−19 271.535 25−29 271.650 135.332.787 50−54 43.581.092.902. Available at: https://esa.org/ unpd/wpp/Download/Standard/Population/.404 44.886.613.281 42.789.010.592 65−69 32.054 180.545 50−54 166.085.332 50−54 209.987.462.252 44.010.005.315 253.374.425 Under 5 349.320.774.256.393 40−44 245.469 85.809.558.056.382.612.036 60−64 148.917 114.138.441 42.082 70−74 51.575.305.461 42.435.378 25−29 42. estimates for 2017 World Males Females 80+ 53.158.391.318 40−44 202.869 286. World Population Prospects: The 2015 Revision.269 70−74 75.311 231.075 210.386 Under 5 314.913 25−29 313.021 40.

World Population Prospects: The 2015 Revision. Data sources: United Nations.org/ unpd/wpp/Download/Standard/Population/.2 DEMOGRAPHIC AND SOCIOECONOMIC FACTORS -4- Figure 3: Population trends in four selected age groups by World. DVD Edition. Population Division (2015).200 100 Women 15−24 yrs Girls 10−14 yrs All Women Women 25−64 yrs 0 200 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 Female population trends Number of women by year and age group Data accessed on 27 Mar 2017.200 400 3.200 400 3.200 500 4.200 200 1. developing and developed regions for 2017 World Projections Projections Women 15−24 yrs Number of women (in millions) Number of women (in millions) 700 All Women 5. Available at: https://esa.200 Girls 10−14 yrs 300 Women 25−64 yrs 2.200 200 1.200 300 2.200 Girls 10−14 yrs Women 25−64 yrs 300 2.200 All Women 500 4. [Accessed on March 21. Please refer to original source for methods of estimation.200 400 3. (Continued on next page) ICO HPV Information Centre . Department of Economic and Social Affairs.200 600 500 4.200 200 1. 2017].200 100 0 200 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 More developed regions Projections Projections Number of women (in millions) Number of women (in millions) 700 600 5.200 100 200 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 Less developed regions Projections Projections Number of women (in millions) Number of women (in millions) 700 Women 15−24 yrs 600 5.un.

2 DEMOGRAPHIC AND SOCIOECONOMIC FACTORS -5- ( Figure 3 – continued from previous page) ICO HPV Information Centre .

56 0.18 Asia 184. k Including Liechtenstein. 19.86 137. .72 18. a Less developed regions comprise all regions of Africa.27 1.22 Less developed regionsa 284.74 685.97 41. f Including Anguilla.27 138.3 3.21 116.60 105.76 180.75 681. Holy See.6 Population living in urban areas (%)2.000)4 (Continued on next page) ICO HPV Information Centre .26 5. . and San Marino.97 14.87 11.49 98.51 Northern Europe i 2.36 43.65 184.org/ unpd/wpp/Download/Standard/Population/.∗ . Department of Economic and Social Affairs.724.61 South-Eastern Asia 28. b More developed regions comprise Europe.80 25.84 158. Cayman Islands.23 216.60 20.46 3.29 382.48 52.15 4. 2017 Region / Country Male Female 10-14 years 15+ years Total 10-14 years 15+ years Total World 319. h Including Falkland Islands (Malvinas).08 85.21 97. - Adult mortality rate (probability of dying between 15 and 60 years .46 366.49 Eastern Europe 7.52 Southern Asia 93.99 127.64 33.87 3724.69 Melanesia 0.22 183.03 0.07 131.82 209.065. 7.20 Eastern Asia 46.04 2.01 94.b Life expectancy at birth (in years) .62 51.61 Oceania 1.07 26.80 87.03 0.18 22.∓ Population growth rate (%) .11 79.000) .2 Median age of the population (in years)1.80 80.38 Western Asia 12. Population Division (2015).∗ .42 264.58 3.70 14.91 72.00 115. 29.18 120.19 0.48 325.27 0.23 3791.35 0.∓ Crude birth rate (births per 1. Dominica.09 Central America 8. British Virgin Islands.20 398.06 1724. Tuvalu. and Saint-Pierre-et-Miquelon.46 793. c Including Saint Helena. Pitcairn.25 40.53 79.60 Southern Africa 3.02 78. Australia/New Zealand and Japan. i Including Faeroe Islands.19 21. and Tristan da Cunha. Gibraltar.69 80. 2017].80 Northern Africa 11. . m Including American Samoa.24 2784.83 2290.59 34.16 963.41 323.24 26. .218.39 Western Africa c.15 500. Micronesia and Polynesia.03 0.70 11. Please refer to original source for methods of estimation.56 15.38 2279.92 Western Europek 5.d 23. and Wallis and Futuna Islands.21 650. Northern Mariana Islands.74 383.93 23.42 296.38 Northern America g 11.44 10. Latin America and the Caribbean plus Melanesia.44 3079.83 16. Cook Islands.16 166.44 Southern Europe j 3. Available at: https://esa. Year of estimate: 2017. Nauru.25 35.18 Central Asia 2.000) .28 188.22 2188.515.± Population in thousands 3.33 89.19 4.27 544.96 74.94 31.25 44.90 62.97 2240. 2017 Indicator Male Female Total 1. DVD Edition.71 666.24 154.69 145.68 1.19 0.44 112.68 372.34 Data accessed on 27 Mar 2017.6 1.791.27 Polynesiam 0. .45 356. l Including Marshall Islands.10 11.87 83.91 88.39 20. Montserrat. d Including Saint Helena.8 3.40 831.07 298.∓ Crude death rate (deaths per 1.60 510.12 South Americah 17.59 Eastern Africa 26.13 167.41 1673.18 207.03 0.03 38.43 117.9 7.90 Micronesial 0.83 22.23 2786. Caribbean Netherlands. Sint Maarten (Dutch part) and Turks and Caicos Islands. j Including Andorra.15 236.59 10.76 16.13 3. Asia (except Japan).30 3178.84 43.47 Europe 19. and Isle of Man. and Palau.37 Americas e 39.08 Africa 74.16 622.33 907.00 32.40 210.14 More developed regionsb 34.41 623. and Monaco.44 645.76 242.a.44 Middle Africa 10.76 Caribbean f 1.20 Australia & New Zealand 0.38 62.92 612. . Tokelau. - old per 1.24 0.36 77.54 3.47 15. Ascension. g Including Bermuda. Northern America. World Population Prospects: The 2015 Revision.37 17. 54 1. Saint Kitts and Nevis. 1.05 65.40 7.25 0. [Accessed on March 21. e Aggregated by the HPV Information Centre pooling its individual areas/countries. Greenland. Ascension and Tristan da Cunha.2 DEMOGRAPHIC AND SOCIOECONOMIC FACTORS -6- Table 3: World population estimates (in millions).23 150.69 67.284.18 324. Table 4: World sociodemographic indicators.92 11. .09 0.04 2.03 23.87 8.04 21.85 506.un.2 1. Niue. Data sources: United Nations.68 104.

? 92.who. a World Population Prospects. Department of Economic and Social Affairs. 6 World Bank.uis.2 DEMOGRAPHIC AND SOCIOECONOMIC FACTORS -7- ( Table 4 – continued from previous page) Indicator Male Female Total 3. f . Please refer to original source for methods of estimation. GNI is the sum of value added by all resident producers plus any product taxes (less subsidies) not included in the valuation of output plus net receipts of primary income (compensation of employees and property income) from abroad. - 5. aspx?source=world-development-indicators#. PPP GNI is gross national income (GNI) converted to international dollars using purchasing power parity rates. CD-ROM Edition.un. e GNI per capita based on purchasing power parity (PPP). ∓ 2010-2015. Geneva (http://www.5 85. Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation. Available at: http://stats. . - 6. . 2017]. World Health Organization.worldbank.main.c Under age five mortality rate (per 1.? 89. Global Health Workforce Statistics. 2017].unesco. accessed 26 March 2016). 7 UNESCO Institute for Statistics Data Centre [online database]. ICO HPV Information Centre . including generalist and specialist medical practitioners. DVD Edition.3 7. [Accessed on March 21.who.6 88. - Adult literacy rate (%) (aged 15 and older)7. World Health Organization. World Development Indicators Database. 5 The 2016 update.org/unpd/wup/CD-ROM/. the 2015 revision (WPP2015). [Accessed on March 21.3 Youth literacy rate (%) (aged 15-24 years)7. [Accessed on March 21. ? 2014.int/hrh/statistics/hwfstats/).1 65 65 Data accessed on 27 Mar 2017.org/data/reports. Available at: http://databank. 2017].d Density of physicians (per 1. f . Data sources: 1 United Nations. on the data held in the WHO Mortality Database and on HIV mortality estimates prepared by UNAIDS. 2017]. World Health Organization. Available at: http://apps.000 population) . World Urbanization Prospects: The 2014 Revision. 2017]. WHO Member States with a population of less than 90 000 in 2015 were not included in the analysis.unicef. 2017].? Net primary school enrollment ratio 90. New York (NY).? Net secondary school enrollment ratio 65. f UIS Estimation Year of estimate: ± 2017. html. 2016. Data are in current international dollars based on the 2011 ICP round.org [Accessed on March 21.6 90. [Accessed on March 21. b WHO annual life tables for 1985–2015 based on the WPP2015. Global Health Observatory data repository. Geneva. Population Division. 2017]. dollar has in the United States. Available at: https://esa. per 1 000 population. Population Division (2015). Population Division (2014).2 81.S. 2 United Nations. Montreal.5 89. 4 World Health Organization. d Number of medical doctors (physicians). International Comparison Program database. Available at: http://who.e Gross national income per capita (PPP current international $) .1360?lang=en. New York (NY): United Nations DESA.000 live births) . DC. [Accessed on March 21.org/publications/files/Child_Mortality_Report_2015_ Web_9_Sept_15.6 7. Report 2015. Washington. World Bank and United Nations. [Accessed on March 21. Available at: https: //esa. c Levels & Trends in Child Mortality. World Population Prospects: The 2015 Revision. Department of Economic and Social Affairs.un. .int/entity/gho/publications/world_health_statistics/2016/en/index.1 88. UNESCO Institute for Statistics.pdf. 2015 (http://www.int/gho/data/view. 3 World Health Statistics 2016. An international dollar has the same purchasing power over GNI as a U. org/unpd/wpp/Download/Standard/Population/. Geneva and Washington (DC): United Nations Children’s Fund. ∗ 2015.

Dikshit R. Suppl 3. Eser S.672 deaths in 2012 (GLOBOCAN). Suppl 5.624 new cervical cancer cases are diagnosed annually in World (estimates for 2012).2. Vol. 2013.624 new cases and 265. For Sudan. (Vaccine 2006. GLOBOCAN 2012 v1. Lyon.fr. About 527. Ranking using age-standardized rate (ASR) may differ.3 BURDEN OF HPV RELATED CANCERS -8- 3 Burden of HPV related cancers 3.1 Cervical cancer Cancer of the cervix uteri is the 4th most common cancer among women worldwide. Rates per 100. Bray F. Figure 4: Age-standardised incidence rates of cervical cancer in the World (estimates for 2012) Data accessed on 15 Nov 2015. The majority of cases are squamous cell carcinoma followed by adenocarcinomas. Cervical cancer ranks* as the 4 th leading cause of female cancer in the World. Parkin DM. Vol.iarc. Mathers C. France: International Agency for Research on Cancer. with an estimated 527. 11 [Internet].000 women per year. Rebelo M. Vol. deaths. Forman D. * Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st).1. 30. South Sudan: Estimate for Sudan and South Sudan Data sources: Ferlay J. Soerjomataram I. incidence and mortality. ICO HPV Information Centre . Vol. Vaccine 2012.1 Incidence KEY STATS. IARC Monographs 2007. Suppl 10. 3. 24. 90) This section describes the current burden of invasive cervical cancer in the World and its regions with estimates of the annual number of new cases. 26. Available from: http://globocan. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Cervical cancer is the 2nd most common female cancer in the women aged 15 to 44 years in World. Vaccine 2008. Ervik M. Ranking is based on crude incidence rates (actual number of cervical cancer cases).

** 0 10 20 30 40 50 60 70 80 Cervical cancer: Age−standardised incidence rate per 100.4 Somalia 33.4 Mali 44.Tome & Prin.2 Liberia 30.6 Uganda 44.1 South Sudan 30.0 Namibia 14.7 Niger 8.3 Seychelles** S.7 Togo 21.4 Tanzania 54.4 Kenya 40.1 Burundi 49. Data accessed on 15 Nov 2015.9 Chad 18.3 Madagascar 44.3 Libya 9.8 Egypt 2.3 Zambia 58.5 Sudan 7.0 Benin 27.8 Eritrea 17.0 Swaziland 53.8 Senegal 41.6 Algeria 8.5 CAR 21.1 South Africa 31. For Sudan.4 DR Congo 33. Female (All ages) ** No rates are available.6 Ethiopia 26.9 Mozambique 65.0 Comoros 61. Guinea 25. Rates per 100.1 Cameroon 30.7 Morocco 14.4 Nigeria 29.1 Burkina Faso 23.0000 women World Standard.1 Lesotho 38.4 Djibouti 17.0 Guinea−Bissau 29.7 Western Sahara 31.4 Angola 35.1 Congo 25.0 Cape Verde 29.5 Ghana 35.3 Côte d'Ivoire 21.000 women per year.0 Zimbabwe 56.2 Rwanda 41.3 Mauritius 15.0 Gabon 19.4 Gambia 26.9 Tunisia 4.8 Mauritania 29.3 BURDEN OF HPV RELATED CANCERS -9- Figure 5: Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Africa (estimates for 2012) Malawi 75. South Sudan: Estimate for Sudan and South Sudan (Continued on next page) ICO HPV Information Centre .3 Sierra Leone 30.4 Botswana 30.4 Guinea 38.2 Eq.

iarc. Bray F.10 - ( Figure 9 – continued from previous page) Data sources: Ferlay J. Available from: http://globocan. Rebelo M.fr. France: International Agency for Research on Cancer. Forman D. Eser S. Ervik M. Dikshit R. Lyon.3 BURDEN OF HPV RELATED CANCERS . Soerjomataram I. 2013. ICO HPV Information Centre . GLOBOCAN 2012 v1. Parkin DM. Mathers C. 11 [Internet]. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.2.

Female (All ages) ** No rates are available.** 0 10 20 30 40 50 Cervical cancer: Age−standardised incidence rate per 100.3 Argentina 20. Mathers C.3 St Vincent** St Lucia** St Kitts & Nev.7 Belize 32.** Grenada** Dominica** Antigua & Bar.0 Nicaragua 36.5 Mexico 23.000 women per year.4 Haiti 24.6 Uruguay 18.fr.2. ICO HPV Information Centre .8 Trinidad & Tob.0000 women World Standard.7 Honduras 29.7 Cuba 17. Data sources: Ferlay J. Lyon.4 Ecuador 29.7 Guyana 46. Dikshit R. France: International Agency for Research on Cancer.9 El Salvador 24.3 Chile 12.7 Colombia 18. Available from: http://globocan. 24.8 Bahamas 20.11 - Figure 6: Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in the Americas (estimates for 2012) Bolivia 47.3 Guatemala 22. Bray F. Rates per 100.2 Paraguay 34. GLOBOCAN 2012 v1.3 Barbados 25. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 30.6 Canada 6. 2013.2 Venezuela 32. Eser S. Soerjomataram I.4 USA 6.0 Jamaica 26.8 Peru 32. Rebelo M.1 Brazil 16. Data accessed on 15 Nov 2015. Parkin DM. 11 [Internet].9 Panama 18.3 BURDEN OF HPV RELATED CANCERS . Ervik M.7 Dominican Rep.9 Suriname 38.iarc. Forman D.8 Costa Rica 11.

5 Bahrain 5. Forman D. Data accessed on 15 Nov 2015.9 Azerbaijan 9.7 India 22.1 Pakistan 7.5 UAE 9.3 Brunei 16.3 BURDEN OF HPV RELATED CANCERS .0 Yemen 3.iarc.0 Taiwan** 0 10 20 30 Cervical cancer: Age−standardised incidence rate per 100. GLOBOCAN 2012 v1.1 Lebanon 4. Parkin DM. Rates per 100.4 Maldives 11.4 Mongolia 24. Mathers C.2.0 Thailand 17.1 Bhutan 12.9 China 7. ICO HPV Information Centre .7 Syria 2.6 Bangladesh 19.000 women per year.5 Timor−Leste 13.6 Israel 4.fr. Soerjomataram I.6 Tajikistan 9.2 Armenia 13.8 Iran 2.8 Saudi Arabia 2. Available from: http://globocan.5 Afghanistan 8.5 DPR Korea 12. Ervik M.3 Cambodia 23.8 Indonesia 17.3 Kuwait 4.1 Iraq 2.8 Kyrgyzstan 23.3 Turkmenistan 13.0 Myanmar 20.4 Palestine 2. Female (All ages) ** No rates are available. 2013.6 Georgia 14.8 Uzbekistan 13. France: International Agency for Research on Cancer.0 Malaysia 15. Bray F.3 Qatar 5.6 Turkey 4.8 Singapore 8. Eser S. Lyon. Korea 9. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.0000 women World Standard.8 Laos 12.9 Philippines 16.6 Jordan 2.8 Rep.12 - Figure 7: Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Asia (estimates for 2012) Kazakhstan 29. 11 [Internet]. Rebelo M.2 Nepal 19.1 Sri Lanka 13. Dikshit R.9 Oman 5.9 Viet Nam 10.0 Japan 10. Data sources: Ferlay J.

6 Slovenia 10.7 Austria 5.0 Belgium 8.0000 women World Standard. Female (All ages) ** No rates are available.fr. Rates per 100. 13. 11 [Internet].0 Latvia 17.1 Netherlands 6.8 Greece 5.6 Belarus 13.1 Russia 15.6 Slovakia 16.2 Denmark 10.2 Macedonia 12. Forman D. ICO HPV Information Centre . Lyon. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.0 Luxembourg 4. Ervik M.6 Hungary 18. 14. Eser S.5 Croatia 10.0 Norway 9. Bray F.6 Lithuania 26.8 Sweden 7.8 Montenegro 20. Dikshit R.2 Albania 5.9 Moldova 19.7 Ireland 13.5 Serbia 23.8 Italy 6.6 Germany 8. Available from: http://globocan.8 Portugal 9.2 Iceland 7.1 Bulgaria 24.3 Ukraine 16.4 Poland 12.3 Czech Rep.4 UK 7. France: International Agency for Research on Cancer.13 - Figure 8: Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Europe (estimates for 2012) Romania 28.9 Finland 4. GLOBOCAN 2012 v1. Mathers C.8 France 6. Parkin DM. Soerjomataram I. 2013. Data accessed on 15 Nov 2015.9 Spain 7.1 Bosnia & H.8 Switzerland 3.3 BURDEN OF HPV RELATED CANCERS .6 San Marino** Monaco** Liechtenstein** Andorra** 0 10 20 30 Cervical cancer: Age−standardised incidence rate per 100.2 Estonia 19.1 Malta 3.000 women per year. Rebelo M.iarc. Data sources: Ferlay J.2.3 Cyprus 4.

2013.fr. Guinea 34. Dikshit R.** Kiribati** FS Micronesia** 0 10 20 30 40 Cervical cancer: Age−standardised incidence rate per 100. Available from: http://globocan.3 BURDEN OF HPV RELATED CANCERS .2 Samoa 17. 28.3 Tuvalu** Tonga** Palau** Nauru** Marshall Is.2. Ervik M. Lyon. Female (All ages) ** No rates are available. Mathers C. France: International Agency for Research on Cancer.8 Papua N.000 women per year. 11 [Internet].5 Vanuatu 19. Eser S. Data accessed on 15 Nov 2015.5 Solomon Is. Parkin DM. GLOBOCAN 2012 v1.1 Australia 5.14 - Figure 9: Age-standardised incidence rate of cervical cancer cases attributable to HPV by country in Oceania (estimates for 2012) Fiji 37.0000 women World Standard. Data sources: Ferlay J. Rates per 100. ICO HPV Information Centre . Rebelo M.5 New Zealand 5. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.iarc. Bray F. Forman D. Soerjomataram I.

285 11.7 12.3 31.566 16. 444.7 14 4 Oceania 2.7 10. Dikshit R.4 4 2 Less developed re. Ranking using ASR may differ.652 29.5 11 4 Europe 58.2 7.6 8.377 8.5 4 2 Northern Europe 5.326 17.3 3.7 7 2 Southern Asia 145.5 12 4 Zealand Melanesia 1.0 1. 83.4 1. Forman D.3 0.fr.6 8.1 2 1 Western Africa 27.7 16.6 3.6 2 2 gions More developed re.5 18.9 8 3 Australia & New 938 6.9 1. b Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years.3 2.8 33. Ranking of cervical cancer incidence to other cancers among all women ages 15-44 years according to highest incidence rates (ranking 1st).6 15.3 2 1 Northern America 14. ICO HPV Information Centre .15 - Table 5: Incidence of cervical cancer by World region and sub regions (estimates for 2012) Cumulative risk (%) Ranking of CC Area N cases Crude ratea ASRa ages 0-74 yearsb All women Women 15-44 years World 527.2 11. Rebelo M.5 0. a Rates per 100.1 2 2 South-Eastern 50.813 5.6 1.7 1.0 2 2 Eastern Africa 45.6 13 4 South America 45.8 11 2 Western Europe 9.6 1 1 Middle Africa 11.1 19.3 2.824 10.2 2 1 Micronesia 23 8.078 13. Available from: http://globocan.3 BURDEN OF HPV RELATED CANCERS .6 16.9 0.6 0.823 13.2 0.3 3 2 Central Asia 5. For cancer.4 4 2 Caribbean 5.850 18.000 women per year. Data sources: 1 Ferlay J.373 15.1 6 2 Eastern Europe 33.3 3. Parkin DM.5 27.018 23.455 3. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Standardised rates have ben estimated using the direct method and the World population as the reference.0 1. Bray F. Ervik M.9 0.8 5.2 29.5 3.540 17.038 18.7 0.4 1 2 Northern Africa 5.7 1.008 22.195 11. Ranking is based on crude incidence rates (actual number of cervical cancer cases). France: International Agency for Research on Cancer.8 2 1 Eastern Asia 78.1 5 3 Data accessed on 15 Nov 2015.iarc.0 2 2 Asia 284.1 14.2 14.546 15.2 20.4 0.198 26.7 0.6 3.7 4 4 Southern Africa 8.9 11 2 gions Africa 99.1 23.5 8.7 2 2 Asia Western Asia 4. it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. 11 [Internet].2.8 4.195 17.1 6.1 7.0 2.8 42.792 23. 2013.382 10.7 4.882 21. Soerjomataram I.6 21.2 30.2 2 2 Americas 83.6 0.5 0.9 6 4 Polynesia 36 10.8 11. GLOBOCAN 2012 v1.8 10 3 Southern Europe 9. Lyon.624 15.0 9.3 1.6 6. Eser S.0 2 2 Central America 18.3 1.707 25.5 2.946 17. Mathers C.006 10.

16 - Figure 10: Ranking of cervical cancer versus other cancers among all women and women aged 15-44 years. ICO HPV Information Centre .3 BURDEN OF HPV RELATED CANCERS . Cancer Incidence and Mortality Worldwide: IARC CancerBase No.2. Soerjomataram I. 2013. according to incidence rates in the World (estimates for 2012) Data accessed on 15 Nov 2015. Eser S. Bray F. Data sources: Ferlay J.iarc. France: International Agency for Research on Cancer. Parkin DM.fr. Lyon. Rebelo M. Available from: http://globocan. 11 [Internet]. Mathers C. Forman D. Dikshit R. Ervik M. GLOBOCAN 2012 v1.

6 Australia & New Zealand 5. Available from: http://globocan.3 More developed 9.2 0 10 20 30 0 10 20 30 40 50 Cervical cancer: Age−standardised mortality rate per 100.3 BURDEN OF HPV RELATED CANCERS . Female (All ages) Data accessed on 15 Nov 2015. ICO HPV Information Centre .000 women per year.3 Central America 23. Forman D. Rebelo M.3 Southern Asia 19. Lyon. GLOBOCAN 2012 v1.6 World 14.9 Asia 12. developed and developing regions Continental sub−regions Less developed 15. Ervik M.5 Eastern Asia 7.fr.5 Western Asia 4.0 Western Africa 29. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Bray F. 2013.iarc.0 South America 20.5 Caribbean 21.0 Africa 27. Parkin DM.4 Oceania 10.9 Central Asia 18.3 Eastern Europe 16.7 Eastern Africa 42. Eser S.3 Five continents Polynesia 11. Mathers C.6 Northern Europe 8.2. 11 [Internet].17 - Figure 11: World age-standardised incidence rates by World and sub regions (estimates for 2012) World. Soerjomataram I.6 0 10 20 South−Eastern Asia 16.4 Northern Africa 6.9 Southern Europe 8. Data sources: Ferlay J.6 Europe 11.7 Melanesia 33.3 Southern Africa 31.000 women World Standard.7 Western Europe 7. Dikshit R. France: International Agency for Research on Cancer.7 Micronesia 8.3 Northern America 6. Rates per 100.5 Middle Africa 30.7 Americas 14.

Ervik M.6 Corpus uteri 14.2.3 BURDEN OF HPV RELATED CANCERS .7 0 15 30 45 60 75 0 15 30 45 60 75 Less developed regions Age−standardised incidence rate per 100.7 Oesophagus 4. developing and devel- oped regions (estimates for 2012) World More developed regions Breast 43.fr. Soerjomataram I. GLOBOCAN 2012 v1.3 Cervix uteri 15.18 - Figure 12: Comparison of the ten most frequent cancers in all women by World.0 Lung 19. Data sources: Ferlay J.7 Lung 11. a Includes anal cancer (C21).1 Melanoma of skin 9.3 Thyroid 6. Rebelo M. Dikshit R. ICO HPV Information Centre .0 Thyroid 4. Lyon.9 Ovary 6.6 Corpus uteri 5.5 Cervix uteri 9. Bray F.4 Non−Hodgkin lymphoma(b) 7.5 Ovary 5.8 Liver 6.1 Colorectum(a) 9.1 Liver 5. Forman D.8 Stomach 7. Parkin DM.7 Corpus uteri 8. France: International Agency for Research on Cancer. 2013. 11 [Internet].iarc. Mathers C.6 Lung 13. Eser S.000 women Breast 31.2 Thyroid 11.1 Breast 73. Available from: http://globocan.1 Ovary 9.1 Non−Hodgkin lymphoma(b) 4.3 Colorectum(a) 23.1 0 15 30 45 60 75 Data accessed on 15 Nov 2015. b Includes HIV disease resulting in malignant neoplasms (B21). Cancer Incidence and Mortality Worldwide: IARC CancerBase No.4 Colorectum(a) 14.1 Stomach 6.6 Cervix uteri 14.1 Stomach 7.

000 women Data accessed on 15 Nov 2015.9 Ovary 4.2 Stomach 9.9 Corpus uteri 3.2 Stomach 6. a Includes anal cancer (C21).2 Ovary 6.1 Colorectum(a) 14.3 Non−Hodgkin lymphoma(b) 7.4 Non−Hodgkin lymphoma(b) 3.8 Stomach 3.6 Colorectum(a) 5.1 Corpus uteri 8.4 0 15 30 45 60 75 0 15 30 45 60 75 Age−standardised incidence rate per 100.2 Colorectum(a) 17.1 Corpus uteri 5.3 Thyroid 12.9 Lung 20.4 Kaposi sarcoma(c) 2.6 Colorectum(a) 23.6 Colorectum(a) 29.9 Oesophagus 3.0 Corpus uteri 12.8 Non−Hodgkin lymphoma(b) 9.19 - Figure 13: Comparison of the ten most frequent cancers in all women by World and continents (esti- mates for 2012) World Asia Breast 43.9 Non−Hodgkin lymphoma(b) 5.4 Melanoma of skin 6.7 Cervix uteri 14.6 Breast 79.9 Cervix uteri 27.8 Corpus uteri 13.0 Non−Hodgkin lymphoma(b) 4.3 Corpus uteri 12.7 Lung 13.8 Lung 15.2 Breast 69.6 Melanoma of skin 25.1 Breast 29.9 Ovary 6.1 Oesophagus 4.5 Cervix uteri 14.3 0 15 30 45 60 75 0 15 30 45 60 75 Africa Europe Breast 36.5 Thyroid 7.2 Lung 21.6 Leukaemia 6.0 Lung 12.0 (HIV disease resulting in Kaposi sarcoma).9 0 15 30 45 60 75 0 15 30 45 60 75 Americas Oceania Breast 67.6 Colorectum(a) 11.8 Cervix uteri 11. (Continued on next page) ICO HPV Information Centre .1 Ovary 5.0 Leukaemia 5.3 Cervix uteri 12.3 Stomach 7.8 Ovary 9. c Includes B21.2 Ovary 8.4 Thyroid 5.5 Liver 6.1 Liver 5.0 Liver 5.1 Thyroid 11.9 Thyroid 6.0 Cervix uteri 10. b Includes HIV disease resulting in malignant neoplasms (B21).3 BURDEN OF HPV RELATED CANCERS .5 Melanoma of skin 8.

France: International Agency for Research on Cancer.000 women Breast 19. Eser S.8 Colorectum(a) 2. 2013. Mathers C. 11 [Internet]. nervous system 1.0 Cervix uteri 11. Parkin DM.5 Ovary 4.1 Leukaemia 2.6 Brain. 2013.5 Non−Hodgkin lymphoma(b) 2. Forman D. Soerjomataram I.fr.8 Thyroid 11.2 Colorectum(a) 4. a Includes anal cancer (C21).7 Ovary 3.1 Melanoma of skin 8. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Dikshit R.7 Hodgkin lymphoma 2. nervous system 2.1 Corpus uteri 3.8 Thyroid 5.3 BURDEN OF HPV RELATED CANCERS . Forman D.7 Lung 1. Rebelo M. Available from: http://globocan. Ervik M. GLOBOCAN 2012 v1.2.9 Non−Hodgkin lymphoma(b) 1. Parkin DM. Data sources: Ferlay J.0 Brain.iarc. GLOBOCAN 2012 v1. ICO HPV Information Centre .2 Colorectum(a) 2. Soerjomataram I.2.20 - ( Figure 13 – continued from previous page) Data sources: Ferlay J. France: International Agency for Research on Cancer. Lyon. Dikshit R.5 Non−Hodgkin lymphoma(b) 1. Bray F.8 Corpus uteri 2.4 Leukaemia 2. Eser S.7 Ovary 2. Available from: http://globocan.6 Stomach 1. 11 [Internet].iarc.7 0 10 20 30 40 0 10 20 30 40 Less developed regions Age−standardised incidence rate per 100. Bray F. Rebelo M.1 Corpus uteri 2.4 Brain.0 Cervix uteri 11.4 0 10 20 30 40 Data accessed on 15 Nov 2015. b Includes HIV disease resulting in malignant neoplasms (B21).8 Breast 37. Lyon. Ervik M. Figure 14: Comparison of the ten most frequent cancers in women aged 15-44 years by World developing and developed regions (estimates for 2012) World More developed regions Breast 21. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Mathers C. nervous system 1.1 Cervix uteri 11.0 Thyroid 4.fr.

5 Brain.8 Leukaemia 1. nervous system 1.2 Thyroid 1.1 Ovary 3.2 Brain.6 Hodgkin lymphoma 3.0 Colorectum(a) 2.3 Lip.6 Stomach 1. oral cavity 0. nervous system 1.2 Kaposi sarcoma(c) 3. (Continued on next page) ICO HPV Information Centre .8 Cervix uteri 11.0 Leukaemia 2.9 Thyroid 11.7 Brain.5 Thyroid 5.1 Cervix uteri 9. a Includes anal cancer (C21).5 Corpus uteri 2.7 Non−Hodgkin lymphoma(b) 2.3 Breast 35.000 women Data accessed on 15 Nov 2015.2 Breast 37.6 Corpus uteri 2.8 Thyroid 5.7 Lung 1.2 Ovary 4.7 Melanoma of skin 3.8 Liver 1.4 Non−Hodgkin lymphoma(b) 2.6 Colorectum(a) 4.5 0 10 20 30 40 0 10 20 30 40 Africa Europe Breast 20.5 Corpus uteri 2.5 Lung 1.4 Corpus uteri 2.8 Breast 18.5 Cervix uteri 13.6 Colorectum(a) 3. nervous system 2.2 Leukaemia 2.2 Cervix uteri 12.2 Ovary 3. b Includes HIV disease resulting in malignant neoplasms (B21).2 Colorectum(a) 2.5 Lip.3 Non−Hodgkin lymphoma(b) 2.4 Non−Hodgkin lymphoma(b) 2.3 Hodgkin lymphoma 2.5 Corpus uteri 2. nervous system 2.5 0 10 20 30 40 0 10 20 30 40 Americas Oceania Breast 27.3 Ovary 5.7 Non−Hodgkin lymphoma(b) 1.4 0 10 20 30 40 0 10 20 30 40 Age−standardised incidence rate per 100.1 Colorectum(a) 1.0 Cervix uteri 12.3 Melanoma of skin 15. c Includes B21.0 Ovary 2.8 Thyroid 12.0 (HIV disease resulting in Kaposi sarcoma).21 - Figure 15: Comparison of the ten most frequent cancers in women aged 15-44 years by World and continents (estimates for 2012) World Asia Breast 21.7 Brain.4 Thyroid 7.9 Colorectum(a) 3.1 Leukaemia 2.9 Melanoma of skin 8.2 Cervix uteri 15.3 BURDEN OF HPV RELATED CANCERS .1 Ovary 3. oral cavity 2.

iarc. Ervik M. Bray F. developed and developing regions and five continents World Asia Africa Europe Americas Oceania Age−specific rates of cervical cancer per 100. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Dikshit R.3 BURDEN OF HPV RELATED CANCERS . Data sources: Ferlay J. Bray F. Parkin DM.2. GLOBOCAN 2012 v1. Ervik M. Forman D. Available from: http://globocan.000 women per year. Available from: http://globocan. Rebelo M. Eser S. Eser S. Mathers C. 11 [Internet]. ICO HPV Information Centre . Lyon. Dikshit R. France: International Agency for Research on Cancer. Forman D. Soerjomataram I. Soerjomataram I. Rebelo M. Mathers C. 2013. Rates per 100.fr. 2013.22 - ( Figure 15 – continued from previous page) Data sources: Ferlay J. 11 [Internet]. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Lyon. Parkin DM.000 100 75 50 25 0 19 0−24 5−29 0−34 5−39 0−44 5−49 0−54 5−59 0−64 5−69 0−74 >=75 15− 2 2 3 3 4 4 5 5 6 6 7 Age group (years) Data accessed on 15 Nov 2015.2. Figure 16: Age-specific incidence of cervical cancer by World. GLOBOCAN 2012 v1.iarc. France: International Agency for Research on Cancer.fr.

* Americas 15-39 years: 22725 cases. 40-64 years: 188892 cases. Data accessed on 15 Nov 2015. 40-64 years: 42915 cases. * More developed regions 15-39 years: 19757 cases. 65+ years: 343 cases.23 - Figure 17: Annual number of new cases of cervical cancer by age group in developing and developed regions and five continents World (estimates for 2012) DEVELOPED AND DEVELOPING REGIONS Less developed regions More developed regions Annual number of new cases of cervical cancer 350000 323619* 315000 280000 245000 210000 175000 140000 111503* 105000 92337* 70000 35000 0 15−39 40−64 65+ FIVE CONTINENTS Asia Americas Oceania Africa Europe Annual number of new cases of cervical cancer 350000 323619* 315000 280000 245000 210000 175000 140000 111503* 105000 92337* 70000 35000 0 15−39 40−64 65+ * Less developed regions 15-39 years: 91746 cases. (Continued on next page) ICO HPV Information Centre . 40-64 years: 32345 cases. 40-64 years: 58316 cases. 65+ years: 17537 cases. 40-64 years: 278880 cases. 65+ years: 21014 cases. * Europe 15-39 years: 13249 cases. * Africa 15-39 years: 19650 cases. 65+ years: 73762 cases.3 BURDEN OF HPV RELATED CANCERS . 65+ years: 12775 cases. 40-64 years: 1151 cases. 65+ years: 18575 cases. * Asia 15-39 years: 55178 cases. 40-64 years: 44739 cases. * Oceania 15-39 years: 701 cases. 65+ years: 40668 cases.

Parkin DM. Dikshit R.2.24 - ( Figure 17 – continued from previous page) Data sources: Ferlay J.iarc. Rebelo M.fr. Lyon. Mathers C. Available from: http://globocan. Forman D. Eser S. ICO HPV Information Centre . Soerjomataram I. France: International Agency for Research on Cancer. Ervik M. 11 [Internet]. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 2013. GLOBOCAN 2012 v1.3 BURDEN OF HPV RELATED CANCERS . Bray F.

Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Mathers C. 2013. Forman D. 40-44 yrs: 66308 cases.iarc. 35-39 yrs: 8686 cases. 20-24 yrs: 6445 cases. 11 [Internet].25 - Figure 18: Annual number of cases and age-specific incidence rates of cervical cancer in the World and its regions (estimates for 2012) World Africa Age−specific rates of cervical cancer(a) 90 90 60 60 ● ● ● ● ● ● ● ● ● ● 30 ● ● ● ● 30 ● ● ● ● ● ● ● ● 0 ● ● ● 0 ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 324000 323619* 190000 270000 Annual number of cases 152000 of cervical cancer 216000 114000 162000 111503* 76000 108000 92337 58316* 54000 38000 19637* 21014 0 0 15−39 40−64 65+ 15−39 40−64 65+ * World 15-19 yrs: 754 cases. a Rates per 100. Data accessed on 15 Nov 2015. 25-29 yrs: 3310 cases. Bray F. 30-34 yrs: 6198 cases.000 women per year. ICO HPV Information Centre . Ervik M. 45-49 yrs: 11987 cases. 55-59 yrs: 63571 cases. Lyon.3 BURDEN OF HPV RELATED CANCERS . 55-59 yrs: 12342 cases. Dikshit R.fr. France: International Agency for Research on Cancer. Parkin DM. 30-34 yrs: 34149 cases. 50-54 yrs: 12753 cases. 60-64 yrs: 48941 cases. GLOBOCAN 2012 v1. 60-64 yrs: 10760 cases. 40-44 yrs: 10474 cases. Soerjomataram I. 45-49 yrs: 73307 cases.2. 35-39 yrs: 50988 cases. Eser S. 20-24 yrs: 1091 cases. 25-29 yrs: 19167 cases. 50-54 yrs: 71492 cases. Data sources: Ferlay J. * Africa 15-19 yrs: 352 cases. Rebelo M. Available from: http://globocan.

20-24 yrs: 2047 cases. 45-49 yrs: 7020 cases. Data accessed on 15 Nov 2015. (Continued on next page) ICO HPV Information Centre .3 BURDEN OF HPV RELATED CANCERS . 45-49 yrs: 278 cases. 40-44 yrs: 317 cases. 55-59 yrs: 7771 cases. 55-59 yrs: 36759 cases. 60-64 yrs: 140 cases. 20-24 yrs: 2443 cases. 25-29 yrs: 2639 cases. 40-44 yrs: 6449 cases. 50-54 yrs: 42416 cases. 30-34 yrs: 6901 cases. 60-64 yrs: 5221 cases. 35-39 yrs: 27561 cases. 35-39 yrs: 5548 cases. * Europe 15-19 yrs: 22 cases. 60-64 yrs: 6514 cases. * Asia 15-19 yrs: 195 cases. 25-29 yrs: 4668 cases. 40-44 yrs: 39251 cases. 20-24 yrs: 798 cases. 20-24 yrs: 60 cases. 30-34 yrs: 16585 cases. 45-49 yrs: 44160 cases. 30-34 yrs: 208 cases. 25-29 yrs: 8394 cases. 50-54 yrs: 235 cases. 35-39 yrs: 8883 cases. 25-29 yrs: 144 cases. 40-44 yrs: 9817 cases. 60-64 yrs: 26306 cases. 50-54 yrs: 8951 cases. 30-34 yrs: 4235 cases.26 - Figure 19: Annual number of cases and age-specific incidence rates of cervical cancer in the World and its regions (estimates for 2012) (Continued) Americas Europe Age−specific rates of cervical cancer(a) 90 90 60 60 ● ● ● ● ● ● ● ● ● ● 30 ● ● ● ● 30 ● ● ● ● ● ● ● ● 0 ● ● ● 0 ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 190000 190000 Annual number of cases 152000 152000 of cervical cancer 114000 114000 76000 76000 42915* 38000 38000 32345* 22679* 17537 13242* 12775 0 0 15−39 40−64 65+ 15−39 40−64 65+ Asia Oceania Age−specific rates of cervical cancer(a) 90 90 60 60 ● ● ● ● ● ● ● ● ● ● 30 ● ● ● ● 30 ● ● ● ● ● ● ● ● 0 ● ● ● 0 ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 190000 188892* 190000 Annual number of cases 152000 152000 of cervical cancer 114000 114000 76000 76000 55178* 40668 38000 38000 0 0 696* 1151* 343 15−39 40−64 65+ 15−39 40−64 65+ * Americas 15-19 yrs: 180 cases. 55-59 yrs: 6518 cases. 35-39 yrs: 280 cases. 55-59 yrs: 181 cases. * Oceania 15-19 yrs: 4 cases. 45-49 yrs: 9862 cases. 50-54 yrs: 7137 cases.

France: International Agency for Research on Cancer. Lyon.fr.iarc. Eser S. Rebelo M. NOTE. Dikshit R.27 - ( Figure 19 – continued from previous page) a Rates per 100.3 BURDEN OF HPV RELATED CANCERS . Bray F.000 women per year. Forman D. ICO HPV Information Centre . Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Data sources: Ferlay J. GLOBOCAN 2012 v1. Mathers C. Soerjomataram I. Ervik M. Parkin DM. please refer to individual country data. 11 [Internet].2. 2013. For time trends in cervical cancer incidence. Available from: http://globocan.

South Sudan: Estimate for Sudan and South Sudan Data sources: Ferlay J. Available from: http://globocan. Bray F.3 BURDEN OF HPV RELATED CANCERS . ASR: Age-standardized rate. Dikshit R.2 Mortality KEY STATS. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon.2.28 - 3. Rebelo M. Mathers C. Eser S. For Sudan. Cervical cancer ranks* as the 4 th leading cause of female cancer deaths in the World. Standardized rates have been estimated using the direct method and the World population as the reference.iarc.1. Rates per 100. 2013. GLOBOCAN 2012 v1. * Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st). Ervik M. France: International Agency for Research on Cancer.000 women per year. ICO HPV Information Centre . About 265. Ranking using age-standardized rate (ASR) may differ. Cervical cancer is the 2nd most common female cancer deaths in women aged 15 to 44 years in the World. Forman D. Parkin DM. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Figure 20: Age-standardised mortality rates of cervical cancer in the World (estimates for 2012) Data accessed on 15 Nov 2015.fr.672 new cervical cancer deaths occur annually in the World (estimations for 2012). Soerjomataram I.

0 17.197 15.4 0.9 2.2 2.526 4. Standardised rates have ben estimated using the direct method and the World population as the reference.9 0.9 27.5 8.374 9.3 0. Bray F.8 22.5 8. For cancer.320 4. Parkin DM.4 3.6 3.6 0. 2013. Dikshit R.6 4 2 Data accessed on 15 Nov 2015.6 0.6 1.108 4.4 8 8 Southern Africa 4. Ranking using AST may differ.958 9.2 11 9 Europe 24.8 5.479 3.0 2 2 Eastern Africa 28.6 5 2 Caribbean 2.1 1 1 Middle Africa 7.6 4. 35.9 3 2 gions More developed re.8 4 2 Less developed re. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.9 1.158 8.2 17 5 Zealand Melanesia 684 15.1 0.9 7. Rebelo M. 230.4 2.4 5.0 1.6 1.673 7. GLOBOCAN 2012 v1.9 1 1 Western Africa 16.3 8 2 Southern Asia 79. Soerjomataram I.2.0 2.063 5.937 8.0 2 1 Northern America 7.7 6 2 Central Asia 2.2 0.098 11. Mathers C.2 0.4 18.iarc.2 13 3 Western Europe 3. ICO HPV Information Centre .717 2.2 2 2 South-Eastern 23. Forman D. Ranking is based on crude mortality rates(actual number of cervical cancer deaths).436 9.4 0.2 16 2 Southern Europe 3.4 7 2 Eastern Europe 15.3 20.5 0. Available from: http://globocan.8 0. Ranking of cervical cancer mortality to other cancers among all women ages 15-44 years according to highest mortality rates (ranking 1st).672 7.3 0.8 0. France: International Agency for Research on Cancer.fr. 11 [Internet].434 7.9 0.9 1.5 0.2 0.514 5.6 1 2 Northern Africa 2.9 4 2 Central America 6.6 3.2 2.2 15 4 Oceania 1.881 1.6 0.404 6.721 16.6 8.989 7. Data sources: 1 Ferlay J.7 3. b Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years.9 3 2 Asia 144.8 0.7 0.1 8.3 0.4 5 12 Polynesia 16 4. a Rates per 100.7 2.254 10.2 7. Eser S.3 9 2 gions Africa 60.2 17.6 3.2 1 1 Micronesia 6 2.963 3.6 6.0 6.5 2.917 11.000 women per year.3 BURDEN OF HPV RELATED CANCERS .1 2 2 Americas 35.9 6.29 - Table 6: Cervical cancer mortality by World region and sub regions (estimates for 2012) Cumulative risk (%) Ranking of CC Area N cases Crude ratea ASRa ages 0-74 yearsb All women Women 15-44 years World 265.3 11 2 South America 19.9 3 2 Asia Western Asia 1. Ervik M.286 7.9 0.5 2. Lyon. it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.8 3 2 Eastern Asia 36.5 6 2 Australia & New 357 2.6 1.7 0.546 10.4 11.6 7 1 Northern Europe 1.

fr. Ervik M. Data sources: Ferlay J. Soerjomataram I. Lyon. GLOBOCAN 2012 v1. Available from: http://globocan. according to mortality rates in the World (estimates for 2012) Data accessed on 15 Nov 2015. Eser S.3 BURDEN OF HPV RELATED CANCERS . 2013. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Dikshit R. Parkin DM.30 - Figure 21: Ranking of cervical cancer versus other cancers among all women and women aged 15-44 years. Mathers C. Bray F.2.iarc. 11 [Internet]. France: International Agency for Research on Cancer. Rebelo M. ICO HPV Information Centre . Forman D.

8 Australia & New Zealand 1. Rebelo M.7 Western Africa 18. Ervik M.iarc.9 Western Europe 1. France: International Agency for Research on Cancer.6 Caribbean 8. Soerjomataram I.3 Eastern Africa 27.31 - Figure 22: World age-standardised mortality rates of cervical cancer by World and sub regions World (estimates for 2012) World.3 Northern Africa 3. Mathers C.7 Eastern Europe 6. Rates per 100.5 Europe 3.5 Eastern Asia 3.4 Northern Europe 2.2 Five continents Polynesia 5.9 Southern Asia 11.4 Micronesia 2. Parkin DM.000 women World Standard. Eser S.9 South America 8. ICO HPV Information Centre . Lyon. 11 [Internet]. 2013. Forman D.6 More developed 3.2 Asia 6. Female (All ages) Data accessed on 15 Nov 2015. Data sources: Ferlay J.2 Oceania 4. Bray F.1 Africa 17.fr. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.7 Northern America 2.5 Western Asia 1. GLOBOCAN 2012 v1. Dikshit R.0 Central America 8.2.2 Melanesia 20.3 South−Eastern Asia 7.9 0 10 Central Asia 7.6 Middle Africa 22. Available from: http://globocan.9 Southern Europe 2.000 women per year.3 BURDEN OF HPV RELATED CANCERS .6 Americas 5.5 World 6.8 0 10 20 0 10 20 30 Cervical cancer: Age−standardised mortality rate per 100.8 Southern Africa 17. developed and developing regions Continental sub−regions Less developed 8.

3 Pancreas 3.1 Leukaemia 2. Eser S. Dikshit R. Bray F.9 Lung 11. Forman D. Mathers C.1 Lung 14. Available from: http://globocan.1 Stomach 4.8 Cervix uteri 8.6 Ovary 3.6 Pancreas 2.9 Breast 14.8 Pancreas 5.fr. Parkin DM. GLOBOCAN 2012 v1.7 Ovary 5. 11 [Internet]. 2013. Lyon.3 Stomach 6.4 Leukaemia 2.5 Lung 9. Data sources: Ferlay J.0 Liver 5.2 Ovary 3. ICO HPV Information Centre .9 Colorectum(a) 9.3 BURDEN OF HPV RELATED CANCERS .8 Leukaemia 2. a Includes anal cancer (C21).3 Colorectum(a) 6. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. France: International Agency for Research on Cancer.7 Liver 2.3 Cervix uteri 6.4 Colorectum(a) 5. Soerjomataram I. Rebelo M. Ervik M.000 women Breast 11. nervous system 2.8 Brain.5 Liver 6.7 Cervix uteri 3.3 0 5 10 15 20 25 Data accessed on 15 Nov 2015.6 Oesophagus 3.7 Oesophagus 2.5 0 5 10 15 20 25 0 5 10 15 20 25 Less developed regions Age−standardised mortality rate per 100.iarc.32 - Figure 23: Comparison of the ten most frequent cancer deaths in all women in the World compared to developing and developed regions (estimates for 2012) World More developed regions Breast 12.5 Stomach 5.2.

4 Leukaemia 2.4 Liver 2.1 Breast 17.7 Oesophagus 3.1 Colorectum(a) 7.000 women Data accessed on 15 Nov 2015.9 Pancreas 5.9 Leukaemia 3.3 BURDEN OF HPV RELATED CANCERS .2 Ovary 5. Data sources: (Continued on next page) ICO HPV Information Centre .7 Leukaemia 2.8 Liver 6.8 Liver 5.2 Colorectum(a) 6.4 Ovary 3. a Includes anal cancer (C21).4 Liver 5.9 Colorectum(a) 4.0 Cervix uteri 3.9 Liver 3.4 Colorectum(a) 8. nervous system 2. nervous system 2.2 Cervix uteri 5.6 Oesophagus 2.0 Leukaemia 2.6 0 5 10 15 20 25 0 5 10 15 20 25 Americas Oceania Lung 15.8 Leukaemia 2.0 Lung 11.9 Lung 11.7 Pancreas 2.7 Cervix uteri 6.8 Non−Hodgkin lymphoma(b) 2.33 - Figure 24: Comparison of the ten most frequent cancer deaths in all women in the World compared to the continents (estimations for 2012) World Asia Breast 12.3 Oesophagus 3.6 Stomach 3.6 0 5 10 15 20 25 0 5 10 15 20 25 Age−standardised mortality rate per 100.8 Lung 2.4 Ovary 3.8 Pancreas 5.5 Stomach 3.5 Breast 16.1 Cervix uteri 6.6 Brain.5 0 5 10 15 20 25 0 5 10 15 20 25 Africa Europe Cervix uteri 17.6 Stomach 5. b Includes HIV disease resulting in malignant neoplasms (B21).6 Colorectum(a) 9.3 Stomach 4.1 Breast 10.9 Ovary 4.0 Leukaemia 2.7 Non−Hodgkin lymphoma(b) 2.6 Ovary 4.9 Brain.0 Ovary 3.3 Lung 11.0 Pancreas 4.9 Breast 15.3 Cervix uteri 4.1 Colorectum(a) 6.9 Stomach 7.3 Brain.0 Lung 14.8 Pancreas 3. nervous system 3.4 Corpus uteri 2.6 Breast 14.

Eser S. Available from: http://globocan.5 Lung 1. Mathers C. Bray F. Forman D. 11 [Internet].7 Non−Hodgkin lymphoma(b) 0. Rebelo M.2 Colorectum(a) 1. Dikshit R. Eser S. GLOBOCAN 2012 v1. Ervik M.4 Breast 4.9 Brain. Mathers C.9 Stomach 1.000 women Breast 5. nervous system 0. b Includes HIV disease resulting in malignant neoplasms (B21). ICO HPV Information Centre .2. Dikshit R.1 Lung 0.34 - ( Figure 24 – continued from previous page) Ferlay J.iarc. a Includes anal cancer (C21). Cancer Incidence and Mortality Worldwide: IARC CancerBase No.1 Brain. nervous system 0.iarc. Ervik M. Lyon. France: International Agency for Research on Cancer.2 Cervix uteri 2. 2013.1 Liver 1. 2013.6 Colorectum(a) 1. Parkin DM. 11 [Internet].2 Cervix uteri 3. GLOBOCAN 2012 v1. France: International Agency for Research on Cancer.8 Non−Hodgkin lymphoma(b) 0.2.9 Melanoma of skin 0.1 Ovary 1. Data sources: Ferlay J. Parkin DM. Forman D.fr.3 BURDEN OF HPV RELATED CANCERS .7 0 5 10 15 Data accessed on 15 Nov 2015.4 0 5 10 15 0 5 10 15 Less developed regions Age−standardised mortality rate per 100.4 Leukaemia 1.6 Non−Hodgkin lymphoma(b) 0. nervous system 1.0 Colorectum(a) 1. Available from: http://globocan.0 Stomach 0.1 Ovary 1.1 Liver 1.fr.6 Cervix uteri 3. Rebelo M. Soerjomataram I. Figure 25: Comparison of the ten most frequent cancer deaths in women aged 15-44 years by World. developing and developed regions (estimates for 2012) World More developed regions Breast 5. Soerjomataram I.1 Ovary 1. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.0 Leukaemia 0. Lyon.1 Stomach 1. Bray F.8 Brain.0 Lung 1.2 Leukaemia 1.

7 Liver 0. nervous system 0.1 Liver 1.0 Ovary 1.1 Stomach 1.2 Stomach 1.35 - Figure 26: Comparison of the ten most frequent cancer deaths in women aged 15-44 years by World and continents (estimates for 2012) World Asia Breast 5.0 Breast 5.0 Cervix uteri 3.9 Stomach 0.7 0 5 10 15 0 5 10 15 Age−standardised mortality rate per 100.3 BURDEN OF HPV RELATED CANCERS .1 Liver 1.0 Leukaemia 1.4 Liver 1.7 Colorectum(a) 1.6 Cervix uteri 3. nervous system 0. nervous system 1.4 Breast 5.9 Ovary 1.9 Brain.8 Ovary 0.1 Colorectum(a) 1.8 Breast 4.2 Colorectum(a) 0.4 Non−Hodgkin lymphoma(b) 0.1 Leukaemia 1.5 Ovary 1.0 Liver 1.2 Leukaemia 0. (Continued on next page) ICO HPV Information Centre .8 Lung 1.7 Oesophagus 0.9 Melanoma of skin 0.5 0 5 10 15 0 5 10 15 Americas Oceania Breast 4. nervous system 0.3 Non−Hodgkin lymphoma(b) 1.7 Leukaemia 1.4 Cervix uteri 5.6 Brain.1 Colorectum(a) 1.0 Colorectum(a) 1.3 Cervix uteri 3.7 Leukaemia 1.1 Lung 1.9 Brain.2 Ovary 1. a Includes anal cancer (C21).2 Cervix uteri 2. nervous system 1. nervous system 0.1 Stomach 1.4 Brain.0 Lung 1.5 Ovary 1.1 Stomach 1.8 Non−Hodgkin lymphoma(b) 0.0 (HIV disease resulting in Kaposi sarcoma).7 Brain.9 Non−Hodgkin lymphoma(b) 0.6 Lip.000 women Data accessed on 15 Nov 2015. c Includes B21.5 Leukaemia 1.5 Kaposi sarcoma(c) 1. oral cavity 0.0 Brain.6 Melanoma of skin 0.3 Cervix uteri 2.2 Colorectum(a) 1.5 Stomach 0. b Includes HIV disease resulting in malignant neoplasms (B21).0 Lung 0.5 0 5 10 15 0 5 10 15 Africa Europe Breast 8.

Eser S. Lyon. Rebelo M. 2013. Soerjomataram I. Figure 27: Age-specific mortality of cervical cancer by World and continents World Asia Africa Europe Americas Oceania Age−specific mortality rates of cervical cancer per 100. GLOBOCAN 2012 v1.2. Dikshit R. Data sources: Ferlay J. Forman D.000 100 80 60 40 20 0 19 0−24 5−29 0−34 5−39 0−44 5−49 0−54 5−59 0−64 5−69 0−74 >=75 15− 2 2 3 3 4 4 5 5 6 6 7 Age group (years) Data accessed on 15 Nov 2015. GLOBOCAN 2012 v1. Parkin DM. Rebelo M. 11 [Internet].3 BURDEN OF HPV RELATED CANCERS . Soerjomataram I.fr. 11 [Internet]. Mathers C.fr. Available from: http://globocan. Mathers C. Ervik M.000 women per year. France: International Agency for Research on Cancer.iarc. Dikshit R.2. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Available from: http://globocan. ICO HPV Information Centre . Parkin DM. Rates per 100. Eser S. Bray F. France: International Agency for Research on Cancer.36 - ( Figure 26 – continued from previous page) Data sources: Ferlay J. Ervik M. Forman D. Bray F. Lyon. 2013.iarc.

40-64 years: 16950 cases. 40-64 years: 134922 cases. * Oceania 15-39 years: 189 cases. * Americas 15-39 years: 4168 cases. 40-64 years: 88208 cases. 65+ years: 42647 cases. * Europe 15-39 years: 2212 cases. 65+ years: 15493 cases. * Asia 15-39 years: 13567 cases. 40-64 years: 545 cases.3 BURDEN OF HPV RELATED CANCERS . 40-64 years: 11779 cases. 40-64 years: 33320 cases. 65+ years: 329 cases. 40-64 years: 18020 cases. 65+ years: 10413 cases. * Africa 15-39 years: 8065 cases.37 - Figure 28: Annual number of deaths of cervical cancer by age group by developing and developed regions and continents (estimates for 2012) DEVELOPED AND DEVELOPING REGIONS Less developed regions More developed regions Annual number of cervical cancer deaths 200000 180000 160000 151872* 140000 120000 100000 85534* 80000 60000 40000 28201* 20000 0 15−39 40−64 65+ FIVE CONTINENTS Asia Americas Oceania Africa Europe Annual number of cervical cancer deaths 200000 180000 160000 151872* 140000 120000 100000 85534* 80000 60000 40000 28201* 20000 0 15−39 40−64 65+ * Less developed regions 15-39 years: 25130 cases. Data accessed on 15 Nov 2015. 65+ years: 18669 cases. * More developed regions 15-39 years: 3071 cases. (Continued on next page) ICO HPV Information Centre . 65+ years: 13476 cases. 65+ years: 70041 cases.

3 BURDEN OF HPV RELATED CANCERS . GLOBOCAN 2012 v1. Bray F. Forman D.38 - ( Figure 28 – continued from previous page) Data sources: Ferlay J. France: International Agency for Research on Cancer. Available from: http://globocan. Parkin DM. Soerjomataram I. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Dikshit R. Rebelo M. Mathers C. ICO HPV Information Centre . Lyon. Ervik M. 11 [Internet].iarc.fr. 2013. Eser S.2.

Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Data sources: Ferlay J. Soerjomataram I. 60-64 yrs: 7601 cases. Ervik M. 2013. 20-24 yrs: 1101 cases. Forman D.000 women per year. France: International Agency for Research on Cancer. 45-49 yrs: 30105 cases. Parkin DM. Dikshit R. Bray F. 35-39 yrs: 3551 cases.2. 40-44 yrs: 4707 cases. GLOBOCAN 2012 v1. 35-39 yrs: 14974 cases. 30-34 yrs: 2360 cases. Available from: http://globocan. Eser S. Africa 15-19 yrs: 265 cases. 55-59 yrs: 7801 cases. Mathers C. ICO HPV Information Centre . 30-34 yrs: 8158 cases. Lyon. 40-44 yrs: 22872 cases. 50-54 yrs: 33939 cases. 45-49 yrs: 6021 cases.iarc. 25-29 yrs: 3654 cases. 25-29 yrs: 1331 cases.39 - Figure 29: Annual number of deaths and age-specific mortality rates of cervical cancer in the World and its regions (estimates for 2012) World Africa Age−specific rates of cervical cancer(a) 90 90 75 75 60 60 45 45 30 ● ● ● ● ● 30 ● ● ● ● ● ● ● 15 ● ● ● 15 ● ● ● ● ● 0 ● ● ● ● 0 ● ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 156000 151872* 144000 84000 Annual number of deaths 132000 120000 72000 of cervical cancer 108000 60000 96000 85534 84000 48000 72000 60000 36000 33320* 48000 36000 24000 18669 28201* 24000 12000 8060* 12000 0 0 15−39 40−64 65+ 15−39 40−64 65+ World 15-19 yrs: 314 cases. a Rates per 100. Rebelo M.fr. 50-54 yrs: 7190 cases. Data accessed on 15 Nov 2015.3 BURDEN OF HPV RELATED CANCERS . 60-64 yrs: 30693 cases. 55-59 yrs: 34263 cases. 20-24 yrs: 553 cases. 11 [Internet].

3 BURDEN OF HPV RELATED CANCERS .fr. 20-24 yrs: 137 cases. Mathers C. France: International Agency for Research on Cancer. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 40-44 yrs: 107 cases. Available from: http://globocan. 45-49 yrs: 111 cases. 30-34 yrs: 56 cases. 35-39 yrs: 1131 cases. 55-59 yrs: 3944 cases. 60-64 yrs: 3598 cases. Rebelo M. Ervik M. 2013.iarc. 50-54 yrs: 2647 cases. Parkin DM.000 women per year. 55-59 yrs: 19563 cases. ICO HPV Information Centre . 35-39 yrs: 80 cases.40 - Figure 30: Annual number of deaths and age-specific mortality rates of cervical cancer in the World and its regions (estimates for 2012) (Continued) Americas Europe Age−specific rates of cervical cancer(a) 90 90 75 75 60 60 45 45 30 ● ● ● ● ● ● 30 ● ● ● ● ● ● 15 ● ● ● 15 ● ● ● ● ● 0 ● ● ● ● 0 ● ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 84000 84000 Annual number of deaths 72000 72000 of cervical cancer 60000 60000 48000 48000 36000 36000 24000 24000 18020* 13476 11779* 10413 12000 12000 4161* 2212* 0 0 15−39 40−64 65+ 15−39 40−64 65+ Asia Oceania Age−specific rates of cervical cancer(a) 90 90 75 75 60 60 45 45 30 ● ● ● ● ● ● 30 ● ● ● ● ● ● 15 ● ● ● 15 ● ● ● ● ● 0 ● ● ● ● 0 ● ● ● ● 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 75+ 88208* 84000 84000 Annual number of deaths 72000 72000 of cervical cancer 60000 60000 48000 42647 48000 36000 36000 24000 24000 13567* 12000 12000 0 0 189* 545* 329 15−39 40−64 65+ 15−39 40−64 65+ Americas 15-19 yrs: 12 cases. 55-59 yrs: 2850 cases. 45-49 yrs: 18256 cases. 45-49 yrs: 3629 cases. 60-64 yrs: 16765 cases. 60-64 yrs: 100 cases. 20-24 yrs: 32 cases. Asia 15-19 yrs: 34 cases. 35-39 yrs: 2067 cases. Data sources: Ferlay J.2. 50-54 yrs: 122 cases. 50-54 yrs: 3997 cases. 50-54 yrs: 19983 cases. 25-29 yrs: 620 cases. Soerjomataram I. 30-34 yrs: 3699 cases. 40-44 yrs: 13641 cases. Lyon. 60-64 yrs: 2629 cases. 40-44 yrs: 1565 cases. GLOBOCAN 2012 v1. 25-29 yrs: 332 cases. 11 [Internet]. Forman D. 45-49 yrs: 2088 cases. Europe 15-19 yrs: 2 cases. Oceania 15-19 yrs: 1 cases. a Rates per 100. 25-29 yrs: 1333 cases. 30-34 yrs: 715 cases. Dikshit R. 30-34 yrs: 1325 cases. 20-24 yrs: 363 cases. 35-39 yrs: 8138 cases. Bray F. 20-24 yrs: 16 cases. 25-29 yrs: 36 cases. Data accessed on 15 Nov 2015. 55-59 yrs: 105 cases. Eser S. 40-44 yrs: 2852 cases.

1.3 BURDEN OF HPV RELATED CANCERS . Mathers C. Lyon. GLOBOCAN 2012 v1. ICO HPV Information Centre . Parkin DM. Rebelo M. Bray F. 2013. 11 [Internet].3 Comparison of incidence and mortality Figure 31: Age-specific incidence and mortality rates of cervical cancer in the World and its regions (estimates for 2012) Africa Europe 110 110 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 of cervical cancer per 100.2. Rates per 100.000 women per year. Ervik M. Dikshit R.000 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 Age−specific rates 110 Americas 110 Oceania 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 0 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 110 Asia 100 90 80 70 60 50 40 30 20 10 0 15−19 20−24 25−29 30−34 35−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 Incidence Mortality Data accessed on 15 Nov 2015. Forman D. Soerjomataram I. Eser S. Data sources: Ferlay J.fr. Available from: http://globocan.iarc. France: International Agency for Research on Cancer.41 - 3. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.

For Australia. Philippines. Sri Lanka. Djibouti. Slovenia. Vignat J. Turkey.000 per year. South Sudan. Azerbaijan. Solomon Islands. Bolivia. Senegal. Tajikistan. New Zealand. Estonia. Ghana. Lebanon. Croatia. Togo: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Equatorial Guinea. Luxembourg. Guam. Central African Republic. New Caledonia. Spain. French Guiana. Singapore. Estonia. Western Sahara. Albania. GLOBOCAN quality index for availability of incidence data: .For United Arab Emirates. Madagascar. Guinea-Bissau. Sierra Leone. Cyprus. Thailand: High quality regional (coverage between 10% and 50%). Zambia: One cancer registry covering part of a country is used as representative of the country profile . Sri Lanka. Burkina Faso. Fiji. Romania. Angola. Austria. Iraq. Burundi. Uganda. Zimbabwe: Estimated as the weighted average of the local rates Data sources: de Martel C. Montenegro. Angola. Honduras. United Kingdom. Russian Federation. Montenegro. Namibia. Netherlands. Madagascar. USA. Tunisia. Worldwide burden of cancer attributable to HPV by site. Guyana. Vanuatu: Estimated from national mortality estimates using modelled survival . Papua New Guinea. Myanmar. Bahrain. Guatemala. Iran.42 - 3. New Zealand. Malta. Guinea-Bissau. Georgia.For Burkina Faso.For Australia. Honduras. Turkmenistan. Kazakhstan. Cuba. Ecuador. Jamaica. Martinique. vaginal. Poland. Suppl 3. Kazakhstan. Cambodia. Niger. Vaccine 2012. Myanmar. Kyr- gyzstan. Japan. Belize. Mexico. Paraguay. Nigeria. IARC Monographs 2007. Reunion. Tajikistan. Zimbabwe: High quality regional (coverage lower than 10%). Finland. Mauritania. Portugal. Denmark. Israel. Botswana. Panama. Greece. Mexico. their association with HPV make them potentially preventable and subject to similar preventative strategies as those for cervical cancer. Venezuela: No data. Guadeloupe. Uruguay. Kenya. Poland: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Costa Rica.For Armenia. Swaziland. . Belarus. Trinidad & Tobago. Ireland.For Benin. Dominican Republic. DPR Korea. Nicaragua. Vol. Bulgaria. Canada. Ukraine. Côte d’Ivoire. Uzbekistan. Samoa. Mauritius. Benin. Brunei. Brazil. Italy. 2017 ICO HPV Information Centre . Other anogenital cancer cases (vulvar. . Palestine. Int J Cancer. Guyana. Portugal. Canada. USA: High quality national data or high quality regional (coverage greater than 50%). Azerbaijan. Croatia. Republic of Moldova. Solomon Islands. Indonesia. Slovakia. Suppl 10. Tunisia. Oman. Mozambique. China. Cuba. Tanzania. Spain. Bhutan. Iran. and penile). Malawi. Latvia. Syria. 90) Figure 32: Age-standardised incidence rates of other anogenital cancer in the World (estimates for 2012) Data accessed on 08 May 2017. Latvia. Bosnia & Herzegovina. Bosnia & Herzegovina.and age-specific incidence rates of cancer for a specific country: . Germany. Austria. Libya. Central African Republic. but there is an increasing body of evidence strongly linking HPV DNA with cancers of the anus. Mongolia. Republic of Korea. Mali. South Africa: National data (rates). Lithuania. vulva. China. Qatar. Peru. Russian Federation. Morocco. Liberia. Netherlands. 30. and penis. Franceschi S. (Vaccine 2006.For Algeria. New Caledonia. anal. Ireland. Colombia. Armenia. . . Rwanda. Iraq. Reunion. Switzerland. Turkmenistan. Yemen. India. Hungary. Comoros. Dominican Republic. Morocco. Vol. Chad. Swaziland. Czech Republic. Bulgaria. French Polynesia. Oman. Colombia. Saudi Arabia. Venezuela. Chile. Puerto Rico. Brazil. Slovakia. Guinea. Guam. Cambodia. Maldives. Romania. Malaysia. Norway. Martinique. Congo. Western Sahara. Laos. Nepal. South Sudan. France.For Chile. Sudan. Finland. Belgium. Liberia. Czech Republic. Haiti. Puerto Rico. Japan. Please refer to original source for methods. 24. Gabon. Gambia.3 BURDEN OF HPV RELATED CANCERS . Switzerland. Macedonia. Gabon. South Africa: Rates projected to 2012 . Niger. Tanzania. Vanuatu. Uganda. Indonesia. Côte d’Ivoire. Suriname.For Afghanistan. Egypt. Congo. Syria. Nepal. Hungary. Egypt. India. Suriname. Rwanda. Germany. Somalia.For Cameroon. Vaccine 2008. Cyprus. Barbados. Malta. Viet Nam. Panama. Iceland. Ukraine. Qatar. Vol. Guatemala. Republic of Moldova. Laos. DPR Korea.For Argentina. Nigeria. Cape Verde. Senegal. Ethiopia.For Albania. Djibouti. ASR: Age-standardized rate. Belarus. Georgia. Sweden. Eritrea. Malawi. Chad. Slovenia. Namibia. Bahamas. El Salvador. Pakistan. Mali. Guinea. Greece. Iceland. Mauritania. DR Congo. Fiji. Papua New Guinea. Bangladesh. Paraguay. country and HPV type. Barbados. Palestine. Haiti. Luxembourg.For Afghanistan. Jamaica. Kyrgyzstan.For Cameroon. Samoa: Most recent rates applied to 2012 population . Libya. Bahrain. Lebanon.For Argentina. Yemen. Lesotho. Denmark. Mauritius. Bhutan. Trinidad & Tobago. Somalia. Ethiopia. Sierra Leone. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Suppl 5. Sweden. Republic of Korea. Comoros.2 Anogenital cancers other than the cervix Data on HPV role in anogenital cancers other than the cervix are limited. Bahamas. 26. French Guiana. El Salvador. Jordan. Viet Nam. Nicaragua. Singapore. DR Congo. Kuwait. Saudi Arabia. Guadeloupe. Macedonia. Peru. Jordan. Equatorial Guinea. Maldives. Uruguay. Sudan. Zambia: Regional data (rates). Ecuador. Pakistan. Serbia: Estimated from national mortality estimates by modelling using incidence mortality ratios derived from recorded data in local cancer registries in neighbouring countries . Kenya. Ghana. Belize. Togo: Frequency data. Malaysia. Cape Verde. Burundi. France. Gambia. Philippines. Serbia. Botswana. Mongolia. Thailand. French Polynesia. Lesotho. Costa Rica. Belgium. Norway. United Kingdom. Algeria. Kuwait. Israel. Brunei. Turkey. Timor-Leste: The rates are those of neighbouring countries or registries in the same area . . Mozambique. Uzbekistan. Although these cancers are much less frequent compared to cervical cancer. . Bolivia. Eritrea. Timor-Leste. Italy. Plummer M. Lithuania. vagina. Bangladesh.For United Arab Emirates. Vol. rates per 100.

3 Gambia 0.3 Western Sahara 0.1 Mali 1.6 Guinea 0.4 South Sudan 1.3 Sudan 0.8 Niger 0.6 Liberia 0.1 Eritrea 1.** 0 0.7 Cape Verde 0.8 Namibia 0.4 Uganda 1.6 Lesotho 0.3 Morocco 0.7 Somalia 1.5 2 2.7 Côte d'Ivoire 0.1 Djibouti 1.9 South Africa 1.8 Cameroon 0.8 Swaziland 0.6 Rwanda 1.Tome & Prin.3 BURDEN OF HPV RELATED CANCERS .5 1 1.1 DR Congo 1.9 Botswana 0. rates per 100.8 Senegal 0.4 Algeria 0. (Continued on next page) ICO HPV Information Centre . ASR: Age-standardized rate.6 Guinea−Bissau 0. Guinea 1.0 Angola 1.5 Age−standardised incidence rate per 100. Please refer to original source for methods.4 Kenya 1.43 - Figure 33: Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Africa (estimates for 2012) Mauritius 2.9 Comoros 0.1 Eq.7 Mauritania 0.9 Togo 0.6 Nigeria 0.8 CAR 0.0 Burkina Faso 1.0 Tanzania 0.7 Congo 0.2 Gabon 1.2 Seychelles** S.5 Zimbabwe 1.8 Chad 0. Data accessed on 08 May 2017.7 Sierra Leone 0.4 Madagascar 1.000 per year.8 Ghana 0.2 Burundi 1.4 Tunisia 0.4 Egypt 0.0000 women World Standard ** No rates are available.3 Malawi 1.2 Zambia 1.5 Libya 0.8 Mozambique 0.2 Ethiopia 1.7 Benin 0.

South Sudan. . Namibia. Egypt. Angola. Swaziland. Cape Verde. Mozambique. 2017 ICO HPV Information Centre .For Morocco. Gabon: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Congo. Rwanda: Frequency data. Ethiopia. Djibouti. Niger. Mali. . Côte d’Ivoire. Nigeria. Chad. Guinea-Bissau. Rwanda. Burkina Faso. Ghana. . Eritrea. and penile).For Western Sahara. Equatorial Guinea. Algeria. Namibia. Worldwide burden of cancer attributable to HPV by site. Ghana. Madagascar. Burundi. South Sudan. Burkina Faso.For Tunisia. Franceschi S. Liberia. Central African Republic. Lesotho. Central African Republic. Malawi. Senegal. Djibouti. Egypt. Botswana. Tanzania. Côte d’Ivoire. Sierra Leone. Togo. Uganda: One cancer registry covering part of a country is used as representative of the country profile . Somalia: The rates are those of neighbouring countries or registries in the same area .For Sudan. Libya.For Sudan. Zimbabwe. Cameroon. GLOBOCAN quality index for availability of incidence data: . Cameroon.For Libya. Mali.and age-specific incidence rates of cancer for a specific country: . Mauritius: National data (rates). Sierra Leone. .For South Africa: Rates projected to 2012 Data sources: de Martel C. Chad. vaginal. Mauritius: Most recent rates applied to 2012 population . Botswana.For Morocco. Mauritania. Tanzania. Zambia. Mozambique. Guinea. Cape Verde. Guinea-Bissau. Malawi. Senegal. Zambia.For Gambia. DR Congo. Angola. Algeria. Comoros. Niger. Int J Cancer. Liberia. South Africa. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Mauritania. Equatorial Guinea. Gabon. DR Congo.For Western Sahara. country and HPV type.For Gambia. Kenya: Estimated as the weighted average of the local rates . Plummer M. Congo. Kenya: Regional data (rates). Togo. Vignat J. Somalia: No data. Guinea. Zimbabwe: High quality regional (coverage lower than 10%). anal. Eritrea. Burundi. Madagascar. Swaziland. Tunisia. Uganda. Comoros. Nigeria.3 BURDEN OF HPV RELATED CANCERS . Ethiopia. Benin. Benin.44 - ( Figure 33 – continued from previous page) Other anogenital cancer cases (vulvar. Lesotho.

1.8 El Salvador 1.9 Mexico 0.7 Canada 1.45 - Figure 34: Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in the Americas (estimates for 2012) Barbados 2.0 Dominican Rep.2 Costa Rica 1.2 Jamaica 1.1 Cuba 1.2 Peru 1. ASR: Age-standardized rate. Data accessed on 08 May 2017.1 Haiti 1.3 BURDEN OF HPV RELATED CANCERS .8 Nicaragua 0.5 Age−standardised incidence rate per 100.1 Chile 1. rates per 100.** Grenada** Dominica** Antigua & Bar.6 St Vincent** St Lucia** St Kitts & Nev.5 1 1.6 Trinidad & Tob.0 Ecuador 1.0 Paraguay 0.3 Suriname 1.8 USA 1. Please refer to original source for methods.3 Bolivia 1.6 Argentina 1. 1.0000 women World Standard ** No rates are available.1 Panama 1.4 Guyana 1.9 Guatemala 0. (Continued on next page) ICO HPV Information Centre .3 Uruguay 1.** 0 0.5 2 2.0 Belize 1.5 Brazil 1.1 Colombia 1.000 per year.9 Venezuela 0.6 Bahamas 1.0 Honduras 1.

Suriname. . Worldwide burden of cancer attributable to HPV by site. Jamaica. Canada. Paraguay. Bolivia.For Nicaragua. Jamaica: High quality regional (coverage lower than 10%). USA: Rates projected to 2012 . GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Haiti. Cuba.For Uruguay: Most recent rates applied to 2012 population Data sources: de Martel C. Panama. Belize. Panama. anal. Guyana. Dominican Republic. Trinidad & Tobago. Dominican Republic.For Brazil. El Salvador. . Canada. Franceschi S.For Mexico. Barbados: No data.For Nicaragua.For Costa Rica. Paraguay. Chile. Guatemala. and penile). Bahamas. Bahamas. Honduras. GLOBOCAN quality index for availability of incidence data: . Barbados: Estimated from national mortality estimates using modelled survival . Honduras. Peru: Regional data (rates).46 - ( Figure 34 – continued from previous page) Other anogenital cancer cases (vulvar.For Ecuador. .3 BURDEN OF HPV RELATED CANCERS . Uruguay: High quality national data or high quality regional (coverage greater than 50%). Argentina: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . vaginal. Cuba. Belize. Brazil. Mexico.For Ecuador. Venezuela. Guatemala. El Salvador.For Bolivia: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Colombia. Venezuela.For Trinidad & Tobago: National data (rates). Chile. 2017 ICO HPV Information Centre . . Int J Cancer. Guyana. country and HPV type. USA. Vignat J. Peru.For Costa Rica. Argentina: High quality regional (coverage between 10% and 50%). Plummer M. Haiti. Suriname. Colombia. .and age-specific incidence rates of cancer for a specific country: .

3 Saudi Arabia 0.4 Japan 0.4 Iraq 0.4 Turkmenistan 0.8 Armenia 0.0 Israel 0.5 Lebanon 0.6 Jordan 0.000 per year.4 Brunei 0.5 2 2.7 Azerbaijan 0.2 Mongolia 0.2 Bhutan 0.0000 women World Standard ** No rates are available.7 Rep. ASR: Age-standardized rate.4 Turkey 0. Korea 0.2 Oman 0.3 Maldives 0.7 DPR Korea 0. (Continued on next page) ICO HPV Information Centre .4 Laos 0.2 UAE 0.2 Bangladesh 0.3 Qatar 0.4 Kyrgyzstan 0.6 Malaysia 0.3 Thailand 0.9 Timor−Leste 0.47 - Figure 35: Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Asia (estimates for 2012) Kazakhstan 1.3 Afghanistan 0.6 Syria 0.5 Iran 0.3 BURDEN OF HPV RELATED CANCERS .2 Nepal 0. Data accessed on 08 May 2017.3 Bahrain 0.3 Pakistan 0.5 Age−standardised incidence rate per 100.3 Tajikistan 0.8 Georgia 0.8 Cambodia 0.8 Singapore 0.2 Taiwan** 0 0.5 Philippines 0.4 Palestine 0.3 Yemen 0.3 Kuwait 0.2 Sri Lanka 0.5 Viet Nam 0.4 Uzbekistan 0.6 Myanmar 0.5 1 1. rates per 100. Please refer to original source for methods.7 China 0.0 India 1.5 Indonesia 0.

Saudi Arabia. Viet Nam: Regional data (rates). 2017 ICO HPV Information Centre . India: High quality regional (coverage lower than 10%). Vignat J. Laos.For Thailand. anal. Afghanistan. Lebanon. Plummer M. Singapore. Jordan.3 BURDEN OF HPV RELATED CANCERS . Republic of Korea.For Nepal. Lebanon: Most recent rates applied to 2012 population .For United Arab Emirates. Kuwait. Syria. Uzbekistan. Viet Nam. Maldives.For Pakistan. Kyrgyzstan. Thailand. country and HPV type. Turkey. Oman. DPR Korea. Kyrgyzstan. Kuwait. Singapore. and penile). Qatar. India: Estimated as the weighted average of the local rates . Sri Lanka. Sri Lanka. Turkmenistan. Int J Cancer. Pakistan. Brunei. Armenia. Azerbaijan. DPR Korea. Israel: Rates projected to 2012 . Palestine. Iran. Brunei.For Yemen.48 - ( Figure 35 – continued from previous page) Other anogenital cancer cases (vulvar. Bahrain. Georgia. Philippines: High quality regional (coverage between 10% and 50%). Japan.For Bangladesh. Mongolia. GLOBOCAN quality index for availability of incidence data: . Iran. Myanmar. Jordan: National data (rates). Timor-Leste. Indonesia: Frequency data. Armenia. Cambodia. Timor-Leste: The rates are those of neighbouring countries or registries in the same area . Afghanistan.For Tajikistan. Worldwide burden of cancer attributable to HPV by site. Syria. Georgia. Israel: High quality national data or high quality regional (coverage greater than 50%). Kazakhstan: No data.For Nepal.For Turkey. Tajikistan. Laos.For Oman. Saudi Arabia. .For Japan. Uzbekistan.For Bahrain. vaginal. Kazakhstan: Estimated from national mortality estimates using modelled survival . Iraq. . . Republic of Korea. Turkmenistan. Mongolia. Palestine: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Bhutan. Indonesia. Myanmar. Bhutan. China. Maldives. . . China: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries Data sources: de Martel C. Malaysia. Franceschi S. Iraq. Cambodia. Malaysia.For United Arab Emirates.For Bangladesh. . Philippines. Qatar. Azerbaijan.and age-specific incidence rates of cancer for a specific country: . GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex.For Yemen: One cancer registry covering part of a country is used as representative of the country profile .

5 Ireland 1.9 Ukraine 0. 0.3 Luxembourg 1.0 Bulgaria 1.2 Austria 1.4 Sweden 1.0 Finland 1.0 Latvia 1.9 Hungary 0.9 Macedonia 0.5 Age−standardised incidence rate per 100. Please refer to original source for methods.8 Russia 0. ASR: Age-standardized rate.4 UK 1.49 - Figure 36: Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Europe (estimates for 2012) Denmark 2.3 BURDEN OF HPV RELATED CANCERS .3 Germany 1.2 Serbia 1.7 Iceland 1.8 Greece 0.0000 women World Standard ** No rates are available.8 Romania 0.000 per year.9 Cyprus 0.1 Switzerland 1.0 Slovakia 0.1 Croatia 1.7 Netherlands 1. Data accessed on 08 May 2017.8 Norway 1.6 San Marino** Monaco** Liechtenstein** Andorra** 0 0.0 Spain 1.1 Malta 1.1 Montenegro 1.5 2 2.3 Slovenia 1.8 Poland 0.9 Portugal 0.2 France 1.7 Belarus 0. 1.9 Albania 0.1 Lithuania 1.1 Italy 1.7 Bosnia & H.5 1 1.5 Belgium 1. rates per 100.0 Estonia 1. (Continued on next page) ICO HPV Information Centre .8 Moldova 0.0 Czech Rep.

Worldwide burden of cancer attributable to HPV by site.For Belarus. Norway. Belgium. Switzerland. Bulgaria. country and HPV type. Franceschi S.For Greece. Italy. Malta. Croatia. Hungary. Int J Cancer. Vignat J. France: High quality regional (coverage between 10% and 50%).50 - ( Figure 36 – continued from previous page) Other anogenital cancer cases (vulvar. Denmark: High quality national data or high quality regional (coverage greater than 50%). Lithuania.For Montenegro: The rates are those of neighbouring countries or registries in the same area Data sources: de Martel C. Spain. Luxembourg: Estimated from national mortality estimates by modelling using incidence mortality ratios derived from recorded data in local cancer registries in neighbouring countries . Slovenia. Serbia. Sweden. . GLOBOCAN quality index for availability of incidence data: . Russian Federation. Slovakia.For Spain. Iceland. Malta.For Greece. Macedonia. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Austria. Germany.For Poland. Bulgaria. anal. . Italy. Romania. Ireland. vaginal. Finland. Portugal. Serbia. Lithuania. Switzerland. Ukraine. Montenegro: No data. Sweden. Norway. . Macedonia. Czech Republic. Albania. Estonia. Cyprus. Germany. Finland. Estonia. Russian Federation.and age-specific incidence rates of cancer for a specific country: . Austria. Croatia. 2017 ICO HPV Information Centre . Portugal: High quality regional (coverage lower than 10%). Republic of Moldova. and penile).For Belarus.For Bosnia & Herzegovina. United Kingdom. Albania. Latvia. Plummer M. . Cyprus. Belgium: Most recent rates applied to 2012 population . Netherlands.For Romania: Regional data (rates). Iceland. Latvia.For Bosnia & Herzegovina. Republic of Moldova.3 BURDEN OF HPV RELATED CANCERS . Slovenia. Netherlands. Luxembourg: National data (rates). Czech Republic. . France: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Ukraine. Slovakia. Ireland. United Kingdom. Hungary. Denmark: Rates projected to 2012 .For Poland.

5 2 2. 0.7 Papua N. Please refer to original source for methods.5 1 1.5 Age−standardised incidence rate per 100.5 Vanuatu 0. rates per 100. ASR: Age-standardized rate.3 New Zealand 1.6 Solomon Is. (Continued on next page) ICO HPV Information Centre .2 Samoa 0.51 - Figure 37: Age-standardised incidence rate of other anogenital cancer cases attributable to HPV by country in Oceania (estimates for 2012) Australia 1.0000 women World Standard ** No rates are available. Guinea 0.3 BURDEN OF HPV RELATED CANCERS .** Kiribati** FS Micronesia** 0 0.000 per year.4 Tuvalu** Tonga** Palau** Nauru** Marshall Is. Data accessed on 08 May 2017.7 Fiji 0.

6 310 1.2 Northern Territory 2003-2007 3 2.2 4.5 (Indigenous) Northern Territory 2003-2007 4 1.4 0. Lancet Oncol 2012.8 0.1 1. women with history of cervical or vulvar cancer.4 0. Plummer M.7 Brazil1 (Continued on next page) ICO HPV Information Centre .0 0.1 Anal cancer Anal cancer is rare in the general population with an average worldwide incidence of 1 per 100.0 0. and penile).6 5 3.7 Tasmania 2003-2007 19 1.6 0.0 Australia1 Australian Capital 2003-2007 6 0.8 2 0. Worldwide burden of cancer attributable to HPV by site.3 Vorarlberg 2003-2007 4 0. Women have higher incidences of anal cancer than men.5 0.000 new cases every year (de Martel C et al.3 0. Samoa: National data (rates).3 1 0. Incidence is particularly high among populations of men who have sex with men (MSM).0 Austria1 National 2003-2007 196 1.9 Northern Territory 2003-2007 7 1.and age-specific incidence rates of cancer for a specific country: .For Vanuatu.8 0.4 0.9 193 1. or basaloid and cloacogenic carcinomas.5 0.For New Zealand.4 0.9 Tyrol 2003-2007 16 0.8 0. Australia: High quality national data or high quality regional (coverage greater than 50%).2.8 0.4 0.2 Victoria 2003-2007 155 1.8 Bahrain1 National (Bahraini) 2003-2007 6 0.7 46 1.0 2. GLOBOCAN quality index for availability of incidence data: .9 0.7 5 1. Franceschi S.0 0.13(6):607-15). 2017 3.For Solomon Islands.For Vanuatu.0 27 2.0 3.52 - ( Figure 37 – continued from previous page) Other anogenital cancer cases (vulvar.0 Western 2003-2007 45 0.7 16 0.5 1. .2 0.4 0.3 South 2003-2007 41 1.6 378 1.9 248 1.7 (Non-Indigenous) Queensland 2003-2007 137 1. including those who are HIV-infected and patients with a history of organ transplantation.For Solomon Islands: The rates are those of neighbouring countries or registries in the same area .6 1.1 10 2.1 0.2 0.3 13 1.4 33 0.0 0.2 0. there are an estimated 27. These cancers are predominantly squamous cell carcinoma. and immunosuppressed populations.6 72 1.3 1.For Papua New Guinea: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) .7 0.9 205 1. .4 0.3 Belarus1 National 2003-2007 55 0.2 109 0.For Samoa: Most recent rates applied to 2012 population .4 10 1.2 0.3 BURDEN OF HPV RELATED CANCERS .4 1.2 1.2 0 0.6 Territory New South Wales 2003-2007 229 1.For New Zealand.3 0. Table 7: Incidence of anal cancer by cancer registry and sex Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Algeria1 Setif 2003-2007 8 0.6 Tierra del Fuego 2003-2007 1 0. Papua New Guinea: No data. Fiji. Fiji: Estimated from national mortality estimates using modelled survival .000. Vignat J. adenocarcinomas. vaginal.8 Cordoba 2004-2007 20 0.0 0.6 38 2. country and HPV type. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex.9 1.6 1.1 Argentina1 Bahia Blanca 2003-2007 3 0.2 Belgium1 National 2004-2007 204 1. but is reported to be increasing in more developed regions. Australia: Rates projected to 2012 Data sources: de Martel C. Int J Cancer.6 7 0.4 Mendoza 2003-2007 21 0.2 0. Globally.5 0.9 0. anal.

0 Yanting County 2003-2007 0 0.0 0.0 1.8 0.0 0.2 0.2 Fortaleza 2003-2006 13 0.1 Cixian County 2003-2007 4 0.9 1.7 0.1 Macao 2003-2007 5 0.2 0.0 1.8 1.1 0.0 0.4 0.3 0.3 0.1 0.2 1 0.7 257 1.0 Valdivia 2003-2007 5 0.0 Zhongshan City 2004-2007 4 0.3 10 1.3 1.8 Labrador Northwest Territories 2003-2007 0 0.3 0.2 0.0 215 2.7 0.3 1.2 Sao Paulo 2003-2007 235 0.3 0.3 0.4 8 2.6 33 1.5 0.9 53 1.7 0.2 Goiania 2003-2007 12 0.4 49 1.1 0.1 Ontario 2003-2007 585 1.5 Quebec 2003-2007 196 1.3 39 0.8 Costa Rica1 National 2003-2007 44 0.4 11 1.4 88 0.8 Saskatchewan 2003-2007 27 1.1 2 0.1 0.9 1.8 0 0.4 0.3 BURDEN OF HPV RELATED CANCERS .3 0.3 Jiashan County 2003-2007 3 0.4 Qidong County 2003-2007 5 0.3 0.9 Newfoundland and 2003-2007 8 0.2 0.0 0.5 135 1.5 127 0.53 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Aracaju 2003-2006 9 1.6 1.8 0.4 0.4 0.7 37 1.1 0.1 Region of Antofagasta 2003-2007 4 0.2 4 0.2 Haining County 2003-2007 6 0.3 0.3 2 0.9 0.3 693 2.3 0.1 Harbin City.1 1.1 7 0.3 2 0.6 0.9 1.8 13 0.7 China1 Beijing City 2003-2007 35 0.1 Shanghai City 2003-2007 70 0.6 0.2 0.0 0.3 2 0.4 0.2 Manitoba 2003-2007 28 1.3 7 0.2 67 0.4 1.5 7 0.6 0.1 0.4 1.0 2 1.9 Manizales 2003-2007 12 1.1 Colombia1 Bucaramanga 2003-2007 6 0.1 National 2003-2007 1114 1.9 47 2.8 Pasto 2003-2007 2 0.0 0.0 387 1.9 1492 1.6 0.4 0.0 0.5 0.7 Nova Scotia 2003-2007 34 1.0 Jiaxing City 2005-2007 1 0.9 1.7 51 1.6 0.0 0. Nangang 2003-2007 7 0.2 2 0.4 17 1.2 0 0.0 1.5 0.4 Cuiaba 2003-2006 10 0.4 14 1.3 Yangcheng County 2003-2007 2 0.4 Cali 2003-2007 29 0.5 56 0.8 30 1.2 Belo Horizonte 2003-2005 25 0.2 0.8 1.6 0.2 0.7 1.4 Canada1 Alberta 2003-2007 60 0.5 0.4 1.8 0.4 0.5 0.1 New Brunswick 2003-2007 23 1.0 1.3 0.2 Wuhan City 2003-2007 40 0.1 0.3 1.2 British Columbia 2003-2007 150 1.3 0.0 1.1 1.3 35 1.3 0.0 0 0.2 1.1 0.1 District Hong Kong 2003-2007 108 0.1 0.4 Prince Edward Island 2003-2007 2 0.1 25 0.7 101 1.2 0.8 Yukon 2003-2007 1 1.3 Bulgaria1 National 2003-2007 167 0.6 (Continued on next page) ICO HPV Information Centre .0 Chile1 Bío Bío Province 2003-2007 3 0.3 8 0.

4 1.4 0.8 Vendee 2003-2007 11 0.7 Calvados 2003-2007 19 1.8 0.8 Hamburg 2003-2007 109 2.2 0.7 Egypt1 Gharbiah 2003-2007 36 0.6 1.9 0.4 1.2 0.4 48 1.0 1.1 0.2 1. Paranda and 2003-2007 3 0.3 0.0 0.0 Haut-Rhin 2003-2007 16 0.8 40 2.3 0.8 Mecklenburg-Western 2003-2007 41 1.1 0.0 0.8 0.4 36 2.6 1.2 8 0.2 Tarn 2003-2007 9 1.54 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Croatia1 National 2003-2007 41 0.5 0.6 10 1.0 0.3 BURDEN OF HPV RELATED CANCERS .5 40 0.3 35 1.3 Germany1 Brandenburg 2003-2007 66 1.8 1.6 1.5 348 1.7 259 2.9 Isere 2003-2007 20 0.8 90 3.6 0.9 Herault 2003-2007 27 1.9 Schleswig-Holstein 2003-2007 123 1.3 Barshi.1 0.5 153 3.5 Czech Rep.0 215 3.7 78 2.1 National 2003-2007 192 0.2 0.9 0.2 0.5 25 2.9 0.2 0.8 India1 Bangalore 2005-2007 33 0.7 0.3 0.5 68 2.8 0.3 Cuba1 Villa Clara 2004-2007 13 0.5 0.3 Loire Atlantique 2003-2007 32 1.8 0.8 1.8 Pomerania Munich 2003-2007 107 1.3 1.5 0.6 36 1.0 Saarland 2003-2007 33 1.0 0.3 0.2 2 0.2 3 0.3 73 0.3 0.7 0.4 0.0 Free State Of Saxony 2003-2007 103 1.4 0.3 14 0.1 0.6 Finland1 National 2003-2007 65 0.6 0.2 0.8 21 1.3 Bhum Bhopal 2004-2007 10 0.4 Ecuador1 Cuenca 2003-2007 2 0.7 Martinique 2003-2007 3 0.3 1.4 1.9 0.8 0.6 126 1.8 0.2 0.6 20 1.1 0.3 Somme 2003-2007 16 1.3 Gambia2 National 1997-1998 1 0.3 0.9 0.5 Estonia1 National 2003-2007 17 0.5 23 0.2 Doubs 2003-2007 14 1.6 77 1.5 214 1.5 1.7 50 1.5 Manche 2003-2007 11 0.0 Bremen 2003-2007 29 1.2 0.4 France1 Bas-Rhin 2003-2007 12 0.2 2 0.3 0.3 115 0.0 0.2 0.1 0.8 Cyprus1 National 2003-2007 8 0.7 332 2.2 25 0.4 19 2.2 Quito 2003-2007 5 0.9 1.1 0.6 144 2.3 0.0 1.8 0.5 Iceland1 National 2003-2007 6 0.2 0.7 Denmark1 National 2003-2007 157 1.4 0.5 1.0 1.3 North Rhine-Westphalia 2003-2007 69 1.4 0.0 0.4 11 0.6 29 2.1 35 2.5 (Continued on next page) ICO HPV Information Centre .

4 30 1.6 Trento 2003-2006 8 0.4 0.4 14 1.4 Poona 2003-2007 31 0.2 0.3 Umbria 2003-2007 26 1.8 South Tyrol 2003-2006 11 1.6 0.1 6 0.1 0.8 1.9 0.0 0.9 0.4 0.1 1.5 0.9 0.8 0.8 15 3.5 Dindigul.3 0.9 Catania and Messina 2003-2005 20 0.1 Brescia 2003-2006 16 0.5 24 0.8 0.0 0.8 0.6 78 2.4 27 0.2 0.2 0.7 Romagna 2003-2007 59 2.2 Salerno 2003-2007 33 1.4 0.4 Lombardy.0 17 3.3 0.0 Friuli-Venezia Giulia 2003-2007 41 1.5 9 1.2 0.7 1.2 1.1 Trapani 2003-2006 13 1.1 1.3 New Delhi 2003-2007 170 0.7 87 0.1 0.4 0.8 29 2.3 101 0. Ambilikkai 2003-2007 14 0.2 0.2 0.8 0.0 0.1 1.2 Mumbai 2003-2007 102 0.3 1.6 0.7 1.2 0.2 0.0 2 0.1 Italy1 Biella 2003-2007 9 2.6 0.55 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Chennai 2003-2007 69 0.4 3 0.2 Reggio Emilia 2003-2007 9 0.2 0.6 18 2.5 Sondrio 2003-2007 8 1.3 99 0.6 5 0.7 31 3.2 Karunagappally 2003-2007 3 0.3 0.3 0.3 0.6 0.1 0.6 0.7 Florence and Prato 2003-2005 42 2.5 Sassari 2003-2007 6 0.7 0.9 46 2.8 Naples 2003-2007 6 0.3 Mizoram 2003-2007 1 0.6 Ragusa 2003-2007 9 1.6 4 0.3 9 0.4 43 2.9 23 2.4 National (Jews) 2003-2007 56 0.9 0.4 9 1.3 BURDEN OF HPV RELATED CANCERS .5 0.5 Catanzaro 2003-2007 7 1.4 0.8 Genoa 2003-2006 44 2.8 0.5 Parma 2003-2007 12 1.6 0.8 0.1 78 2.7 0.2 0.7 49 0.3 13 1.4 Ireland1 National 2003-2007 64 0.6 Israel1 National 2003-2007 57 0.4 0.1 0.7 0.9 0. South 2003-2005 5 0.4 Latina 2003-2007 20 1.4 Palermo 2003-2006 27 1.2 0.2 0.8 (Continued on next page) ICO HPV Information Centre .4 7 1.7 24 0.6 1.3 Iran1 Golestan Province 2005-2007 10 0.9 1.4 Trivandrum 2005-2007 2 0.5 0.8 0.4 0.6 17 1.5 1.5 Turin 2003-2007 45 2.4 0.5 Syracuse 2003-2007 10 1.4 22 1.5 94 0.7 Mantua 2003-2005 7 1.4 Nuoro 2003-2007 4 0.0 0.7 24 0.6 0.3 0.3 4 0.0 0.4 0.4 0.3 0.5 58 2.4 70 0.3 Milan 2003-2006 22 0.0 65 2.3 9 0.8 1.9 11 1.3 Lecco 2003-2007 6 0.5 0.3 19 1.7 Como 2003-2007 19 1.1 1.5 National (Non-Jews) 2003-2007 1 0.2 0.5 0.7 40 1.7 0.9 Ferrara 2003-2007 21 2.1 0.8 1.5 0.0 0.3 72 3.1 0.2 0.1 3 0.4 Sikkim State 2003-2007 3 0.7 37 2.1 0.4 0.1 0.8 0.5 5 0.0 Modena 2003-2007 18 1.

7 0.4 0.3 0.0 0.6 0.4 0.3 Miyagi Prefecture 2003-2007 39 0.1 0.4 Libya1 Benghazi 2003-2005 5 0.8 Veneto 2003-2006 58 1.7 Jamaica1 Kingston and St Andrew 2003-2007 6 0.3 38 0.5 180 1.0 Japan1 Aichi Prefecture 2003-2007 18 0.2 Niigata Prefecture 2003-2007 41 0.1 0.3 3 0.2 0.0 0.8 0.8 0.2 0.7 0.5 0.6 0.5 0.2 0.2 12 0.7 1 0.5 229 2.1 0.2 0.3 0.8 0.0 0.5 0.5 0.9 1.8 41 1.3 51 0.6 6 0.6 72 1.3 National (Kuwaitis) 2003-2007 4 0.4 38 0.5 New Zealand1 National 2003-2007 77 0.2 23 0.1 0.8 0.9 0.1 Islander) Norway1 National 2003-2007 97 0.4 141 0.2 4 0.0 1.1 Penang (Indian) 2004-2007 0 0.1 Pakistan3 South Karachi 1998-2002 19 0.2 Nagasaki Prefecture 2003-2007 18 0.6 0.5 0.0 1 0.1 National (Maori) 2003-2007 8 0.2 0.3 21 0.7 8 0.3 0.2 0.2 2 0.3 0.3 0.3 Penang (Malay) 2004-2007 4 0.3 Malawi1 Blantyre 2003-2007 3 0.7 0.4 0.1 National (Other) 2003-2007 69 0.1 3 0.7 0.9 0.2 Philippines1 (Continued on next page) ICO HPV Information Centre .3 23 0.9 0.1 Latvia1 National 2004-2007 23 0.2 0.2 Saga Prefecture 2003-2007 11 0.3 13 0.2 0.2 Fukui Prefecture 2003-2007 12 0.9 0.4 Peru3 Trujillo 1998-2002 4 0.4 National (Non-Kuwaitis) 2003-2007 7 0.6 3 0.5 374 0.4 0.5 0.5 0.6 0.1 8 0.4 Mali2 Bamako 1994-1996 4 0.0 Oman3 Omani 1998-2001 11 0.3 0.8 1.3 6 0.3 45 0.2 Penang (Chinese) 2004-2007 2 0.56 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Varese 2003-2007 31 1.5 1.0 1.9 0.7 1.4 0.2 Osaka Prefecture 2003-2007 186 0.3 0.9 15 0.5 0.2 Lithuania1 National 2003-2007 35 0.6 0.5 Malaysia1 Penang 2004-2007 6 0.2 0.0 1 0.6 0.1 0.5 National 2003-2007 293 0.3 6 0.5 13 0.4 16 0.2 National (Pacific 2003-2007 0 0.2 9 0.1 Kuwait1 National 2003-2007 11 0.9 1.2 Hiroshima 2003-2007 15 0.7 0.5 164 2.2 0.1 Malta1 National 2003-2007 3 0.1 9 0.3 BURDEN OF HPV RELATED CANCERS .2 0.5 Netherlands1 Eindhoven 2003-2007 13 0.2 0.5 0.

6 0.1 0.9 0.3 0.9 0.2 0.5 0.6 Gwangju 2003-2007 10 0.3 Canary Islands 2003-2006 28 0.3 BURDEN OF HPV RELATED CANCERS .5 Saudi Arabia1 Riyadh (Saudi) 2003-2007 9 0.6 0.7 0.5 0.5 0 0.8 Kielce 2003-2007 9 0.6 15 0.3 18 0.5 0.2 Slovakia1 National 2003-2007 63 0.3 0.4 86 0.7 2 0.4 0.9 0.1 Spain1 Albacete 2003-2007 5 0.2 24 1.1 2 0.0 0.4 0.1 0.5 0.4 9 0.4 0.7 0.3 0.8 0.6 Qatar1 National (Qatari) 2003-2007 1 0.4 0.3 0.2 0.5 0.6 38 0.1 0.5 5 1.3 23 0.3 0.1 0.1 0.4 0.2 0.6 43 0.2 0.2 19 0.1 0.4 Granada 2003-2007 10 0.3 0.3 28 0.3 Portugal1 Azores 2003-2007 4 0.7 0.4 Mallorca 2003-2007 29 1.2 15 0.3 0.7 0.2 0.1 6 0.6 Girona 2003-2007 15 0.3 Ulsan 2003-2007 9 0.5 0.3 Rizal 2003-2007 17 0.7 0.8 0.6 0.5 4 0.2 Lower Silesia 2003-2007 55 0.5 Ciudad Real 2004-2007 7 0. Korea1 Busan 2003-2007 29 0.7 3 0.7 0.8 0.4 5 0.3 National 2003-2007 450 0.9 0.4 91 0.7 Podkarpackie 2003-2007 22 0.4 0.6 0.5 0.3 35 0.3 Serbia1 Central 2003-2007 90 0.4 0.5 South Africa1 PROMEC 2003-2007 9 0.3 Singapore1 National 2003-2007 59 0.0 0.4 482 0.57 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Manila 2003-2007 28 0.5 Murcia 2003-2007 29 0.3 0.3 La Rioja 2003-2007 2 0.0 0.2 0.3 Daejeon 2003-2007 13 0.4 1 0.5 101 1.5 0.1 Cuenca 2003-2007 5 1.5 0.2 0.7 14 0.8 0.2 (Continued on next page) ICO HPV Information Centre .2 Poland1 Cracow 2003-2006 4 0.9 0.4 Slovenia1 National 2003-2007 45 0.5 40 0.3 31 0.4 21 0.4 0.4 3 0.3 Jejudo 2004-2007 5 0.6 0.2 Russia1 Saint Petersburg 2003-2007 22 0.1 117 0.4 0.4 0.7 0.3 0.3 Basque Country 2003-2007 43 0.7 0.3 National (Chinese) 2003-2007 51 0.9 0.3 0.2 14 0.2 National (Malay) 2003-2007 7 0.4 National (Indian) 2003-2007 1 0.4 25 0.2 Navarra 2003-2007 9 0.0 18 0.4 104 0.6 27 0.8 0.1 0.1 0.5 1.8 0.7 19 0.3 13 0.3 Seoul 2003-2007 106 0.2 Daegu 2003-2007 24 0.8 0.6 56 1.6 6 1.6 0.1 0.0 Rep.0 0.0 Asturias 2003-2007 29 1.4 Incheon 2003-2007 15 0.3 0.

4 0.9 76 4.4 Edirne 2004-2007 3 0.3 Chonburi 2003-2007 2 0.7 151 2.5 UK1 England 2003-2007 1491 1.1 Valais 2003-2007 8 1.0 0 0.2 Turkey1 Antalya 2003-2007 8 0.3 (Continued on next page) ICO HPV Information Centre .2 1.1 Khon Kaen 2003-2007 7 0.2 Trabzon 2005-2007 0 0.2 0.0 Graubunden and Glarus 2003-2007 4 0. North Western 2003-2007 188 1. Trent 2005-2007 71 1.9 Northern Ireland 2003-2007 50 1. West Midlands 2003-2007 162 1.2 0.1 Tunisia1 North 2003-2005 23 0.0 6 0.6 36 4.9 0.0 0.5 10 1.0 Neuchatel 2003-2007 12 2.6 115 1.0 Switzerland1 Basel 2003-2007 11 1.6 134 1.0 1.2 0.6 0.4 0.7 336 1.1 16 0.1 3 0.8 1.9 0.0 England.4 0.9 1.1 England.0 0.9 1.6 Vaud 2003-2007 24 1.4 0.1 0.1 0.0 Wales 2003-2007 98 1.3 0.3 0.8 103 3.9 73 1.2 63 5.3 2 0.0 England.2 0.6 22 1.9 Ticino 2003-2007 8 1.4 0.5 0.3 Uruguay1 National 2005-2007 62 1.8 51 1.8 Scotland 2003-2007 136 1.4 0.6 21 1.8 USA1 Alabama 2003-2007 137 1.2 0.7 254 1.9 0.1 Lampang 2003-2007 1 0.9 1.5 0.5 0.0 0.9 Geneva 2003-2007 19 1.7 0.2 Sweden1 National 2003-2007 198 0.7 England.6 0.58 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Tarragona 2003-2007 18 1.3 BURDEN OF HPV RELATED CANCERS .9 513 1.3 7 0. South and 2003-2007 197 1.9 England. Northern and 2003-2007 229 1.2 0.9 238 2.9 1.2 0.6 1.7 19 2.0 1. Oxford Region 2003-2007 67 1.2 6 0.1 Yorkshire England.3 0. Thames 2003-2007 384 1. East of 2003-2007 134 1.0 1.5 0.4 1 0.2 0.1 0.3 2.3 0.2 0.1 Izmir 2003-2007 33 0.3 Zurich 2003-2007 40 1.0 0.0 England Region England.3 640 0.8 0.4 0.2 St Gall-Appenzell 2003-2007 11 0.2 15 0.1 0.1 2.5 2.1 0.9 1.1 0.2 0.6 270 1.2 Chiang Mai 2003-2007 6 0.7 1.0 0.7 211 1.0 0.1 0.3 0.1 0.2 0.7 2274 1.1 0.7 1.3 22 0.0 1.2 Songkhla 2004-2007 7 0.5 9 0.9 Western Regions England.6 3.2 40 0.0 0.4 0.2 0.7 Thailand1 Bangkok 2003-2007 28 0.8 335 2.5 459 2.3 11 0.3 0.7 0.0 Uganda1 Kyadondo county 2003-2007 5 0.7 288 1.1 0.2 0.1 Ukraine1 National 2003-2007 438 0.0 0.2 0.6 22 5.

6 0.7 1.0 Alabama (White) 2003-2007 106 1.3 40 2.5 1. Los Angeles 2003-2007 4 0.1 1.1 0. Los Angeles 2003-2007 4 0.3 1.0 1.0 Arizona (White) 2003-2007 139 1. Los Angeles 2003-2007 34 1.7 227 1.5 0.1 1481 2.1 1.8 241 1.7 1.2 10 0.1 0.6 1.5 15 1. Los Angeles 2003-2007 3 1.2 2.3 0.3 Indian) California (Asian and 2003-2007 48 0.1 408 1.1 County (Filipino) California.4 0.4 Alaska 2003-2007 25 1.0 1.3 1.0 Alaska (American 2003-2007 8 2.1 1673 1.4 County (Asian and Pacific Islander) California.3 0.0 0. Los Angeles 2003-2007 5 0.4 Arkansas (Black) 2003-2007 12 1.6 California 2003-2007 1184 1.4 0.1 Arkansas 2003-2007 92 1.0 6 1.6 7 2. Los Angeles 2003-2007 262 1.1 County (Korean) California.5 26 0.59 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Alabama (Black) 2003-2007 30 1. Los Angeles 2003-2007 20 0.3 County (Black) California.5 0.4 1.5 2.1 0.6 252 3.7 1.3 Francisco (Asian and Pacific Islander) California: San 2003-2007 23 2.0 3 0.5 1.5 183 1.3 County (White) California: San 2003-2007 218 2.6 Pacific Islander) Arizona (Black) 2003-2007 12 1.9 County (Chinese) California.5 0.3 45 1. Los Angeles 2003-2007 201 2.3 Indian) Arizona 2003-2007 155 1.8 0.8 1.7 0.0 6 2.0 42 1.7 1.4 1.3 1.4 0.9 148 2.4 0.4 1.0 0.6 Francisco (Black) California: San 2003-2007 14 0.3 1.5 1 0.4 5 0.7 1.3 1.2 334 1.6 1.5 California.1 0.8 3.5 0.9 195 2. Los Angeles 2003-2007 318 1.3 California (American 2003-2007 6 0.4 12 0.8 0.6 1.6 0.2 105 1.9 1.1 0.1 Francisco California: San 2003-2007 12 0. Los Angeles 2003-2007 61 0.5 0.1 Indian) Arizona (Asian and 2003-2007 0 0.1 Arizona (American 2003-2007 2 0.4 1.4 Pacific Islander) California (Black) 2003-2007 87 1.2 County California.7 Arkansas (White) 2003-2007 80 1.7 0.9 0.9 160 2.1 1.7 82 0.1 1.8 25 2.3 California (White) 2003-2007 1028 1.5 0.3 BURDEN OF HPV RELATED CANCERS .9 18 1.7 0.0 Francisco (Hispanic White) (Continued on next page) ICO HPV Information Centre .7 County (Non-Hispanic White) California.3 1.4 0.4 1.8 County (Hispanic White) California.3 1 0.3 66 0.9 2.6 0.6 2 0.8 County (Japanese) California.

2 Connecticut (Black) 2003-2007 12 1.0 1.8 0.4 0.1 1227 2.8 2 0.3 BURDEN OF HPV RELATED CANCERS .6 1.0 0.8 Delaware (Black) 2003-2007 6 1.3 Indiana (White) 2003-2007 160 1.4 1.3 Francisco (Non-Hispanic White) California: San 2003-2007 182 2.0 Georgia.6 0.2 Pacific Islander) Georgia (Black) 2003-2007 73 1.3 32 1.4 0.0 2004.8 144 2.9 46 2.5 1.7 165 2.3 1.3 0.2 0.2 1.9 1.6 1.0 579 1.9 83 1.6 Hawaii (Chinese) 2003-2007 1 0.3 1.2 Francisco (White) Colorado 2003-2007 119 1.1 Illinois (White) 2003-2007 319 1.1 1.8 376 2.9 7 1. 31 1.6 Florida (Asian and 2003-2007 6 0.5 Indiana (Black) 2003-2007 15 1.1 69 1.0 382 1.0 0.0 0.0 0 0.0 0.2 Delaware 2003-2007 28 1.0 161 1.3 Illinois 2003-2007 421 1.4 Georgia.1 0.9 0.1 1.1 0.4 1.0 1.2 128 1.4 4 0.2 1.2 Hawaii (White) 2003-2007 22 2.8 353 2.7 65 1.3 Pacific Islander) Florida (Black) 2003-2007 66 1.8 1.7 Colorado (White) 2003-2007 111 1.3 Delaware (White) 2003-2007 21 1.1 1.0 0.2 Connecticut (White) 2003-2007 102 1.4 1.6 1.7 1.2 Illinois (Asian and 2003-2007 4 0.9 54 2.9 Florida 2003-2007 727 1.8 1.9 505 2.0 22 1.1 8 1.0 1.3 0.2 0.8 1.9 4 0.4 1.7 0.4 2.5 Hawaii 2003-2007 39 1.9 0.5 1.9 Georgia (White) 2003-2007 198 1.9 1.4 Kentucky 2003-2007 135 1.2 Pacific Islander) Illinois (Black) 2003-2007 89 1.0 0.0 1.8 1.1 2004.2006- 2007 (Continued on next page) ICO HPV Information Centre . Atlanta (Black) 2003-2007 40 1.8 221 1.4 0.0 268 2.3 Colorado (Asian and 2003-2007 0 0.9 174 1.0 0.1 Hawaii (Hawaiian) 2003-2007 7 1.3 3 0.0 0.7 1.2 0.8 1.3 1.6 17 2.8 214 2.2 3 0.0 Pacific Islander) Colorado (Black) 2003-2007 5 0.4 16 1.9 157 2.1 0.2 1.3 1.8 68 1.4 1.0 Florida (White) 2003-2007 646 1.3 96 2.2006- 2007 Louisiana (Black) 2003.4 0.4 1.60 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c California: San 2003-2007 168 3.0 126 2.7 Georgia 2003-2007 273 1. 110 1.2 2 1.9 1.3 0. Atlanta (White) 2003-2007 75 1.5 1.6 1.2 Indiana 2003-2007 177 1.5 0.0 311 2.2 0.2 Georgia. Atlanta 2003-2007 117 1.0 0.6 Louisiana 2003.6 Iowa 2003-2007 75 1.1 1.3 Idaho 2003-2007 31 0.1 1.7 1.1 1.2 Georgia (Asian and 2003-2007 0 0.0 1.8 33 1.7 1.5 1.0 1 0.4 0.9 0.3 0.4 1.8 Hawaii (Filipino) 2003-2007 4 0.1 1.4 Connecticut 2003-2007 114 1.5 1.1 Hawaii (Japanese) 2003-2007 2 0.5 1.1 1.1 1132 3.1 37 1.

0 0.5 1.2 New York State (Asian 2003-2007 13 0.8 202 1.7 68 1.0 332 2.3 13 0.6 1.9 429 1.4 1.9 0.9 1.5 1.1 0.2 0.2 New Mexico 2003-2007 51 1.2 Michigan 2003-2007 265 1.9 1.9 1.9 294 2.4 1.2 119 1.8 85 2.2006- 2007 Louisiana.9 316 1.1 832 2.6 Missouri (Black) 2003-2007 22 1.9 0.1 0.0 0.4 1.3 (White) Mississippi 2003-2007 106 1.7 1.0 0.7 437 2.1 1.0 Missouri 2003-2007 202 1.1 1.6 1.0 123 2. 10 1.2 2004.6 1. New Orleans 2003.4 12 1.1 0.2 0.3 1 0.9 1.7 1.5 Nebraska (White) 2003-2007 36 0.0 0.6 0.4 (Black) Michigan.6 Montana 2003-2007 23 1.3 and Pacific Islander) New York State (Black) 2003-2007 144 1.8 1.6 Indian) Nebraska 2003-2007 40 0.5 1.2 New Jersey (Black) 2003-2007 41 1.1 4 0.1 2004.5 1.2006- 2007 Maine 2003-2007 59 1.6 1.1 1. Detroit 2003-2007 114 1.9 0.3 Michigan (Asian and 2003-2007 1 0.0 1.2 0.4 0.8 1.5 1.6 1.3 (Continued on next page) ICO HPV Information Centre .8 507 2.6 (Non-Hispanic White) New Mexico (White) 2003-2007 49 1.6 1.7 64 1.1 996 2.4 Michigan (White) 2003-2007 201 1. 78 1.6 48 1.4 Massachusetts 2003-2007 197 1.1 Nebraska (Black) 2003-2007 0 0.2 64 3.1 1.9 1.0 0.4 1.0 1.5 64 1.3 19 2.3 Michigan. Detroit 2003-2007 45 1.3 86 2.3 31 1.1 New Jersey 2003-2007 249 1.8 0.1 1.6 65 2.3 1.3 21 1.5 1.2006- 2007 Louisiana.3 58 1.1 0.8 91 1.6 153 2.6 1.6 1. Detroit 2003-2007 67 1.0 1.0 1.1 New York State (White) 2003-2007 569 1.0 0.2 0 0.6 Missouri (White) 2003-2007 177 1.3 New Mexico (Hispanic 2003-2007 7 0.0 1.6 1.9 13 1.0 3 1.3 0.6 48 2.3 (Black) 2004.9 White) New Mexico 2003-2007 42 2.2 0.4 0.9 1.5 and Pacific Islander) Massachusetts (Black) 2003-2007 9 0.3 Michigan.1 (White) 2004. New Orleans 2003.3 1.2006- 2007 Louisiana.0 New Hampshire 2003-2007 30 0. 16 1.3 0.6 134 1.8 1.0 367 2.3 BURDEN OF HPV RELATED CANCERS .3 1.0 Pacific Islander) Michigan (Black) 2003-2007 57 1.9 Massachusetts (White) 2003-2007 186 1.3 New York State 2003-2007 745 1.0 1.2 Massachusetts (Asian 2003-2007 1 0.61 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c Louisiana (White) 2003.2 0.3 New Jersey (White) 2003-2007 202 1.2 1.8 366 2.1 1.4 34 1. New Orleans 2003. 26 1.6 1.5 0.3 Montana (American 2003-2007 2 1.4 0.8 1.

3 and Pacific Islander) NPCR (42 States) 2003-2007 1125 1.62 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c North Carolina 2003-2007 253 1.1 1.2 2 0.0 SEER (18 Registries) 2003-2007 2535 1.5 (Non-Hispanic White) SEER (18 Registries) 2003-2007 2123 1.3 1.2 0.0 1.5 Rhode Island (White) 2003-2007 35 1.0 1.3 1.9 13207 2.3 0.3 North Carolina 2003-2007 3 1.3 0.0 46 1.3 Ohio (Asian and Pacific 2003-2007 0 0.9 0.1 North Carolina (White) 2003-2007 192 1.4 1.4 1.9 0.3 1.3 1.8 (American Indian) NPCR (42 States) (Asian 2003-2007 93 0.3 1.3 1.3 95 0.6 NPCR (42 States) 2003-2007 8243 1.8 389 2.7 1.1 Rhode Island (Black) 2003-2007 1 0.9 Indian) Oklahoma (Black) 2003-2007 7 1.7 1.3 Puerto Rico 2003-2007 79 0.0 (Black) NPCR (42 States) 2003-2007 6869 1.3 SEER (18 Registries) 2003-2007 72 0.1 1.4 1.4 1.4 0.0 0 0.7 0.6 1.6 0.0 3912 1.3 Pennsylvania (Asian and 2003-2007 4 0.3 (Asian and Pacific Islander) SEER (18 Registries) 2003-2007 308 1.7 62 0.0 Pacific Islander) Oregon (Black) 2003-2007 2 0.8 533 2.3 0.3 45 1.4 1.6 1.0 1.1 1.8 0.2 0.7 Pennsylvania 2003-2007 415 1.4 North Dakota 2003-2007 6 0.6 1.4 (White) Ohio 2003-2007 347 1.9 588 2.4 0.0 10 1.5 1.2 0.2 (Black) SEER (18 Registries) 2003-2007 182 0.5 Oregon 2003-2007 140 1.2 358 1.4 (White) (Continued on next page) ICO HPV Information Centre .2 1.6 (American Indian) North Carolina (Asian 2003-2007 1 0.2 Oregon (White) 2003-2007 132 1.1 237 2.3 Oklahoma 2003-2007 116 1.1 0.6 166 1.1 3109 2.0 0.0 3419 2.5 0.6 3 1.2 1.5 Pacific Islander) Pennsylvania (Black) 2003-2007 55 1.5 and Pacific Islander) North Carolina (Black) 2003-2007 55 1.3 18 1.6 0.5 1.7 1.1 2.7 66 1.1 1.0 Ohio (White) 2003-2007 295 1.0 Rhode Island 2003-2007 36 1.3 0.3 0.3 NPCR (42 States) 2003-2007 53 0.4 1.9 690 2.1 Oklahoma (White) 2003-2007 102 1.0 0.0 Islander) Ohio (Black) 2003-2007 48 1.9 1.3 1.2 1.1 233 2.8 1.8 1.9 (Hispanic White) SEER (18 Registries) 2003-2007 1941 1.0 210 2.8 0.7 4 0.2 0 0.1 67 1.6 1.5 0.6 310 0.3 1171 1.9 11726 2.6 Oregon (Asian and 2003-2007 1 0.2 1.0 1.2 0.6 1.3 1.6 Oklahoma (American 2003-2007 7 0.4 0.2 1.9 25 3.4 Pennsylvania (White) 2003-2007 351 1.3 135 0.4 0.9 463 2.3 BURDEN OF HPV RELATED CANCERS .5 0.9 0.7 1.0 0.0 43 1.0 2 0.8 610 2.0 173 2.2 1.2 0.7 0.9 2 1.4 0.

IX. 160.1 0. L. J. J.63 - ( Table 7 – continued from previous page) Male Female Country / Registry Period N casesa Crude rateb ASRb N casesa Crude rate c ASR c SEER (9 Registries) 2003-2007 911 1.4 1. D. Brewster DH.1 0.8 Vermont 2003-2007 21 1.6 248 1.1 0.1 Utah 2003-2007 35 0.0 Texas (White) 2003-2007 512 1. B.B.3 0.1 Wyoming 2003-2007 14 1.8 296 2.1 Wisconsin (Black) 2003-2007 11 1. For time trends in anal cancer incidence.8 1.6 36 0.5 Wisconsin (White) 2003-2007 113 0.1 0.7 0.1 Texas (Asian and Pacific 2003-2007 5 0.5 Texas 2003-2007 603 1.4 0.8 294 2.4 Zimbabwe1 Harare (African) 2003-2006 3 0. H. IARC Scientific Publications No.5 1. P.1 46 1.1 0.6 West Virginia 2003-2007 53 1.fr 2 Parkin.8 1.2 4 0. a Accumulated number of cases during the period in the population covered by the corresponding registry. please refer to individual country data. IARC. X (electronic version) Lyon.3 BURDEN OF HPV RELATED CANCERS .8 354 1. Seattle 2003-2007 148 1.4 14 1.3 1.iarc.1 0.9 738 1. ICO HPV Information Centre ..2 0.. M.2 5 0.8 South Carolina (White) 2003-2007 85 1. Edwards. Gombe Mbalawa C. Data sources: 1 Forman D.0 1304 1.2 0..6 1. and Boyle.4 1.6 0.2 1.7 22 1. eds (2002).2 Data accessed on 05 May 2015.2 SEER (9 Registries) 2003-2007 133 1.3 (White) South Carolina 2003-2007 131 1.2 South Carolina (Black) 2003-2007 44 1. VIII.5 59 0..0 Tennessee (White) 2003-2007 138 1. Vol.R.0 27 1. Ferlay.6 1. Teppo. 3 Curado.5 1. NOTE. Swaminathan R and Ferlay J eds (2013). Cancer Incidence in Five Continents. and Thomas. Heanue.4 0.L..8 117 2.9 0.1 Ho Chi Minh City 1995-1998 32 0. IARC Scientific Publications No.1 1.2 0. M.M. Vol.. Bray F.9 371 2.4 1.4 2 0.1 1.1 0.9 0. Cancer Incidence in Five Continents.1 0.8 Virginia (White) 2003-2007 159 1.1 1.8 175 2.000 men per year.4 1.5 131 1. S. H.2 (Black) SEER (9 Registries) 2003-2007 743 1.4 1.6 1.9 213 1.6 228 1.3 1. Ferlay.8 1.1 1.1 0.1 1..2 0. Storm.8 1..0 32 1. http://ci5. D.1 Virginia 2003-2007 204 1.7 1.9 0.4 South Dakota 2003-2007 13 0.3 8 0. P.4 Islander) Texas (Black) 2003-2007 80 1...4 0. IARC.5 Wisconsin 2003-2007 128 0..4 1.8 1.2 77 1.2 0. b Rates per 100.0 Tennessee 2003-2007 163 1.4 Tennessee (Black) 2003-2007 24 1. eds (2007).2 Virginia (Asian and 2003-2007 2 0.9 1.5 1. Steliarova-Foucher E.3 Washington State 2003-2007 192 1. c Rates per 100. Whelan. IARC.1 0.4 36 1. Lyon.1 0.4 Pacific Islander) Virginia (Black) 2003-2007 41 1. 155. Kohler B.5 1.5 32 1.5 Washington.3 1. Vol.2 1.0 269 2.8 329 2.1 Viet Nam2 Hanoi 1993-1997 7 0.0 1125 2.0 1. Piñeros M.1 0. Cancer Incidence in Five Continents.9 827 1.4 0. Shin. Lyon.4 1.2 0.000 women per year.

9 Cuba1 Villa Clara 2004-2007 29 1.0 (Continued on next page) ICO HPV Information Centre . Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinizing types.6 Uganda1 Kyadondo county 2003-2007 12 0. Worldwide.2 Vulvar cancer Cancer of the vulva is rare among women worldwide.3 0.3 BURDEN OF HPV RELATED CANCERS .3 1.1 0. with an estimated 27. rep- resenting 4% of all gynaecologic cancers (de Martel C et al. Basaloid/warty lesions are more common in young women.6 1.1 1.5 0.4 Malawi1 Blantyre 2003-2007 16 0.5 1.2 South Africa1 PROMEC 2003-2007 8 0.3 1.2 Tierra del Fuego 2003-2007 5 1.6 Costa Rica1 National 2003-2007 92 0.2 Egypt1 Gharbiah 2003-2007 49 0.6 0.0 Chile1 Bío Bío Province 2003-2007 4 0.5 1.000 new cases in 2008.5 British Columbia 2003-2007 207 2.0 0.8 Ontario 2003-2007 827 2.3 Cordoba 2004-2007 49 1.3 0.0 1.13(6):607-15).4 Prince Edward Island 2003-2007 7 2.3 Tunisia1 North 2003-2005 41 0.2.8 0.3 Region of Antofagasta 2003-2007 17 1.8 Quebec 2003-2007 472 2.2 Nova Scotia 2003-2007 83 3.5 1.0 0.8 3.6 Canada1 Alberta 2003-2007 189 2.8 1.8 1.0 1.2 0.4 New Brunswick 2003-2007 55 2.3 Pasto 2003-2007 5 0.4 0.6 Yukon 2003-2007 0 0.0 0.5 0.64 - 3.3 1.8 1.6 Zimbabwe1 Harare (African) 2003-2006 14 0.0 Mali2 Bamako 1994-1996 1 0.0 Manitoba 2003-2007 84 2.7 1.8 1. about 60% of all vulvar cancer cases occur in more developed countries.5 1. Lancet Oncol 2012.3 Northwest Territories 2003-2007 1 1.8 1.9 Manizales 2003-2007 5 0.6 1.7 Newfoundland and Labrador 2003-2007 36 2. and have a similar risk factor profile as cervical cancer.0 Belo Horizonte 2003-2005 33 0. they occur more often in older women and are more rarely associated with HPV (IARC Monograph Vol 100B) Table 8: Incidence of vulvar cancer by cancer registry Female Country name Cancer registry Period N casesa Crude rateb ASRb Africa Algeria1 Setif 2003-2007 5 0. Keratinizing vulvar carcinomas represent the majority of the vulvar lesions (>60%).0 1.7 Cali 2003-2007 55 1.4 Goiania 2003-2007 34 1.3 Sao Paulo 2003-2007 510 1.8 1.1 0.9 1.0 0.2 0.1 Mendoza 2003-2007 69 1.3 Valdivia 2003-2007 9 1.5 0.9 0. are very often associated with HPV DNA detection (75-100%).8 Gambia2 National 1997-1998 1 0.9 0.8 Cuiaba 2003-2006 12 0.0 Fortaleza 2003-2006 17 0.1 Americas Argentina1 Bahia Blanca 2003-2007 6 0.8 National 2003-2007 2044 2.1 0.0 Brazil1 Aracaju 2003-2006 10 1.2 Saskatchewan 2003-2007 83 3.6 Colombia1 Bucaramanga 2003-2007 20 0.2 Libya1 Benghazi 2003-2005 5 0.7 0.

2 Arkansas 2003-2007 215 3.8 0.6 Quito 2003-2007 28 0.8 1.3 BURDEN OF HPV RELATED CANCERS .3 Colorado 2003-2007 251 2.0 1.8 Jamaica1 Kingston and St Andrew 2003-2007 8 0.6 California: San Francisco 2003-2007 209 2.9 1.5 Arizona (White) 2003-2007 273 2.1 1.6 1.6 0.2 California. Los Angeles County (Asian and 2003-2007 27 0.2 1.5 Delaware (Black) 2003-2007 6 1.5 0.3 California.6 California.8 Arizona 2003-2007 287 1.4 Connecticut 2003-2007 287 3.5 Alabama 2003-2007 301 2. Los Angeles County (Hispanic 2003-2007 116 1.5 Connecticut (White) 2003-2007 267 3.2 1.7 1.0 1.1 White) California.2 0.0 Uruguay1 National 2005-2007 110 2.3 California 2003-2007 1735 1. Los Angeles County (Chinese) 2003-2007 10 1.5 0.6 1.7 0. Los Angeles County 2003-2007 447 1.9 1.0 0.65 - ( Table 8 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Ecuador1 Cuenca 2003-2007 9 0.5 0.4 Colorado (Asian and Pacific Islander) 2003-2007 2 0. Los Angeles County 2003-2007 251 3.6 California (American Indian) 2003-2007 4 0.7 0.3 Alabama (White) 2003-2007 240 2.0 1.2 California.9 1.5 Colorado (Black) 2003-2007 5 1.0 USA1 Alabama (Black) 2003-2007 52 1.6 Alaska (American Indian) 2003-2007 5 1.0 1.9 Arkansas (White) 2003-2007 187 3.3 Connecticut (Black) 2003-2007 17 1.5 Florida 2003-2007 1297 2.7 0.7 California.4 1.1 0.9 1.3 Arizona (American Indian) 2003-2007 6 0.1 1.0 0.6 Pacific Islander) California: San Francisco (Hispanic White) 2003-2007 10 0.1 0.3 1.7 0.0 0.1 California (White) 2003-2007 1508 2. Los Angeles County (Japanese) 2003-2007 2 0.3 California.4 Peru3 Trujillo 1998-2002 21 1. Los Angeles County (Filipino) 2003-2007 6 0.5 California (Black) 2003-2007 95 1.5 1.1 California: San Francisco (Black) 2003-2007 20 1. Los Angeles County (Korean) 2003-2007 6 1.1 (Continued on next page) ICO HPV Information Centre .9 Arkansas (Black) 2003-2007 24 2.2 1.9 1.7 Arizona (Asian and Pacific Islander) 2003-2007 1 0.8 1.5 Florida (Asian and Pacific Islander) 2003-2007 1 0.3 0.1 Delaware (White) 2003-2007 49 3.2 1.0 1.9 1. Los Angeles County (Black) 2003-2007 45 1.6 0.4 California.8 0.2 1.4 Pacific Islander) California: San Francisco (Asian and 2003-2007 26 1.6 Delaware 2003-2007 56 2.2 California (Asian and Pacific Islander) 2003-2007 90 0.3 2.2 Arizona (Black) 2003-2007 3 0.8 1.4 White) California: San Francisco (White) 2003-2007 159 2.6 1.5 Alaska 2003-2007 30 1.0 1.5 (Non-Hispanic White) California.1 1.3 1.9 Colorado (White) 2003-2007 233 2.3 1.3 California: San Francisco (Non-Hispanic 2003-2007 149 3.2 California. Los Angeles County (White) 2003-2007 367 2.

3 1.5 Hawaii (Filipino) 2003-2007 5 1.6 Georgia (Asian and Pacific Islander) 2003-2007 4 0.2 1.66 - ( Table 8 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Florida (Black) 2003-2007 91 1.2006- 2007 Louisiana.2006- 2007 Louisiana (White) 2003.8 Mississippi 2003-2007 211 2.3 0.3 0.0 Massachusetts (White) 2003-2007 520 3.9 1.7 1.3 1.1 1. Atlanta (Black) 2003-2007 44 1.0 Hawaii 2003-2007 65 2.4 2004.7 Michigan.6 1.3 1.0 0. Atlanta (White) 2003-2007 97 2.9 Hawaii (White) 2003-2007 24 3.5 Indiana (Black) 2003-2007 24 1.0 1.7 1.3 BURDEN OF HPV RELATED CANCERS .8 Michigan 2003-2007 772 3. 13 1.3 2.2006- 2007 Louisiana.1 1.3 Georgia.0 Florida (White) 2003-2007 1190 3.6 Georgia (Black) 2003-2007 93 1.9 1.0 0. Detroit (Black) 2003-2007 56 2.8 Massachusetts (Asian and Pacific Islander) 2003-2007 3 0. New Orleans 2003.0 2004. Atlanta 2003-2007 150 1.6 1.3 1.0 1.4 Indiana (White) 2003-2007 446 3.3 Illinois (White) 2003-2007 748 2.2006- 2007 Louisiana.0 Hawaii (Japanese) 2003-2007 22 3.2 Illinois 2003-2007 857 2. New Orleans (White) 2003.8 1.6 Illinois (Asian and Pacific Islander) 2003-2007 4 0.3 1.6 2.3 1.9 (Continued on next page) ICO HPV Information Centre .8 Indiana 2003-2007 479 3. Detroit 2003-2007 307 3.1 Hawaii (Chinese) 2003-2007 0 0.5 Michigan (White) 2003-2007 686 3.9 2.7 Michigan (Asian and Pacific Islander) 2003-2007 2 0.0 2004.8 1.9 Massachusetts 2003-2007 545 3. 50 2.4 Michigan (Black) 2003-2007 68 1.7 1.4 1.2 Louisiana 2003.7 Hawaii (Hawaiian) 2003-2007 9 1.1 Idaho 2003-2007 87 2.8 2004.1 Georgia (White) 2003-2007 425 2. 207 3.3 1.4 2004.7 Georgia.8 1.4 0.8 Missouri 2003-2007 485 3.5 2.8 1.2006- 2007 Maine 2003-2007 128 3.8 1.8 Iowa 2003-2007 280 3.2 1.7 2004.9 Kentucky 2003-2007 384 3.2 1.4 Georgia.6 Michigan. 37 3. 52 1.4 1.7 1.6 Georgia 2003-2007 530 2.5 Massachusetts (Black) 2003-2007 14 1. 262 2.0 1.0 1.3 1.8 Michigan.7 1.4 Illinois (Black) 2003-2007 83 1.6 0.2006- 2007 Louisiana (Black) 2003. New Orleans (Black) 2003. Detroit (White) 2003-2007 247 3.4 0.6 1.

7 New Mexico (Non-Hispanic White) 2003-2007 58 2.6 1.2 Pennsylvania 2003-2007 1195 3.6 Oregon (Asian and Pacific Islander) 2003-2007 0 0.5 Nebraska (Black) 2003-2007 3 1.0 0.67 - ( Table 8 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Missouri (Black) 2003-2007 36 2.5 0.2 1.5 1.5 Islander) SEER (18 Registries) (Black) 2003-2007 394 1.0 Rhode Island 2003-2007 119 4.0 Ohio (White) 2003-2007 810 3.4 New York State (Asian and Pacific 2003-2007 12 0.3 (Continued on next page) ICO HPV Information Centre .3 BURDEN OF HPV RELATED CANCERS .7 Pennsylvania (Asian and Pacific Islander) 2003-2007 2 0.6 Oregon (White) 2003-2007 238 2.5 1.5 1.9 1.9 Puerto Rico 2003-2007 200 2.8 1.6 1.0 SEER (18 Registries) (Asian and Pacific 2003-2007 155 0.5 1.9 1.3 North Carolina (Black) 2003-2007 83 1.0 Ohio (Black) 2003-2007 47 1.0 1.0 0.0 1.8 Oklahoma 2003-2007 293 3.1 1.7 Ohio (Asian and Pacific Islander) 2003-2007 0 0.3 1.2 2.5 1.5 0.9 0.1 Montana 2003-2007 75 3.5 Nebraska (White) 2003-2007 116 2.6 Ohio 2003-2007 870 3.8 1.3 0.4 New Hampshire 2003-2007 112 3.3 Rhode Island (Black) 2003-2007 4 2.5 NPCR (42 States) (American Indian) 2003-2007 78 1.0 Oklahoma (American Indian) 2003-2007 19 2.5 Rhode Island (White) 2003-2007 108 4.1 1.2 New Mexico 2003-2007 90 1.7 Missouri (White) 2003-2007 446 3.0 Montana (American Indian) 2003-2007 2 1.9 1.4 0.5 NPCR (42 States) 2003-2007 17514 2.4 New Jersey (White) 2003-2007 523 3.8 1.7 1.4 2.1 Oregon 2003-2007 255 2.3 2.5 1.0 Oklahoma (White) 2003-2007 265 3.3 2.0 1.2 1.7 1.4 North Carolina (American Indian) 2003-2007 1 0.9 Pennsylvania (White) 2003-2007 1097 4.6 1.2 1.4 New Mexico (White) 2003-2007 77 1.6 2.2 New Mexico (Hispanic White) 2003-2007 19 0.6 North Carolina (Asian and Pacific Islander) 2003-2007 2 0.8 1.7 1.2 1.2 North Dakota 2003-2007 50 3.5 2.2 Oklahoma (Black) 2003-2007 8 1.3 1.2 Islander) New York State (Black) 2003-2007 148 1.8 0.4 1.3 2.7 Nebraska 2003-2007 126 2.0 NPCR (42 States) (Asian and Pacific 2003-2007 151 0.1 New York State 2003-2007 1346 2.0 Oregon (Black) 2003-2007 3 1.7 New Jersey 2003-2007 595 2.5 North Carolina (White) 2003-2007 461 2.7 1.3 0.6 Pennsylvania (Black) 2003-2007 78 2.2 New York State (White) 2003-2007 1159 3.2 NPCR (42 States) (White) 2003-2007 15617 2.1 1.1 1.4 Islander) NPCR (42 States) (Black) 2003-2007 1374 1.5 New Jersey (Black) 2003-2007 52 1.5 North Carolina 2003-2007 551 2.0 1.8 1.

6 White) SEER (9 Registries) (White) 2003-2007 1499 2.5 Karunagappally 2003-2007 3 0.5 0.3 0.5 1.2 1.3 Wyoming 2003-2007 27 2.5 1.2 0.7 1.6 Texas (White) 2003-2007 987 2.3 0.68 - ( Table 8 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb SEER (18 Registries) (Hispanic White) 2003-2007 370 1.4 South Carolina (Black) 2003-2007 42 1.5 SEER (18 Registries) 2003-2007 4909 2.7 Barshi.7 0.4 India1 Bangalore 2005-2007 43 0.5 1.1 0.3 0.5 0.2 Mizoram 2003-2007 13 0.6 West Virginia 2003-2007 167 3.9 South Carolina 2003-2007 306 2.6 1. Seattle 2003-2007 287 2.7 1.8 1. Ambilikkai 2003-2007 20 0.3 Harbin City.3 0.9 Tennessee (Black) 2003-2007 33 1.0 Vermont 2003-2007 49 3.4 0.9 South Dakota 2003-2007 66 3.4 Haining County 2003-2007 6 0.7 South Carolina (White) 2003-2007 259 3.2 Qidong County 2003-2007 3 0.4 Texas (Asian and Pacific Islander) 2003-2007 6 0.0 Shanghai City 2003-2007 98 0.8 1.3 Zhongshan City 2004-2007 13 0.4 Utah 2003-2007 82 1.3 0.2 Texas (Black) 2003-2007 111 1.7 1.3 Hong Kong 2003-2007 147 0. Nangang District 2003-2007 10 0.2 1.2 0.3 BURDEN OF HPV RELATED CANCERS . Paranda and Bhum 2003-2007 2 0.4 Cixian County 2003-2007 5 0.5 0.3 1.4 0.0 SEER (18 Registries) (White) 2003-2007 4264 2.2 0.0 0.3 Chennai 2003-2007 51 0.0 1.7 Tennessee 2003-2007 415 2.7 1.1 1.2 Jiaxing City 2005-2007 6 0.8 0.5 Jiashan County 2003-2007 4 0.2 Yangcheng County 2003-2007 1 0.3 Texas 2003-2007 1130 2.1 1.8 0.3 1.0 1.4 1.5 SEER (9 Registries) (Black) 2003-2007 145 1.0 1.3 Asia Bahrain1 National (Bahraini) 2003-2007 0 0.4 0.5 SEER (9 Registries) 2003-2007 1757 2.0 China1 Beijing City 2003-2007 121 0.6 1.4 Virginia (Black) 2003-2007 56 1.5 Washington.1 Bhopal 2004-2007 5 0.6 0.1 1.1 Yanting County 2003-2007 5 0.4 Wisconsin 2003-2007 380 2.4 0.6 1.8 1.7 1.5 Virginia (Asian and Pacific Islander) 2003-2007 4 0.5 Macao 2003-2007 3 0.8 (Continued on next page) ICO HPV Information Centre .4 Washington State 2003-2007 388 2.4 0.9 Wisconsin (Black) 2003-2007 12 1.1 0.0 Tennessee (White) 2003-2007 378 3.2 0.4 Wisconsin (White) 2003-2007 358 2.4 1.4 SEER (18 Registries) (Non-Hispanic 2003-2007 3894 3.4 0.3 1.7 Virginia 2003-2007 451 2.0 Virginia (White) 2003-2007 380 2.3 Wuhan City 2003-2007 27 0.5 Dindigul.4 1.

8 0.3 0.3 0.9 0.0 0.4 0.3 Penang (Indian) 2004-2007 2 0.3 Lampang 2003-2007 21 1.3 BURDEN OF HPV RELATED CANCERS . Korea1 Busan 2003-2007 24 0.3 Oman3 Omani 1998-2001 3 0.2 0.1 0.0 0.69 - ( Table 8 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Mumbai 2003-2007 65 0.6 National (Malay) 2003-2007 4 0.2 Daejeon 2003-2007 4 0.2 Nagasaki Prefecture 2003-2007 46 1.1 0.3 0.6 National 2003-2007 69 0.3 Kuwait1 National 2003-2007 10 0.4 Penang (Chinese) 2004-2007 5 0.2 Chiang Mai 2003-2007 39 1.8 Songkhla 2004-2007 9 0.2 Izmir 2003-2007 66 0.7 0.3 Miyagi Prefecture 2003-2007 41 0.8 Chonburi 2003-2007 15 0.3 Saga Prefecture 2003-2007 20 0.2 Pakistan3 South Karachi 1998-2002 3 0.4 0.3 Incheon 2003-2007 18 0.5 0.3 Turkey1 Antalya 2003-2007 15 0.4 Qatar1 National (Qatari) 2003-2007 0 0.1 Israel1 National 2003-2007 229 1.4 Khon Kaen 2003-2007 17 0.3 0.4 0.4 0.8 0.2 0.2 0.1 Philippines1 Manila 2003-2007 42 0.3 Ulsan 2003-2007 8 0.2 Jejudo 2004-2007 2 0.1 Singapore1 National (Indian) 2003-2007 2 0.3 National (Chinese) 2003-2007 62 0.2 Viet Nam2 Hanoi 1993-1997 53 0.8 National (Jews) 2003-2007 213 1.4 Malaysia1 Penang (Malay) 2004-2007 3 0.5 0.3 Thailand1 Bangkok 2003-2007 34 0.4 0.9 National (Non-Jews) 2003-2007 16 0.3 0.3 Trivandrum 2005-2007 4 0.4 Edirne 2004-2007 4 0.2 Iran1 Golestan Province 2005-2007 1 0.1 Gwangju 2003-2007 14 0.3 National (Kuwaitis) 2003-2007 6 0.3 Osaka Prefecture 2003-2007 164 0.9 0.1 0.5 Rizal 2003-2007 41 0.3 Saudi Arabia1 Riyadh (Saudi) 2003-2007 5 0.2 0.9 Penang 2004-2007 10 0.0 0.1 National 2003-2007 426 0.2 0.2 0.3 Sikkim State 2003-2007 2 0.2 0.4 0.2 0.3 0.3 0.0 0.2 0.6 0.3 Seoul 2003-2007 101 0.9 0.2 Fukui Prefecture 2003-2007 22 1.4 0.5 0.3 National (Non-Kuwaitis) 2003-2007 4 0.1 0.4 0.9 1.7 0.1 0.5 Poona 2003-2007 25 0.1 0.3 0.5 0.3 Niigata Prefecture 2003-2007 50 0.7 0.0 Rep.3 0.7 0.3 0.2 0.2 Daegu 2003-2007 17 0.9 Japan1 Aichi Prefecture 2003-2007 18 0.4 0.0 (Continued on next page) ICO HPV Information Centre .4 Hiroshima 2003-2007 26 0.6 Trabzon 2005-2007 4 0.3 New Delhi 2003-2007 104 0.

3 BURDEN OF HPV RELATED CANCERS - 70 -

( Table 8 – continued from previous page)
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
Ho Chi Minh City 1995-1998 35 0.4 0.4
Europe
Austria1 National 2003-2007 660 3.1 1.5
Tyrol 2003-2007 44 2.5 1.5
Vorarlberg 2003-2007 27 3.0 1.5
Belarus1 National 2003-2007 755 2.9 1.3
Belgium1 National 2004-2007 710 3.3 1.5
Bulgaria1 National 2003-2007 619 3.1 1.3
Croatia1 National 2003-2007 346 3.0 1.2
Cyprus1 National 2003-2007 39 2.0 1.1
Czech Rep.1 National 2003-2007 1000 3.8 1.8
Denmark1 National 2003-2007 471 3.4 1.7
Estonia1 National 2003-2007 132 3.6 1.4
Finland1 National 2003-2007 376 2.8 1.2
France1 Bas-Rhin 2003-2007 84 3.1 1.3
Calvados 2003-2007 26 1.5 0.7
Doubs 2003-2007 46 3.5 1.5
Haut-Rhin 2003-2007 51 2.7 1.3
Herault 2003-2007 42 1.6 0.5
Isere 2003-2007 44 1.5 0.7
Loire Atlantique 2003-2007 51 1.6 0.7
Manche 2003-2007 21 1.7 0.8
Martinique 2003-2007 3 0.3 0.2
Somme 2003-2007 29 2.0 0.9
Tarn 2003-2007 20 2.1 0.8
Vendee 2003-2007 22 1.5 0.9
Germany1 Brandenburg 2003-2007 301 4.7 1.9
Bremen 2003-2007 90 5.3 2.0
Free State Of Saxony 2003-2007 603 5.5 1.8
Hamburg 2003-2007 257 5.8 2.5
Mecklenburg-Western Pomerania 2003-2007 199 4.6 1.7
Munich 2003-2007 420 4.2 1.7
North Rhine-Westphalia 2003-2007 326 4.9 2.1
Saarland 2003-2007 255 9.4 4.1
Schleswig-Holstein 2003-2007 585 8.1 3.6
Iceland1 National 2003-2007 11 1.5 0.9
Ireland1 National 2003-2007 217 2.1 1.3
Italy1 Biella 2003-2007 27 5.5 1.7
Brescia 2003-2006 50 2.3 0.9
Catania and Messina 2003-2005 72 2.7 1.1
Catanzaro 2003-2007 22 3.6 1.6
Como 2003-2007 56 3.9 1.2
Ferrara 2003-2007 42 4.6 1.5
Florence and Prato 2003-2005 72 3.9 1.1
Friuli-Venezia Giulia 2003-2007 131 4.2 1.1
Genoa 2003-2006 101 5.4 1.7
Latina 2003-2007 44 3.3 1.4
Lecco 2003-2007 21 2.6 0.9
Lombardy, South 2003-2005 42 3.8 1.3
Mantua 2003-2005 27 4.5 1.3
Milan 2003-2006 73 2.7 0.7
Modena 2003-2007 77 4.5 1.3
Naples 2003-2007 41 2.9 1.8
Nuoro 2003-2007 8 1.3 0.6

(Continued on next page)

ICO HPV Information Centre

3 BURDEN OF HPV RELATED CANCERS - 71 -

( Table 8 – continued from previous page)
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
Palermo 2003-2006 78 3.0 1.4
Parma 2003-2007 30 2.8 0.8
Ragusa 2003-2007 21 2.7 1.2
Reggio Emilia 2003-2007 49 3.9 1.3
Romagna 2003-2007 117 4.0 1.1
Salerno 2003-2007 77 2.8 1.2
Sassari 2003-2007 19 1.6 0.8
Sondrio 2003-2007 19 4.2 1.3
South Tyrol 2003-2006 35 3.6 1.6
Syracuse 2003-2007 22 2.2 1.0
Trapani 2003-2006 38 4.3 1.5
Trento 2003-2006 41 4.0 1.5
Turin 2003-2007 84 3.6 1.0
Umbria 2003-2007 105 4.7 1.4
Varese 2003-2007 67 3.1 1.0
Veneto 2003-2006 174 3.7 1.3
Latvia1 National 2004-2007 162 3.3 1.4
Lithuania1 National 2003-2007 274 3.0 1.3
Malta1 National 2003-2007 36 3.5 1.6
Netherlands1 Eindhoven 2003-2007 84 3.3 1.7
National 2003-2007 1416 3.4 1.7
Norway1 National 2003-2007 451 3.9 1.9
Poland1 Cracow 2003-2006 33 2.0 0.9
Kielce 2003-2007 70 2.1 0.8
Lower Silesia 2003-2007 196 2.6 1.3
Podkarpackie 2003-2007 106 2.0 1.0
Portugal1 Azores 2003-2007 8 1.3 0.7
Russia1 Saint Petersburg 2003-2007 354 2.8 1.1
Serbia1 Central 2003-2007 459 3.3 1.6
Slovakia1 National 2003-2007 350 2.5 1.3
Slovenia1 National 2003-2007 247 4.8 2.1
Spain1 Albacete 2003-2007 29 3.0 1.0
Asturias 2003-2007 101 3.6 1.2
Basque Country 2003-2007 160 3.0 1.2
Canary Islands 2003-2006 62 1.9 1.0
Ciudad Real 2004-2007 24 2.4 1.0
Cuenca 2003-2007 17 3.3 1.2
Girona 2003-2007 43 2.7 1.1
Granada 2003-2007 50 2.3 1.0
La Rioja 2003-2007 22 3.0 0.8
Mallorca 2003-2007 68 3.5 1.5
Murcia 2003-2007 66 2.0 1.0
Navarra 2003-2007 47 3.2 1.0
Tarragona 2003-2007 56 3.3 1.2
Sweden1 National 2003-2007 803 3.5 1.4
Switzerland1 Basel 2003-2007 40 3.5 1.2
Geneva 2003-2007 31 2.8 1.3
Graubunden and Glarus 2003-2007 20 3.5 1.6
Neuchatel 2003-2007 12 2.8 1.6
St Gall-Appenzell 2003-2007 34 2.5 1.1
Ticino 2003-2007 24 2.9 0.8
Valais 2003-2007 16 2.2 0.7
Vaud 2003-2007 56 3.3 1.4
Zurich 2003-2007 102 3.2 1.4

(Continued on next page)

ICO HPV Information Centre

3 BURDEN OF HPV RELATED CANCERS - 72 -

( Table 8 – continued from previous page)
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
UK1 England 2003-2007 4408 3.4 1.6
England, East of England Region 2003-2007 440 3.1 1.4
England, North Western 2003-2007 580 3.5 1.7
England, Northern and Yorkshire 2003-2007 649 3.8 1.8
England, Oxford Region 2003-2007 210 3.0 1.6
England, South and Western Regions 2003-2007 731 4.2 1.7
England, Thames 2003-2007 759 2.5 1.3
England, Trent 2005-2007 322 4.3 1.9
England, West Midlands 2003-2007 523 3.8 1.8
Northern Ireland 2003-2007 122 2.8 1.5
Scotland 2003-2007 493 3.7 1.9
Wales 2003-2007 342 4.5 2.0
Ukraine1 National 2003-2007 3345 2.6 1.1
Oceania
Australia1 Australian Capital Territory 2003-2007 16 1.9 1.3
New South Wales 2003-2007 445 2.6 1.4
Northern Territory (Indigenous) 2003-2007 7 4.4 4.6
Northern Territory 2003-2007 15 3.0 3.0
Northern Territory (Non-Indigenous) 2003-2007 8 2.4 2.5
Queensland 2003-2007 208 2.1 1.2
South 2003-2007 107 2.7 1.2
Tasmania 2003-2007 36 2.9 1.4
Victoria 2003-2007 333 2.6 1.4
Western 2003-2007 120 2.4 1.4
New Zealand1 National (Other) 2003-2007 219 2.6 1.3
National (Pacific Islander) 2003-2007 3 0.5 0.6
National (Maori) 2003-2007 23 1.4 1.7
National 2003-2007 245 2.3 1.4
Data accessed on 05 May 2015.
a Accumulated number of cases during the period in the population covered by the corresponding registry.
b Rates per 100,000 women per year.
Data sources:
1 Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds (2013). Cancer Incidence in Five Continents, Vol. X
(electronic version) Lyon, IARC. http://ci5.iarc.fr
2 Parkin, D.M., Whelan, S.L., Ferlay, J., Teppo, L., and Thomas, D.B., eds (2002). Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Publications No. 155, Lyon, IARC.
3 Curado. M. P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M. and Boyle. P., eds (2007). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160,
Lyon, IARC.

NOTE.

For time trends in vulvar cancer incidence, please refer to individual country data.

ICO HPV Information Centre

3 BURDEN OF HPV RELATED CANCERS - 73 -

3.2.3 Vaginal cancer

Cancer of the vagina is a rare cancer, with an estimated 13,000 new cases in 2008, representing 2% of
all gynaecologic cancers (de Martel C et al. Lancet Oncol 2012;13(6):607-15). Although unreported and
similar to cervical cancer, the majority of vaginal cancer cases (68%) occur in less developed countries.
Most vaginal cancers are squamous cell carcinoma (90%) generally attributable to HPV, followed by
clear cell adenocarcinomas and melanoma. Metastatic cervical cancer can be misclassified as cancer of
the vagina. Invasive vaginal cancer is diagnosed primarily in old women (>=65 years) and the diagnosis
is rare in women under 45 years whereas the peak incidence of carcinoma in situ is observed between
ages 55 and 70 (Vaccine 2008, Vol. 26, Suppl 10)

Table 9: Incidence of vaginal cancer by cancer registry
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
Africa
Algeria1 Setif 2003-2007 3 0.1 0.1
Egypt1 Gharbiah 2003-2007 15 0.2 0.2
Gambia2 National 1997-1998 2 0.2 0.2
Libya1 Benghazi 2003-2005 3 0.1 0.2
Malawi1 Blantyre 2003-2007 16 0.7 1.4
Mali2 Bamako 1994-1996 1 0.1 0.1
South Africa1 PROMEC 2003-2007 8 0.3 0.3
Tunisia1 North 2003-2005 20 0.3 0.3
Uganda1 Kyadondo county 2003-2007 9 0.2 0.6
Zimbabwe1 Harare (African) 2003-2006 4 0.1 0.2
Americas
Argentina1 Bahia Blanca 2003-2007 11 1.5 1.0
Cordoba 2004-2007 14 0.5 0.4
Mendoza 2003-2007 24 0.6 0.5
Tierra del Fuego 2003-2007 1 0.4 0.4
Brazil1 Aracaju 2003-2006 6 0.6 0.9
Belo Horizonte 2003-2005 24 0.6 0.6
Cuiaba 2003-2006 7 0.4 0.6
Fortaleza 2003-2006 22 0.4 0.5
Goiania 2003-2007 22 0.7 0.8
Sao Paulo 2003-2007 348 1.2 1.1
Canada1 Alberta 2003-2007 53 0.6 0.4
British Columbia 2003-2007 84 0.8 0.4
Manitoba 2003-2007 20 0.7 0.4
National 2003-2007 621 0.8 0.4
New Brunswick 2003-2007 21 1.1 0.5
Newfoundland and Labrador 2003-2007 7 0.5 0.3
Northwest Territories 2003-2007 1 1.0 1.7
Nova Scotia 2003-2007 33 1.4 0.7
Ontario 2003-2007 251 0.8 0.5
Prince Edward Island 2003-2007 3 0.9 0.5
Quebec 2003-2007 135 0.7 0.3
Saskatchewan 2003-2007 13 0.5 0.3
Yukon 2003-2007 0 0.0 0.0
Chile1 Bío Bío Province 2003-2007 9 1.0 0.8
Region of Antofagasta 2003-2007 7 0.5 0.6
Valdivia 2003-2007 2 0.2 0.2
Colombia1 Bucaramanga 2003-2007 20 0.7 0.8
Cali 2003-2007 31 0.6 0.6
Manizales 2003-2007 5 0.5 0.5
Pasto 2003-2007 0 0.0 0.0
Costa Rica1 National 2003-2007 25 0.2 0.2
Cuba1 Villa Clara 2004-2007 4 0.2 0.1

(Continued on next page)

ICO HPV Information Centre

3 BURDEN OF HPV RELATED CANCERS - 74 -

( Table 9 – continued from previous page)
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
Ecuador1 Cuenca 2003-2007 5 0.4 0.4
Quito 2003-2007 15 0.4 0.5
Jamaica1 Kingston and St Andrew 2003-2007 3 0.2 0.1
Peru3 Trujillo 1998-2002 2 0.1 0.2
Uruguay1 National 2005-2007 39 0.8 0.4
USA1 Alabama (Black) 2003-2007 25 0.8 0.6
Alabama (White) 2003-2007 67 0.8 0.4
Alabama 2003-2007 94 0.8 0.5
Alaska 2003-2007 12 0.7 0.6
Alaska (American Indian) 2003-2007 2 0.7 0.6
Arizona (Asian and Pacific Islander) 2003-2007 1 0.2 0.3
Arizona (American Indian) 2003-2007 1 0.1 0.2
Arizona 2003-2007 81 0.5 0.3
Arizona (Black) 2003-2007 0 0.0 0.0
Arizona (White) 2003-2007 77 0.6 0.3
Arkansas 2003-2007 64 0.9 0.5
Arkansas (White) 2003-2007 52 0.9 0.5
Arkansas (Black) 2003-2007 12 1.0 0.8
California (American Indian) 2003-2007 1 0.1 0.1
California (Asian and Pacific Islander) 2003-2007 47 0.4 0.3
California (Black) 2003-2007 52 0.8 0.6
California (White) 2003-2007 476 0.7 0.4
California 2003-2007 593 0.7 0.4
California, Los Angeles County 2003-2007 177 0.7 0.5
California, Los Angeles County (Black) 2003-2007 18 0.7 0.6
California, Los Angeles County (Chinese) 2003-2007 6 0.6 0.4
California, Los Angeles County (Filipino) 2003-2007 4 0.5 0.3
California, Los Angeles County (Hispanic 2003-2007 64 0.6 0.6
White)
California, Los Angeles County (Japanese) 2003-2007 1 0.3 0.1
California, Los Angeles County (Korean) 2003-2007 3 0.5 0.3
California, Los Angeles County 2003-2007 75 1.0 0.5
(Non-Hispanic White)
California, Los Angeles County (White) 2003-2007 139 0.8 0.5
California, Los Angeles County (Asian and 2003-2007 18 0.5 0.3
Pacific Islander)
California: San Francisco (Asian and 2003-2007 14 0.6 0.4
Pacific Islander)
California: San Francisco (Hispanic White) 2003-2007 10 0.6 0.6
California: San Francisco 2003-2007 71 0.7 0.4
California: San Francisco (Black) 2003-2007 12 1.1 0.8
California: San Francisco (Non-Hispanic 2003-2007 35 0.7 0.4
White)
California: San Francisco (White) 2003-2007 45 0.7 0.4
Colorado 2003-2007 71 0.6 0.4
Colorado (Asian and Pacific Islander) 2003-2007 5 1.4 1.1
Colorado (Black) 2003-2007 4 0.8 0.8
Colorado (White) 2003-2007 62 0.6 0.4
Connecticut (Black) 2003-2007 9 0.9 0.8
Connecticut 2003-2007 80 0.9 0.4
Connecticut (White) 2003-2007 69 0.9 0.4
Delaware (Black) 2003-2007 5 1.1 0.8
Delaware (White) 2003-2007 10 0.6 0.4
Delaware 2003-2007 15 0.7 0.4
Florida 2003-2007 363 0.8 0.4
Florida (Asian and Pacific Islander) 2003-2007 5 0.4 0.3

(Continued on next page)

ICO HPV Information Centre

3 BURDEN OF HPV RELATED CANCERS - 75 -

( Table 9 – continued from previous page)
Female
Country name Cancer registry Period N casesa Crude rateb ASRb
Florida (Black) 2003-2007 62 0.8 0.7
Florida (White) 2003-2007 290 0.8 0.4
Georgia 2003-2007 203 0.9 0.6
Georgia (Asian and Pacific Islander) 2003-2007 2 0.3 0.3
Georgia (Black) 2003-2007 69 1.0 0.9
Georgia (White) 2003-2007 132 0.9 0.5
Georgia, Atlanta 2003-2007 63 0.8 0.6
Georgia, Atlanta (Black) 2003-2007 31 0.9 1.1
Georgia, Atlanta (White) 2003-2007 31 0.7 0.4
Hawaii (Filipino) 2003-2007 2 0.4 0.3
Hawaii (Hawaiian) 2003-2007 4 0.6 0.6
Hawaii (Japanese) 2003-2007 3 0.5 0.1
Hawaii (White) 2003-2007 8 1.1 0.5
Hawaii (Chinese) 2003-2007 1 0.6 0.1
Hawaii 2003-2007 22 0.7 0.4
Idaho 2003-2007 28 0.8 0.5
Illinois (Black) 2003-2007 59 1.1 0.8
Illinois (White) 2003-2007 182 0.7 0.4
Illinois (Asian and Pacific Islander) 2003-2007 7 0.5 0.4
Illinois 2003-2007 252 0.8 0.5
Indiana (Black) 2003-2007 13 0.9 0.7
Indiana (White) 2003-2007 112 0.8 0.4
Indiana 2003-2007 126 0.8 0.5
Iowa 2003-2007 65 0.9 0.4
Kentucky 2003-2007 105 1.0 0.6
Louisiana 2003- 82 0.9 0.6
2004,2006-
2007
Louisiana (White) 2003- 59 1.0 0.6
2004,2006-
2007
Louisiana (Black) 2003- 23 0.8 0.6
2004,2006-
2007
Louisiana, New Orleans 2003- 17 1.0 0.6
2004,2006-
2007
Louisiana, New Orleans (Black) 2003- 3 0.4 0.3
2004,2006-
2007
Louisiana, New Orleans (White) 2003- 14 1.5 0.9
2004,2006-
2007
Maine 2003-2007 32 1.0 0.5
Massachusetts 2003-2007 123 0.7 0.4
Massachusetts (Asian and Pacific Islander) 2003-2007 2 0.2 0.3
Massachusetts (Black) 2003-2007 16 1.3 1.3
Massachusetts (White) 2003-2007 103 0.7 0.4
Michigan 2003-2007 224 0.9 0.5
Michigan (Asian and Pacific Islander) 2003-2007 1 0.2 0.2
Michigan (Black) 2003-2007 30 0.8 0.6
Michigan (White) 2003-2007 186 0.9 0.5
Michigan, Detroit 2003-2007 94 0.9 0.5
Michigan, Detroit (Black) 2003-2007 28 1.0 0.8
Michigan, Detroit (White) 2003-2007 66 0.9 0.5
Mississippi 2003-2007 68 0.9 0.6
Missouri 2003-2007 112 0.8 0.4

(Continued on next page)

ICO HPV Information Centre

7 0.1 0.3 Islander) SEER (18 Registries) (Black) 2003-2007 227 0.5 0.1 0.1 0.6 0.3 New Jersey 2003-2007 191 0.8 0.4 Montana 2003-2007 17 0.4 Ohio 2003-2007 224 0.4 NPCR (42 States) (American Indian) 2003-2007 25 0.4 Ohio (Asian and Pacific Islander) 2003-2007 3 0.9 0.4 Oregon (Asian and Pacific Islander) 2003-2007 1 0.7 Missouri (White) 2003-2007 95 0.8 0.3 New Hampshire 2003-2007 17 0.2 0.8 0.5 New York State (Asian and Pacific 2003-2007 10 0.4 Oklahoma 2003-2007 76 0.8 0.8 (Continued on next page) ICO HPV Information Centre .4 Montana (American Indian) 2003-2007 2 1.8 New York State (White) 2003-2007 286 0.3 Rhode Island (Black) 2003-2007 0 0.8 0.0 0.4 New Mexico (White) 2003-2007 34 0.0 SEER (18 Registries) (Asian and Pacific 2003-2007 87 0.4 New Jersey (Black) 2003-2007 35 1.3 0.1 Oregon (White) 2003-2007 54 0.9 New Mexico 2003-2007 36 0.4 Nebraska (Black) 2003-2007 2 1.6 0.4 Oklahoma (White) 2003-2007 64 0.6 0.0 1.7 Rhode Island 2003-2007 16 0.5 0.9 0.5 Oklahoma (American Indian) 2003-2007 8 1.3 0.5 0.3 Islander) NPCR (42 States) (Black) 2003-2007 808 0.5 North Carolina (White) 2003-2007 129 0.7 0.7 Ohio (Black) 2003-2007 29 0.4 Pennsylvania (Black) 2003-2007 34 1.6 0.7 NPCR (42 States) (White) 2003-2007 4035 0.2 Oregon (Black) 2003-2007 2 1.7 Pennsylvania (Asian and Pacific Islander) 2003-2007 1 0.5 Oregon 2003-2007 58 0.0 0.1 North Carolina (American Indian) 2003-2007 1 0.4 North Carolina 2003-2007 173 0.8 0.0 1.7 0.7 0.4 North Carolina (Asian and Pacific Islander) 2003-2007 1 0.8 0.5 New Jersey (White) 2003-2007 143 0.0 Nebraska (White) 2003-2007 26 0.0 0.8 0.3 0.3 1.3 0.3 NPCR (42 States) (Asian and Pacific 2003-2007 116 0.6 0.9 0.8 0.8 Oklahoma (Black) 2003-2007 4 0.5 0.6 New Mexico (Non-Hispanic White) 2003-2007 20 0.4 North Carolina (Black) 2003-2007 42 0.5 Ohio (White) 2003-2007 189 0.1 Pennsylvania 2003-2007 277 0.4 New Mexico (Hispanic White) 2003-2007 14 0.4 Pennsylvania (White) 2003-2007 237 0.7 0.8 0.4 0.9 0.7 0.6 North Dakota 2003-2007 8 0.9 0.8 0.76 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Missouri (Black) 2003-2007 16 0.7 0.3 BURDEN OF HPV RELATED CANCERS .4 Puerto Rico 2003-2007 110 1.2 Islander) New York State (Black) 2003-2007 99 1.5 New York State 2003-2007 403 0.9 0.3 Nebraska 2003-2007 29 0.9 0.2 NPCR (42 States) 2003-2007 5057 0.3 Rhode Island (White) 2003-2007 15 0.8 0.0 0.9 0.

5 SEER (18 Registries) 2003-2007 1578 0.8 0.0 0.5 South Dakota 2003-2007 13 0.3 0.8 South Carolina (Black) 2003-2007 24 0.2 0.6 0.5 West Virginia 2003-2007 47 1.0 Jiaxing City 2005-2007 1 0.3 Yanting County 2003-2007 1 0.7 Virginia 2003-2007 139 0.7 Texas 2003-2007 391 0.1 Haining County 2003-2007 2 0.9 0.77 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb SEER (18 Registries) (Hispanic White) 2003-2007 175 0.8 Karunagappally 2003-2007 2 0.5 South Carolina (White) 2003-2007 74 1.7 0.5 0.8 Dindigul.5 Texas (White) 2003-2007 315 0.5 0.4 Texas (Asian and Pacific Islander) 2003-2007 6 0.4 Washington.0 0.5 SEER (9 Registries) (Black) 2003-2007 85 0.9 0.1 0.7 Tennessee (White) 2003-2007 110 0.7 0.3 India1 Bangalore 2005-2007 54 0.2 0.8 0.7 0.1 Harbin City.7 0.3 BURDEN OF HPV RELATED CANCERS .4 White) SEER (9 Registries) (White) 2003-2007 410 0.3 Wyoming 2003-2007 11 0.0 0.3 Vermont 2003-2007 17 1.3 Hong Kong 2003-2007 97 0.8 Barshi.2 Cixian County 2003-2007 2 0.1 Macao 2003-2007 6 0.4 Virginia (Asian and Pacific Islander) 2003-2007 5 0.9 0.3 Tennessee (Black) 2003-2007 21 0.2 Yangcheng County 2003-2007 3 0.1 0.5 SEER (18 Registries) (Non-Hispanic 2003-2007 1068 0.1 0.9 0.1 0.8 0.1 0. Paranda and Bhum 2003-2007 6 0.4 0.5 Tennessee 2003-2007 136 0. Seattle 2003-2007 82 0.3 0.0 0.8 0.7 Wisconsin 2003-2007 81 0.2 0.0 China1 Beijing City 2003-2007 41 0.5 0.4 SEER (9 Registries) 2003-2007 536 0.5 Washington State 2003-2007 118 0.3 0.6 0.4 Chennai 2003-2007 79 0.3 0.5 Wisconsin (Black) 2003-2007 7 0.6 0. Ambilikkai 2003-2007 39 0.5 0.8 0.7 Virginia (White) 2003-2007 91 0.2 0.1 Wuhan City 2003-2007 29 0.8 0.4 0.8 0.8 0.7 Asia Bahrain1 National (Bahraini) 2003-2007 0 0.1 Shanghai City 2003-2007 39 0.7 0.9 0. Nangang District 2003-2007 10 0.3 0.0 0.3 Jiashan County 2003-2007 0 0.7 0.3 Wisconsin (White) 2003-2007 73 0.5 Utah 2003-2007 23 0.5 SEER (18 Registries) (White) 2003-2007 1243 0.1 Zhongshan City 2004-2007 9 0.1 0.3 (Continued on next page) ICO HPV Information Centre .3 Texas (Black) 2003-2007 65 0.4 Qidong County 2003-2007 2 0.9 0.4 Virginia (Black) 2003-2007 40 1.9 0.6 0.2 Mizoram 2003-2007 4 0.5 0.5 Bhopal 2004-2007 7 0.7 0.5 South Carolina 2003-2007 100 0.

3 Qatar1 National (Qatari) 2003-2007 0 0.3 0.2 0.3 0.2 (Continued on next page) ICO HPV Information Centre .3 National (Non-Jews) 2003-2007 1 0.2 Incheon 2003-2007 12 0.2 0.1 Gwangju 2003-2007 8 0.1 Trabzon 2005-2007 2 0.0 National (Jews) 2003-2007 70 0.2 0.2 0.2 0.3 Chonburi 2003-2007 5 0.0 0.0 National (Kuwaitis) 2003-2007 1 0.3 0.2 Seoul 2003-2007 67 0.2 0.0 0.1 Viet Nam2 Hanoi 1993-1997 8 0.0 0.2 Miyagi Prefecture 2003-2007 23 0.1 0.4 0.2 0.6 Sikkim State 2003-2007 4 0.6 0.1 0.3 0.1 Niigata Prefecture 2003-2007 21 0.2 0.3 0.4 0.3 BURDEN OF HPV RELATED CANCERS .0 0.1 Singapore1 National (Indian) 2003-2007 2 0.5 0.1 Songkhla 2004-2007 3 0.78 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Mumbai 2003-2007 160 0.2 Kuwait1 National 2003-2007 1 0.5 0.2 Jejudo 2004-2007 3 0.8 Penang 2004-2007 9 0.3 National (Malay) 2003-2007 4 0.3 0.4 0.2 Ulsan 2003-2007 10 0.1 Lampang 2003-2007 3 0.1 0.6 Trivandrum 2005-2007 8 0.5 0.3 National (Chinese) 2003-2007 31 0.1 0.2 Osaka Prefecture 2003-2007 75 0.2 0.2 0.4 0.3 0.4 Poona 2003-2007 44 0.2 0. Korea1 Busan 2003-2007 15 0.4 0.4 National 2003-2007 38 0.1 Daegu 2003-2007 24 0.3 0.2 Edirne 2004-2007 1 0.4 0.7 0.1 Saga Prefecture 2003-2007 15 0.2 Khon Kaen 2003-2007 7 0.3 0.3 Thailand1 Bangkok 2003-2007 47 0.3 Fukui Prefecture 2003-2007 8 0.2 Oman3 Omani 1998-2001 6 0.7 New Delhi 2003-2007 97 0.0 Rep.2 National 2003-2007 295 0.1 0.1 Izmir 2003-2007 16 0.3 Penang (Chinese) 2004-2007 4 0.3 0.1 National (Non-Kuwaitis) 2003-2007 0 0.2 0.0 0.2 0.3 Chiang Mai 2003-2007 13 0.7 0.4 0.4 0.2 0.4 Iran1 Golestan Province 2005-2007 3 0.1 Nagasaki Prefecture 2003-2007 12 0.3 Japan1 Aichi Prefecture 2003-2007 15 0.1 Turkey1 Antalya 2003-2007 6 0.2 0.1 Malaysia1 Penang (Malay) 2004-2007 3 0.2 Hiroshima 2003-2007 11 0.3 0.3 Rizal 2003-2007 31 0.4 Saudi Arabia1 Riyadh (Saudi) 2003-2007 6 0.3 Daejeon 2003-2007 5 0.2 Israel1 National 2003-2007 71 0.1 0.3 Pakistan3 South Karachi 1998-2002 6 0.3 0.3 0.3 Penang (Indian) 2004-2007 2 0.3 Philippines1 Manila 2003-2007 33 0.4 0.

9 0.2 0.2 Vendee 2003-2007 12 0.2 Loire Atlantique 2003-2007 22 0.1 0.6 0.8 0.8 Belarus1 National 2003-2007 168 0.5 Ferrara 2003-2007 11 1.4 0. South 2003-2005 13 1.4 North Rhine-Westphalia 2003-2007 61 0.1 (Continued on next page) ICO HPV Information Centre .3 0.4 Estonia1 National 2003-2007 29 0.4 0.3 Genoa 2003-2006 18 1.4 Vorarlberg 2003-2007 13 1.1 0.4 Belgium1 National 2004-2007 197 0.9 0.6 0.1 Friuli-Venezia Giulia 2003-2007 26 0.3 Isere 2003-2007 14 0.9 0.2 0.3 Germany1 Brandenburg 2003-2007 62 1.0 0.0 0.4 0.2 0.5 Somme 2003-2007 12 0.3 Free State Of Saxony 2003-2007 131 1.6 0.0 0.5 0.1 Lecco 2003-2007 6 0.1 0.8 0.4 Italy1 Biella 2003-2007 3 0.2 Lombardy.79 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Ho Chi Minh City 1995-1998 16 0.2 0.8 0.4 Saarland 2003-2007 32 1.5 Denmark1 National 2003-2007 122 0.7 0.0 0.5 0.4 Bulgaria1 National 2003-2007 139 0.7 0.7 0.3 Nuoro 2003-2007 2 0.6 Mecklenburg-Western Pomerania 2003-2007 45 1.2 Florence and Prato 2003-2005 12 0.3 Croatia1 National 2003-2007 76 0.6 0.0 0.3 BURDEN OF HPV RELATED CANCERS .7 0.3 France1 Bas-Rhin 2003-2007 15 0.3 Calvados 2003-2007 12 0.9 0.3 Cyprus1 National 2003-2007 3 0.3 Naples 2003-2007 6 0.2 Europe Austria1 National 2003-2007 239 1.3 0.7 0.4 Bremen 2003-2007 18 1.2 Latina 2003-2007 4 0.1 Ireland1 National 2003-2007 59 0.2 Haut-Rhin 2003-2007 14 0.3 Modena 2003-2007 9 0.3 0.0 0.4 Finland1 National 2003-2007 97 0.1 Czech Rep.4 0.4 Munich 2003-2007 97 1.4 Mantua 2003-2005 6 1.6 0.7 0.2 0.3 0.8 0.3 Catanzaro 2003-2007 8 1.8 0.2 0.1 Catania and Messina 2003-2005 16 0.0 0.1 Martinique 2003-2007 10 0.7 0.4 Hamburg 2003-2007 63 1.1 National 2003-2007 247 0.2 0.6 0.5 Tyrol 2003-2007 19 1.9 0.1 Brescia 2003-2006 8 0.3 Manche 2003-2007 3 0.4 0.4 Iceland1 National 2003-2007 2 0.4 Milan 2003-2006 23 0.5 Como 2003-2007 14 1.4 Doubs 2003-2007 5 0.5 0.5 Schleswig-Holstein 2003-2007 71 1.3 Herault 2003-2007 15 0.3 Tarn 2003-2007 5 0.5 0.

8 0.3 Umbria 2003-2007 25 1.4 Slovakia1 National 2003-2007 94 0.4 0.5 Basque Country 2003-2007 34 0.3 0.6 0.7 0.3 Norway1 National 2003-2007 77 0.8 0.1 0.1 0.3 Malta1 National 2003-2007 5 0.0 0.2 La Rioja 2003-2007 2 0.2 Valais 2003-2007 1 0.4 0.5 0.7 0.2 0.3 Serbia1 Central 2003-2007 112 0.1 Lower Silesia 2003-2007 54 0.4 Podkarpackie 2003-2007 29 0.6 0.5 Turin 2003-2007 20 0.2 Navarra 2003-2007 3 0.4 Neuchatel 2003-2007 4 0.9 0.2 Latvia1 National 2004-2007 31 0.3 Lithuania1 National 2003-2007 53 0.1 Vaud 2003-2007 13 0.5 0.4 Slovenia1 National 2003-2007 46 0.4 Trapani 2003-2006 4 0.3 Salerno 2003-2007 17 0.3 National 2003-2007 247 0.3 Romagna 2003-2007 25 0.3 BURDEN OF HPV RELATED CANCERS .9 0.1 Mallorca 2003-2007 8 0.4 Spain1 Albacete 2003-2007 3 0.4 0.1 0.80 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb Palermo 2003-2006 17 0.9 0.3 Trento 2003-2006 11 1.3 Canary Islands 2003-2006 11 0.4 Reggio Emilia 2003-2007 10 0.3 0.2 0.3 Ragusa 2003-2007 6 0.3 Murcia 2003-2007 14 0.1 0.4 Geneva 2003-2007 5 0.2 Asturias 2003-2007 32 1.3 0.6 0.8 0.8 0.0 0.7 0.4 Russia1 Saint Petersburg 2003-2007 80 0.9 0.5 0.6 0.3 Parma 2003-2007 7 0.8 0.2 0.4 0.3 0.3 Sondrio 2003-2007 1 0.6 0.2 St Gall-Appenzell 2003-2007 13 1.3 Poland1 Cracow 2003-2006 7 0.2 0.7 0.8 0.7 0.6 0.4 0.6 0.5 Ticino 2003-2007 5 0.0 Girona 2003-2007 4 0.2 0.2 Ciudad Real 2004-2007 2 0.8 0.3 Switzerland1 Basel 2003-2007 11 1.3 Veneto 2003-2006 34 0.6 0.3 Syracuse 2003-2007 7 0.0 0.1 Granada 2003-2007 11 0.2 Netherlands1 Eindhoven 2003-2007 14 0.1 Cuenca 2003-2007 0 0.3 Zurich 2003-2007 25 0.2 Graubunden and Glarus 2003-2007 5 0.3 Portugal1 Azores 2003-2007 5 0.6 0.7 0.0 Tarragona 2003-2007 5 0.7 0.2 Sweden1 National 2003-2007 205 0.9 0.5 0.2 South Tyrol 2003-2006 6 0.4 Varese 2003-2007 15 0.2 Kielce 2003-2007 6 0.4 (Continued on next page) ICO HPV Information Centre .7 0.3 Sassari 2003-2007 7 0.

Heanue.. Cancer Incidence in Five Continents.L..0 0. IARC. Whelan. J.iarc.9 0. Data sources: 1 Forman D.8 0. Brewster DH.6 0. Shin.6 0. please refer to individual country data. ICO HPV Information Centre .4 England.. 160. Northern and Yorkshire 2003-2007 151 0. Cancer Incidence in Five Continents.fr/CI5i-ix/ci5i-ix.3 Scotland 2003-2007 104 0.7 0.6 0. D. Please refer to original source (available at http://ci5. Teppo. Lyon.7 0.5 England.. 155. Ferlay. Vol.4 South 2003-2007 32 0..2 Victoria 2003-2007 62 0. eds (2002).fr 2 Parkin.iarc.6 Northern Territory (Non-Indigenous) 2003-2007 2 0.8 0.6 Queensland 2003-2007 62 0.4 England.4 Northern Territory (Indigenous) 2003-2007 1 0.7 New Zealand1 National (Other) 2003-2007 50 0.8 0. B. Kohler B. Piñeros M.4 England.4 Data accessed on 05 May 2015. Steliarova-Foucher E. b Rates per 100. Swaminathan R and Ferlay J eds (2013).3 National (Pacific Islander) 2003-2007 2 0.B. H.4 National (Maori) 2003-2007 8 0. 3 Curado..5 0.8 0.6 0. IARC.0 Northern Territory 2003-2007 3 0. S. East of England Region 2003-2007 79 0.4 Northern Ireland 2003-2007 21 0.6 0.6 1. Gombe Mbalawa C. West Midlands 2003-2007 102 0.5 New South Wales 2003-2007 130 0.9 0.000 women per year. IARC. Edwards. Oxford Region 2003-2007 53 0. X (electronic version) Lyon.1 0.4 Tasmania 2003-2007 6 0. L. Lyon. Ferlay.6 0..R.8 0.81 - ( Table 9 – continued from previous page) Female Country name Cancer registry Period N casesa Crude rateb ASRb UK1 England 2003-2007 1001 0. Vol. Cancer Incidence in Five Continents.3 Western 2003-2007 53 1.. South and Western Regions 2003-2007 163 0.4 Wales 2003-2007 70 0. and Thomas. Storm. H. IARC Scientific Publications No.3 0.4 England. D.5 England. J.4 England.htm) a Accumulated number of cases during the period in the population covered by the corresponding registry.8 0. IARC Scientific Publications No.. Trent 2005-2007 79 1. http://ci5. For time trends in vaginal cancer incidence.. Bray F. IX.8 0. and Boyle. eds (2007).5 0. P. NOTE.6 0. P. M. North Western 2003-2007 138 0.3 Oceania Australia1 Australian Capital Territory 2003-2007 6 0.5 0.M.7 National 2003-2007 60 0.9 0..4 Ukraine1 National 2003-2007 765 0.3 England. M.3 BURDEN OF HPV RELATED CANCERS . Vol. Thames 2003-2007 195 0.5 0. VIII.

0 Newfoundland and Labrador 2003-2007 18 1.4 Penile cancer The annual burden of penile cancer has been estimated to be 22. verrucous (8%) warty (6%).3 1. Precursor cancerous penile lesions (PeIN) are rare.2 Zimbabwe1 Harare (African) 2003-2006 14 0.8 0.8 0.3 Manitoba 2003-2007 31 1.9 0.5 0. mixed warty-basaloid (17%).6 Valdivia 2003-2007 10 1.5 0.5 Belo Horizonte 2003-2005 24 0.4 South Africa1 PROMEC 2003-2007 11 0.6 1.7 1.2 1.4 Tierra del Fuego 2003-2007 2 0.8 0.2 Cordoba 2004-2007 33 1.7 Canada1 Alberta 2003-2007 77 0.5 1.1 0. South America and Asia.8 2.82 - 3.0 Malawi1 Blantyre 2003-2007 33 1. accounting for up to 10% of male cancers in some parts of Africa.7 0.1 Gambia2 National 1997-1998 5 0.9 Northwest Territories 2003-2007 0 0.3 BURDEN OF HPV RELATED CANCERS .9 2.9 Cuiaba 2003-2006 20 1.3 2. and basaloid (4%). Incidence rates are higher in less developed countries than in more developed countries.9 Libya1 Benghazi 2003-2005 0 0. Table 10: Incidence of penile cancer by cancer registry Male Country name Cancer registry Period N casesa Crude rateb ASRb Africa Algeria1 Setif 2003-2007 0 0. Lancet Oncol 2012.0 0.7 Nigeria4 Ibadan 1960-1969 2 0.2.2 Senegal5 Dakar 1969-1974 5 0.0 0.9 Yukon 2003-2007 0 0.8 Ontario 2003-2007 233 0.2 0.5 Prince Edward Island 2003-2007 3 0.1 Americas Argentina1 Bahia Blanca 2003-2007 11 1. Penile cancer is rare and most commonly affects men aged 50-70 years.5 New Brunswick 2003-2007 32 1.6 1.6 National 2003-2007 662 0.3 0.8 0.1 0.4 2.7 2.8 Region of Antofagasta 2003-2007 19 1.0 Chile1 Bío Bío Province 2003-2007 8 0.9 0.3 3.5 1.1 0.9 (Continued on next page) ICO HPV Information Centre .0 Egypt1 Gharbiah 2003-2007 3 0.13(6):607- 15).4 0.2 Brazil1 Aracaju 2003-2006 17 1.1 Uganda1 Kyadondo county 2003-2007 30 0.7 Goiania 2003-2007 65 2.1 Fortaleza 2003-2006 51 1.5 Quebec 2003-2007 147 0.5 0.0 Mozambique3 Lourenco Marques 1956-1960 5 1. Cancers of the penis are primarily of squamous cell carcinomas (SCC) (95%) and the most common penile SCC histologic sub-types are keratinising (49%).0 Nova Scotia 2003-2007 30 1.5 Saskatchewan 2003-2007 34 1.000 cases worldwide with incidence rates strongly correlating with those of cervical cancer (de Martel C et al.2 Mendoza 2003-2007 58 1.3 Sao Paulo 2003-2007 403 1.4 0.3 1.6 Mali2 Bamako 1994-1996 0 0.0 0. HPV is most commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours.7 1.1 0.0 0.7 British Columbia 2003-2007 57 0.0 0. Approximately 60-100% of PeIN lesions are HPV DNA positive.8 Tunisia1 North 2003-2005 8 0.0 0.

1 0.6 California.9 Colorado (White) 2003-2007 57 0.3 0.2 Manizales 2003-2007 20 2.3 1.7 0.6 0.4 0. Los Angeles County (Filipino) 2003-2007 1 0.4 Costa Rica1 National 2003-2007 110 1.5 Alaska 2003-2007 13 0.7 Alaska (American Indian) 2003-2007 2 0.8 0.5 USA1 Alabama 2003-2007 90 0.2 California (Black) 2003-2007 35 0.3 BURDEN OF HPV RELATED CANCERS .2 Peru7 Trujillo 1998-2002 15 1.4 Connecticut 2003-2007 66 0.6 Alabama (Black) 2003-2007 20 0. Los Angeles County 2003-2007 149 0.6 Ecuador1 Cuenca 2003-2007 1 0.2 1.6 4.5 California.3 California (Asian and Pacific Islander) 2003-2007 31 0.5 0.3 White) California: San Francisco (White) 2003-2007 35 0.7 0. Los Angeles County (Korean) 2003-2007 2 0.5 0.4 Colorado (Asian and Pacific Islander) 2003-2007 1 0.6 Jamaica1 Kingston and St Andrew 2003-2007 18 1.1 1.6 0.5 Arizona (American Indian) 2003-2007 6 0.6 0.0 1.5 0. Los Angeles County (Chinese) 2003-2007 3 0.83 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Colombia1 Bucaramanga 2003-2007 31 1.5 (Continued on next page) ICO HPV Information Centre .7 Arkansas (Black) 2003-2007 4 0.7 Alabama (White) 2003-2007 69 0.8 Arkansas 2003-2007 65 1.5 0.2 1.6 California: San Francisco (Non-Hispanic 2003-2007 24 0.6 0.0 0.0 California.6 0.5 California (American Indian) 2003-2007 3 0.4 0.6 0.2 0.7 Arkansas (White) 2003-2007 61 1.4 (Non-Hispanic White) California.5 Arizona (Asian and Pacific Islander) 2003-2007 1 0.7 0.7 Colorado 2003-2007 62 0.8 0.1 California.2 Cuba1 Villa Clara 2004-2007 41 2.2 2.3 Arizona (Black) 2003-2007 4 0.1 0.0 0.4 California 2003-2007 561 0.5 California.1 Pacific Islander) California.5 1.5 0.3 0.1 Paraguay6 Asuncion Region 1988-1989 46 2.7 0.3 0.1 Quito 2003-2007 18 0.0 1.9 0.3 Colorado (Black) 2003-2007 4 0.7 0.7 0.3 0.2 California.8 Uruguay1 National 2005-2007 96 2.1 1.8 White) California.5 California.6 0.4 Cali 2003-2007 54 1.7 0.3 California: San Francisco (Hispanic White) 2003-2007 11 0.1 0. Los Angeles County (Japanese) 2003-2007 0 0. Los Angeles County 2003-2007 54 0. Los Angeles County (Hispanic 2003-2007 70 0.8 Arizona 2003-2007 106 0. Los Angeles County (Black) 2003-2007 14 0.7 0.8 0.5 0.6 California (White) 2003-2007 477 0. Los Angeles County (White) 2003-2007 124 0.7 0.3 California: San Francisco 2003-2007 48 0.2 0.3 0.2 Pacific Islander) California: San Francisco (Black) 2003-2007 7 0.9 Arizona (White) 2003-2007 95 0.3 California: San Francisco (Asian and 2003-2007 6 0.2 Pasto 2003-2007 11 1.7 0. Los Angeles County (Asian and 2003-2007 7 0.

3 Hawaii (Filipino) 2003-2007 3 0.6 0.2 Connecticut (White) 2003-2007 61 0.7 0.9 0.6 Massachusetts (Black) 2003-2007 4 0.0 Georgia.8 Massachusetts 2003-2007 153 1.5 Georgia (White) 2003-2007 90 0.7 0.8 0.5 Hawaii (Hawaiian) 2003-2007 4 0.8 Louisiana (White) 2003. Atlanta (White) 2003-2007 15 0.2006- 2007 Louisiana (Black) 2003. 12 0.7 0.5 2004.9 0.5 Illinois (Asian and Pacific Islander) 2003-2007 3 0. Atlanta (Black) 2003-2007 11 0.5 Michigan (White) 2003-2007 149 0.2006- 2007 Louisiana.2 Hawaii (White) 2003-2007 9 1.4 Indiana (White) 2003-2007 118 0.84 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Connecticut (Black) 2003-2007 2 0.3 0.2006- 2007 Louisiana 2003.4 0. New Orleans 2003.6 2004.0 0.0 0.7 0.0 Florida (White) 2003-2007 336 1.7 0.4 Hawaii (Japanese) 2003-2007 2 0.6 Massachusetts (Asian and Pacific Islander) 2003-2007 5 0.9 0.6 Iowa 2003-2007 76 1.7 0.5 Florida (Asian and Pacific Islander) 2003-2007 0 0.7 0. New Orleans (Black) 2003.2 0.9 0.0 0.4 0.5 Delaware (White) 2003-2007 3 0.4 0.5 Delaware 2003-2007 7 0.2006- 2007 Louisiana. 6 0.5 Georgia (Black) 2003-2007 28 0.3 0.7 0.4 Georgia (Asian and Pacific Islander) 2003-2007 0 0.2006- 2007 Louisiana.3 Hawaii (Chinese) 2003-2007 1 0.6 0.4 0.9 2004.4 (Continued on next page) ICO HPV Information Centre . 23 0.4 Illinois (Black) 2003-2007 32 0.8 2004.2 0.5 Massachusetts (White) 2003-2007 140 1.3 Georgia.1 Florida 2003-2007 405 0.7 Illinois (White) 2003-2007 182 0.6 Kentucky 2003-2007 119 1.3 BURDEN OF HPV RELATED CANCERS .2 0.7 0.0 0.5 0. New Orleans (White) 2003.7 0.8 Michigan 2003-2007 177 0.0 Georgia 2003-2007 120 0.5 Florida (Black) 2003-2007 60 0. 53 0.2 0.6 0.1 0.5 Indiana 2003-2007 123 0.9 0.6 Indiana (Black) 2003-2007 5 0. Atlanta 2003-2007 27 0.7 2004.6 Georgia. 76 0.9 1.3 0.3 0. 6 0.3 2004.0 0.3 Hawaii 2003-2007 19 0.7 0.2006- 2007 Maine 2003-2007 40 1.6 0.0 0.9 0.2 Delaware (Black) 2003-2007 3 0.8 0.2 Illinois 2003-2007 223 0.3 0.6 Idaho 2003-2007 22 0.

4 Pennsylvania 2003-2007 233 0.6 Oklahoma (Black) 2003-2007 3 0.7 0.7 0.5 Montana 2003-2007 18 0.5 North Carolina (American Indian) 2003-2007 0 0.3 0.5 North Dakota 2003-2007 11 0.4 Mississippi 2003-2007 61 0.7 0.9 0.4 0.5 Ohio (Asian and Pacific Islander) 2003-2007 0 0.6 Missouri (Black) 2003-2007 5 0.6 Michigan.5 0.4 New Jersey 2003-2007 157 0.0 Ohio (Black) 2003-2007 15 0.0 North Carolina (Asian and Pacific Islander) 2003-2007 0 0.8 North Carolina 2003-2007 150 0.2 Islander) NPCR (42 States) (Black) 2003-2007 524 0.8 0.1 0.5 Michigan.2 0.7 0.4 0.0 0.6 New York State (White) 2003-2007 299 0.8 0.5 Nebraska (Black) 2003-2007 0 0.0 Nebraska (White) 2003-2007 32 0.85 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Michigan (Black) 2003-2007 21 0.8 0.6 NPCR (42 States) (Asian and Pacific 2003-2007 67 0.8 0.3 0.5 Montana (American Indian) 2003-2007 3 1.5 NPCR (42 States) (White) 2003-2007 4139 0.3 Missouri (White) 2003-2007 108 0.0 0.4 New Mexico (Hispanic White) 2003-2007 16 0. Detroit (Black) 2003-2007 18 0.0 0.5 New Jersey (Black) 2003-2007 11 0.7 0.7 0.3 NPCR (42 States) 2003-2007 4858 0.6 0.8 0.5 Michigan.3 Oklahoma (White) 2003-2007 69 1.8 0.5 (Continued on next page) ICO HPV Information Centre .8 0.5 Oklahoma 2003-2007 83 0. Detroit 2003-2007 72 0.5 Missouri 2003-2007 115 0.0 0.4 New Mexico (Non-Hispanic White) 2003-2007 9 0.3 Oregon (Black) 2003-2007 0 0.3 1.5 New Hampshire 2003-2007 21 0.6 0.5 NPCR (42 States) (American Indian) 2003-2007 38 0.3 BURDEN OF HPV RELATED CANCERS .5 Ohio (White) 2003-2007 178 0.8 New York State 2003-2007 392 0.8 0.8 0.7 0.4 0.5 New York State (Asian and Pacific 2003-2007 12 0.7 Oklahoma (American Indian) 2003-2007 10 1.3 0.4 Pennsylvania (Black) 2003-2007 19 0.4 0.5 Oregon (Asian and Pacific Islander) 2003-2007 1 0.8 0.5 New Jersey (White) 2003-2007 138 0.4 Pennsylvania (Asian and Pacific Islander) 2003-2007 1 0.0 Oregon 2003-2007 62 0.3 New Mexico 2003-2007 30 0.9 0.7 0.0 0.4 0.7 North Carolina (White) 2003-2007 118 0.8 0.6 0.7 0.2 Pennsylvania (White) 2003-2007 210 0.8 0.7 0.8 0.2 Nebraska 2003-2007 33 0.5 Michigan (Asian and Pacific Islander) 2003-2007 2 0.2 New Mexico (White) 2003-2007 25 0.4 Oregon (White) 2003-2007 57 0.6 0.3 Islander) New York State (Black) 2003-2007 68 0.0 North Carolina (Black) 2003-2007 31 0.0 0.9 0.6 0.7 0.7 0. Detroit (White) 2003-2007 52 0.9 2.6 Ohio 2003-2007 195 0.7 0.

7 0.5 0.4 SEER (9 Registries) (Black) 2003-2007 41 0.9 0.7 0.3 0.3 0.5 0.5 Virginia (Asian and Pacific Islander) 2003-2007 2 0.7 0.5 0.4 0.8 0.4 0.3 Wuhan City 2003-2007 40 0.5 0.6 Texas 2003-2007 435 0.1 Texas (Black) 2003-2007 37 0.8 0.8 1.4 0.6 Texas (White) 2003-2007 384 0.6 0.3 0.3 Yangcheng County 2003-2007 8 0.8 0.5 Virginia (Black) 2003-2007 28 0.86 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Puerto Rico 2003-2007 237 2.3 Qidong County 2003-2007 11 0.5 SEER (18 Registries) (Asian and Pacific 2003-2007 58 0.2 Harbin City.0 China1 Beijing City 2003-2007 95 0.2 0.6 Tennessee 2003-2007 97 0.1 0.5 1.5 0.3 Washington State 2003-2007 82 0.5 South Carolina (Black) 2003-2007 23 0.5 SEER (9 Registries) 2003-2007 417 0.6 0.8 Haining County 2003-2007 5 0.0 0.5 Wisconsin (Black) 2003-2007 3 0.4 West Virginia 2003-2007 53 1.5 Wyoming 2003-2007 11 0.3 BURDEN OF HPV RELATED CANCERS .2 0.9 SEER (18 Registries) (Non-Hispanic 2003-2007 902 0.6 0.6 Asia Bahrain1 National (Bahraini) 2003-2007 0 0.7 South Dakota 2003-2007 22 1.6 1.3 Shanghai City 2003-2007 107 0.5 South Carolina (White) 2003-2007 55 0.0 1.4 Wisconsin (White) 2003-2007 97 0.4 White) SEER (18 Registries) (White) 2003-2007 1166 0.6 Virginia (White) 2003-2007 97 0.5 SEER (9 Registries) (White) 2003-2007 344 0.7 0.4 South Carolina 2003-2007 80 0.5 0.5 Tennessee (Black) 2003-2007 11 0.7 0.3 Washington.5 Tennessee (White) 2003-2007 86 0.7 0.8 0.4 0.6 Utah 2003-2007 23 0.8 0.2 0.3 Virginia 2003-2007 129 0.0 (Continued on next page) ICO HPV Information Centre .5 0. Nangang District 2003-2007 17 0. Seattle 2003-2007 56 0.7 0.3 0.7 0.7 Wisconsin 2003-2007 104 0.5 Texas (Asian and Pacific Islander) 2003-2007 2 0.4 Macao 2003-2007 4 0.8 Rhode Island 2003-2007 31 1.0 Rhode Island (White) 2003-2007 28 1.3 Jiashan County 2003-2007 5 0.4 Zhongshan City 2004-2007 27 1.2 0.6 Hong Kong 2003-2007 72 0.7 SEER (18 Registries) 2003-2007 1377 0.3 Islander) SEER (18 Registries) (Black) 2003-2007 124 0.8 0.4 0.5 SEER (18 Registries) (Hispanic White) 2003-2007 264 0.7 0.8 Rhode Island (Black) 2003-2007 1 0.5 0.3 Cixian County 2003-2007 10 0.8 0.7 0.1 0.3 Vermont 2003-2007 8 0.0 Yanting County 2003-2007 6 0.6 0.8 0.3 Jiaxing City 2005-2007 5 0.8 0.

9 Poona 2003-2007 71 0. Paranda and Bhum 2003-2007 25 1.2 Nagasaki Prefecture 2003-2007 28 0.4 Qatar1 National (Qatari) 2003-2007 0 0.5 0.9 New Delhi 2003-2007 246 0.2 0.0 Israel1 National 2003-2007 17 0.2 0.2 Jejudo 2004-2007 3 0.2 0.6 0.4 0.1 0.5 Rizal 2003-2007 32 0.7 Mumbai 2003-2007 239 0.0 Sikkim State 2003-2007 10 0.8 0.5 Penang (Indian) 2004-2007 2 0.2 0.2 Japan1 Aichi Prefecture 2003-2007 8 0.3 (Continued on next page) ICO HPV Information Centre .3 Oman7 Omani 1998-2001 0 0.3 Malaysia1 Penang (Malay) 2004-2007 1 0.1 Singapore1 National 2003-2007 52 0.7 0.2 Bhopal 2004-2007 12 0.7 0.5 Penang 2004-2007 9 0.2 0.2 0.7 Iran1 Golestan Province 2005-2007 0 0.6 1.7 1.8 2.7 1.2 Osaka Prefecture 2003-2007 83 0.3 0.3 0.2 Hiroshima 2003-2007 21 0.5 0.5 0.1 0.1 0.1 0.1 National (Jews) 2003-2007 14 0.4 0.2 Incheon 2003-2007 9 0.3 0.1 National (Kuwaitis) 2003-2007 0 0. Ambilikkai 2003-2007 72 1.0 0.8 Dindigul.87 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb India1 Bangalore 2005-2007 101 0.5 Chiang Mai 2003-2007 70 1.0 Trivandrum 2005-2007 12 0.3 Daegu 2003-2007 11 0.2 0.2 Saga Prefecture 2003-2007 21 1.0 0.5 Chonburi 2003-2007 32 1.0 0.2 Seoul 2003-2007 44 0.4 Kuwait1 National (Non-Kuwaitis) 2003-2007 1 0.5 National (Indian) 2003-2007 3 0.2 Daejeon 2003-2007 5 0.4 Niigata Prefecture 2003-2007 30 0.0 Pakistan7 South Karachi 1998-2002 1 0.3 National (Malay) 2003-2007 2 0.5 Karunagappally 2003-2007 13 1.1 National 2003-2007 1 0.3 Barshi.0 Philippines1 Manila 2003-2007 37 0.2 National (Chinese) 2003-2007 43 0.9 1.0 Kyrgyzstan6 National 1986-1987 7 0.0 0.3 1. Korea1 Busan 2003-2007 24 0.0 Rep.3 Miyagi Prefecture 2003-2007 31 0.1 Fukui Prefecture 2003-2007 9 0.9 1.7 1.5 Thailand1 Bangkok 2003-2007 64 0.3 0.4 0.4 Saudi Arabia1 Riyadh (Saudi) 2003-2007 2 0.3 National 2003-2007 282 0.2 0.1 0.0 0.3 0.0 0.2 Ulsan 2003-2007 8 0.5 0.3 0.7 0.0 0.1 National (Non-Jews) 2003-2007 3 0.2 Penang (Chinese) 2004-2007 6 0.6 Chennai 2003-2007 179 1.0 1.0 0.2 Mizoram 2003-2007 26 1.1 1.0 0.1 0.6 0.3 BURDEN OF HPV RELATED CANCERS .4 1.8 0.1 Gwangju 2003-2007 6 0.

0 Florence and Prato 2003-2005 28 1.4 0.6 0.8 0.6 0.2 0.7 Free State Of Saxony 2003-2007 177 1.9 Somme 2003-2007 19 1.8 Turkey1 Antalya 2003-2007 1 0.8 Hamburg 2003-2007 61 1.2 1.7 (Continued on next page) ICO HPV Information Centre .6 1.7 North Rhine-Westphalia 2003-2007 94 1.7 Cyprus1 National 2003-2007 28 1.6 0.3 Ferrara 2003-2007 20 2.4 Manche 2003-2007 19 1.0 Denmark1 National 2003-2007 234 1.4 1.0 1.9 Como 2003-2007 9 0.2 0.0 Izmir 2003-2007 8 0.5 0.7 Vendee 2003-2007 10 0.5 0.6 Lampang 2003-2007 26 1.7 0.7 Croatia1 National 2003-2007 114 1.9 Martinique 2003-2007 14 1.7 0.9 1.6 0.6 0.3 BURDEN OF HPV RELATED CANCERS .4 Loire Atlantique 2003-2007 19 0.0 Viet Nam2 Hanoi 1993-1997 95 1.5 Catania and Messina 2003-2005 56 2.7 County Vas 1983-1987 4 0.4 0.8 0.4 Iceland1 National 2003-2007 11 1.7 2.1 National 2003-2007 403 1.8 Bulgaria1 National 2003-2007 228 1.9 0.8 0.2 Munich 2003-2007 116 1.7 1.1 0.9 Haut-Rhin 2003-2007 22 1.6 France1 Bas-Rhin 2003-2007 42 1.0 Brescia 2003-2006 18 0.2 0.5 1.1 Trabzon 2005-2007 0 0.9 0.7 Herault 2003-2007 37 1.2 Catanzaro 2003-2007 9 1.7 Doubs 2003-2007 18 1.8 Isere 2003-2007 22 0.8 Belgium1 National 2004-2007 286 1.1 0.6 1.3 1.3 Ho Chi Minh City 1995-1998 85 0.6 0.1 0.8 Italy1 Biella 2003-2007 11 2.6 Vorarlberg 2003-2007 5 0.4 1.0 Tarn 2003-2007 17 1.4 Belarus1 National 2003-2007 250 1.9 Schleswig-Holstein 2003-2007 134 1.9 Ireland1 National 2003-2007 111 1.6 1.2 0.0 Edirne 2004-2007 0 0.1 Bremen 2003-2007 23 1.2 1.0 Finland1 National 2003-2007 119 0.4 0.8 1.0 Calvados 2003-2007 22 1.0 0.0 Estonia1 National 2003-2007 44 1.1 Czech Rep.4 Europe Austria1 National 2003-2007 249 1.0 0.6 0.7 0.9 1.8 0.4 0.8 Tyrol 2003-2007 14 0.5 1.0 0.8 Mecklenburg-Western Pomerania 2003-2007 93 2.1 0.1 Songkhla 2004-2007 48 1.4 0.88 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Khon Kaen 2003-2007 72 1.9 0.8 Saarland 2003-2007 46 1.5 0.0 Hungary6 County Szabolcs-Szatmar 1983-1987 12 0.4 Germany1 Brandenburg 2003-2007 126 2.4 1.

5 1.0 1.9 1.0 Parma 2003-2007 11 1.1 Trento 2003-2006 15 1.7 1.9 Netherlands1 Eindhoven 2003-2007 23 0.9 0.1 1.4 Romagna 2003-2007 44 1.9 Girona 2003-2007 24 1.0 Poland1 Cracow 2003-2006 21 1.6 Ragusa 2003-2007 10 1.3 BURDEN OF HPV RELATED CANCERS .9 Romania6 County Cluj 1983-1987 17 0.6 National 2003-2007 560 1.1 0.0 Basque Country 2003-2007 101 2.3 Navarra 2003-2007 23 1.0 Malta1 National 2003-2007 15 1.2 0.6 Lombardy.2 0.1 0.8 Genoa 2003-2006 23 1.7 0.5 0.9 0.0 1.5 Latina 2003-2007 30 2.6 Mallorca 2003-2007 35 1.5 0.89 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Friuli-Venezia Giulia 2003-2007 51 1. South 2003-2005 13 1.4 0.1 0.2 0.7 0.1 0.1 Ciudad Real 2004-2007 21 2.3 0.7 Salerno 2003-2007 53 2.0 Palermo 2003-2006 38 1.3 1.1 1.1 Milan 2003-2006 21 0.2 0.5 0.8 Trapani 2003-2006 17 2.4 Veneto 2003-2006 54 1.8 Slovakia1 National 2003-2007 147 1.0 Nuoro 2003-2007 9 1.7 Spain1 Albacete 2003-2007 20 2.4 1.0 0.8 Lower Silesia 2003-2007 61 0.9 0.2 0.1 0.6 1.1 Murcia 2003-2007 68 2.3 0.7 Portugal1 Azores 2003-2007 7 1.9 0.4 0.6 0.5 0.6 Naples 2003-2007 18 1.5 Sondrio 2003-2007 5 1.5 Mantua 2003-2005 12 2.6 Syracuse 2003-2007 12 1.9 Kielce 2003-2007 39 1.5 Serbia1 Central 2003-2007 175 1.7 0.6 1.2 0.6 South Tyrol 2003-2006 10 1.8 Turin 2003-2007 25 1.6 Latvia1 National 2004-2007 64 1.5 1.8 Granada 2003-2007 42 2.9 Slovenia1 National 2003-2007 52 1.8 Reggio Emilia 2003-2007 9 0.9 0.0 1.0 1.6 0.3 1.8 (Continued on next page) ICO HPV Information Centre .4 Modena 2003-2007 20 1.0 0.0 Sassari 2003-2007 9 0.9 Canary Islands 2003-2006 51 1.1 Asturias 2003-2007 53 2.9 0.5 Umbria 2003-2007 52 2.3 Lecco 2003-2007 8 1.1 Varese 2003-2007 18 0.8 Norway1 National 2003-2007 197 1.8 0.2 0.5 1.0 Lithuania1 National 2003-2007 108 1.1 1.2 Cuenca 2003-2007 20 3.1 1.7 Podkarpackie 2003-2007 48 0.5 0.8 1.8 Russia1 Saint Petersburg 2003-2007 73 0.2 La Rioja 2003-2007 11 1.

2 1.S... West Midlands 2003-2007 229 1. VI. D. Y.9 Neuchatel 2003-2007 9 2.90 - ( Table 10 – continued from previous page) Male Country name Cancer registry Period N casesa Crude rateb ASRb Tarragona 2003-2007 44 2. Cancer Incidence in Five Continents.. J. Lyon.. P.2 0.S.6 1..iarc. Trent 2005-2007 128 1... Oxford Region 2003-2007 91 1.5 Data accessed on 05 May 2015. 15. J. J.8 0. Lyon. H. III. B. Cancer Incidence in Five Continents... Steliarova-Foucher E. IARC Scientific Publications No. 42. Heanue. eds (1966). Teppo.fr/CI5i-ix/ci5i-ix.B. and Boyle. Vol. S.7 0. IARC Scientific Publications No. J.8 0. IARC. L..Muir. P.0 Switzerland1 Basel 2003-2007 12 1. 160. Cancer Incidence in Five Continents. 120.4 Tasmania 2003-2007 7 0.4 National (Pacific Islander) 2003-2007 2 0. Lyon. Union Internationale Contre le Cancer. 7 Curado. K. Kohler B.Muir.. Ferlay..0 0..7 1. J. VIII..7 1. IARC. Brewster DH.8 0.Ferlay. P.. IV. East of England Region 2003-2007 193 1. S. Storm.. 155. C.0 0.4 St Gall-Appenzell 2003-2007 18 1. IARC Scientific Publications No. Lyon. Thames 2003-2007 320 1.0 England.6 0.8 0. I.7 0.9 0.7 0. please refer to individual country data.4 National (Other) 2003-2007 57 0.iarc.. 3 Doll. X (electronic version) Lyon.Gao.. Swaminathan R and Ferlay J eds (2013).9 1.Powell. Ferlay. eds (1976).1 Graubunden and Glarus 2003-2007 10 1. IX..2 0.-T.000 men per year. 4 Waterhouse.7 0.3 Victoria 2003-2007 87 0. D.. Lyon.7 1.6 New Zealand1 National (Maori) 2003-2007 0 0.Waterhouse.5 1.htm) a Accumulated number of cases during the period in the population covered by the corresponding registry.Correa.8 Valais 2003-2007 6 0. eds (2002).0 Northern Ireland 2003-2007 78 1. Geneva. ICO HPV Information Centre .L.0 England.8 1. IARC Scientific Publications No..4 0. IARC. Whelan. J.5 Northern Territory 2003-2007 1 0. C...6 0. Data sources: 1 Forman D. IARC Scientific Publications No. For time trends in penile cancer incidence. J. NOTE. Bray F..1 England.8 Ticino 2003-2007 13 1.3 BURDEN OF HPV RELATED CANCERS . R. Vol. IARC.A. Please refer to original source (available at http://ci5.3 Scotland 2003-2007 212 1.L.6 Oceania Australia1 Australian Capital Territory 2003-2007 1 0. eds (2007).3 0.1 0.0 National 2003-2007 59 0. IARC.H.0 Wales 2003-2007 135 1. eds (1982). b Rates per 100.8 1.4 0.5 South 2003-2007 30 0.3 0.S. and Thomas.Shanmugaratnam.5 Geneva 2003-2007 19 1.M.6 UK1 England 2003-2007 1870 1. Vol..0 Queensland 2003-2007 68 0. Piñeros M.0 England.Muir. South and Western Regions 2003-2007 291 1. http://ci5. Cancer Incidence in Five Continents..5 0. Shin. M. Vol.9 1.fr 2 Parkin.. eds (1992). 5 Waterhouse. Edwards. P. Cancer Incidence in Five Continents.9 Zurich 2003-2007 36 1.Powell.9 England.M. J.8 0.2 Northern Territory (Indigenous) 2003-2007 0 0. IARC.7 England.3 0.1 Northern Territory (Non-Indigenous) 2003-2007 1 0.1 Ukraine1 National 2003-2007 980 0. Vol.6 Vaud 2003-2007 24 1.. C. M. Vol.1 0.R. D. North Western 2003-2007 276 1.Powell. Cancer Incidence in Five Continents.7 1. H. J. Vol. Cancer Incidence in Five Continents.4 Western 2003-2007 39 0.1 0.4 Sweden1 National 2003-2007 412 1. 6 Parkin.9 England.7 1. Northern and Yorkshire 2003-2007 261 1. Gombe Mbalawa C.1 New South Wales 2003-2007 139 0.Whelan.5 0.8 England.Payne.

Azerbaijan. Zimbabwe: High quality regional (coverage lower than 10%). Albania. Italy. Bahamas. Namibia. Bolivia. Mongolia. Nicaragua. Kuwait. Slovakia. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Uganda. Comoros. Palestine. Maldives. Denmark. Nepal. Jamaica. Qatar. Palestine. Nigeria. Lebanon.For Cameroon. Tanzania.For Argentina. Turkey. Djibouti. Israel. Franceschi S. Greece. Qatar. Zimbabwe: Estimated as the weighted average of the local rates Data sources: de Martel C. Republic of Korea. Bosnia & Herzegovina.For Albania. Iran. Belize. Fiji. Singapore. Algeria. Equatorial Guinea. Bahamas. Georgia. Current evidence suggests that HPV16 is associated with tonsil cancer (including Waldeyer ring cancer). in particular with oropharyngeal cancer. Estonia. Liberia.For Argentina. Syria. oral cavity and larynx). Iceland. Figure 38: Age-standardised incidence rates of head and neck cancer in the World (estimates for 2012) Data accessed on 08 May 2017. Guinea-Bissau. Oman. El Salvador. New Zealand. Zambia: One cancer registry covering part of a country is used as representative of the country profile . Trinidad & Tobago. Egypt. Botswana. increasing trends in the incidence at specific sites suggest that other etiological factors are in- volved. DPR Korea. Mali. Israel. Czech Republic. Tajikistan. Mozambique. Brazil. Republic of Korea. Cambodia. Somalia. Malawi. Panama. Viet Nam. Bhutan. Saudi Arabia. Plummer M. Estonia. Puerto Rico. Congo. Kyrgyzstan. Brunei. Suriname. Cyprus. France. Sierra Leone. Peru. Kazakhstan. Denmark. Eritrea. Mexico. Mozambique. Venezuela. Bangladesh. Uruguay. USA. China. Associations with other head and neck cancer sites such as oral can- cer are neither strong nor consistent when compared to molecular-epidemiological data on HPV and oropharyngeal cancer. Ireland. Ireland. Uzbekistan. Laos. Lesotho. Tunisia. Romania. . Ecuador. Libya. Cape Verde. Turkey. Iraq. Switzerland. Austria. Maldives. Slovakia. Timor-Leste. Indonesia. Montenegro. Ukraine. Central African Republic. Martinique. Libya. Sudan. Benin. South Africa: National data (rates). Italy. Cuba. Singapore.For Chile. Japan. Belize.For Afghanistan. Martinique. Luxembourg. Costa Rica. Cuba. Czech Republic. Iran. Bangladesh. Int J Cancer. DPR Korea. Jordan. Ecuador. Gabon. Samoa. Honduras. Reunion. Sri Lanka. Senegal. Spain. Nepal. Guadeloupe. Latvia. . Côte d’Ivoire. Bulgaria. Worldwide burden of cancer attributable to HPV by site. Lithuania. Guam. Luxembourg. Syria. Colombia. Guyana.and age-specific incidence rates of cancer for a specific country: . base of tongue cancer and other oropharyngeal cancer sites. Malta. Papua New Guinea. Philippines. Germany. GLOBOCAN quality index for availability of incidence data: . United Kingdom. Tunisia. Gambia. Angola. New Zealand. South Africa: Rates projected to 2012 . Switzerland. Lebanon. Guyana. Greece. Swaziland. Swaziland.For Algeria.For United Arab Emirates. USA: High quality national data or high quality regional (coverage greater than 50%). Suriname.91 - 3. Vignat J. New Caledonia. Thailand. Reunion. Guatemala. Norway. Croatia. Côte d’Ivoire. Brunei. Vanuatu: Estimated from national mortality estimates using modelled survival . Guatemala.e.For Afghanistan. Somalia. Morocco. DR Congo. Guinea. Sweden. Belgium.For Burkina Faso. Slovenia. Sri Lanka. Mali. Gambia. Congo. Brazil. Sudan. ASR: Age-standardized rate. Rwanda. Montenegro. Djibouti. Republic of Moldova. Bahrain. Turkmenistan. Mauritius. Thailand: High quality regional (coverage between 10% and 50%). Association with laryngeal cancer is still unclear (IARC Monograph Vol 100B). Solomon Islands. Guinea. Azerbaijan. Togo: Frequency data. Guadeloupe. Kenya.For Benin. Laos. Paraguay. . Equatorial Guinea. Samoa: Most recent rates applied to 2012 population . Cyprus. Liberia. Russian Federation. Central African Republic. Russian Federation. Iraq. Oman. Belarus. Colombia. Chad. Mauritius. Morocco. French Guiana. Paraguay. Lesotho. Solomon Islands. Bhutan. Bulgaria. Georgia. Pakistan. Portugal. rates per 100. El Salvador. Bahrain. Cape Verde. Iceland. Yemen. HPV16) have been reported to be associated with head and neck cancers. India. Republic of Moldova. Malta. Barbados. Saudi Arabia. Madagascar. Papua New Guinea. Ethiopia. India. Please refer to original source for methods. Senegal. Eritrea. Western Sahara. Jamaica. Kenya. Timor-Leste: The rates are those of neighbouring countries or registries in the same area . Canada. Puerto Rico. Dominican Republic. Kyr- gyzstan. Myanmar. Armenia. Burkina Faso. Germany. French Polynesia. DR Congo. Kazakhstan. Venezuela: No data. France. Romania. Canada. Poland. Lithuania.3 Head and neck cancers The majority of head and neck cancers are associated with high tobacco and alcohol consumption. Jordan. and infection by certain high-risk types of HPV (i. Vanuatu. South Sudan. Kuwait.3 BURDEN OF HPV RELATED CANCERS . Egypt. Niger. Mauritania. Mongolia. Serbia: Estimated from national mortality estimates by modelling using incidence mortality ratios derived from recorded data in local cancer registries in neighbouring countries .000 per year. Head and neck cancer cases (oropharynx. Spain. Bosnia & Herzegovina. Netherlands. Mauritania. China. Chile. Myanmar. Norway. Austria. Poland: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Niger. Honduras. Fiji. Malaysia. Cambodia. Turkmenistan. . Indonesia. Chad. South Sudan.For Cameroon. Burundi. Ukraine. Finland. Portugal. Bolivia. Uganda. Trinidad & Tobago. Slovenia. Netherlands.For United Arab Emirates. Ethiopia. Nigeria. Zambia: Regional data (rates). Costa Rica. Madagascar. Philippines. Belgium. Uruguay. Malawi. Rwanda. Mexico. Comoros.For Australia. Tajikistan. New Caledonia. Panama. 2017 ICO HPV Information Centre . Macedonia. Gabon. Ghana. Hungary. Barbados. Nicaragua. Dominican Republic. United Kingdom. Belarus. Hungary. Tanzania. Burundi. Croatia.For Armenia. . Serbia. Finland. Guinea-Bissau. Latvia. Haiti.For Australia. . Sweden. Western Sahara. Togo: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Japan. Peru. Uzbekistan. French Polynesia. Viet Nam. Guam. French Guiana. Malaysia. Botswana. Yemen. Pakistan. Namibia. Macedonia. Sierra Leone. country and HPV type. Angola. How- ever. Haiti. Ghana.

1 Swaziland 0.1 Egypt 0.0000 women World Standard ** No rates are available.1 Lesotho 0.1 DR Congo 0. (Continued on next page) ICO HPV Information Centre .1 Burkina Faso 0.1 Western Sahara 0.2 Gabon 0.3 Tanzania 0.1 Mozambique 0.1 Guinea 0.1 Burundi 0.1 Zambia 0. Guinea 0.1 Uganda 0.1 Sudan 0.1 Niger 0.** Nigeria** Malawi** Mauritania** Liberia** Guinea−Bissau** Gambia** Ethiopia** Cape Verde** Congo** Côte d'Ivoire** 0 0.1 Somalia 0.2 Mauritius 0.1 Togo 0.3 BURDEN OF HPV RELATED CANCERS .1 Eritrea 0.1 South Sudan 0.2 Eq.Tome & Prin.1 Tunisia 0.1 CAR 0.1 Angola 0. rates per 100.1 Seychelles** S.2 Zimbabwe 0. ASR: Age-standardized rate.1 Sierra Leone 0.2 Cameroon 0.1 Benin 0.1 Ghana 0.1 Morocco 0.2 Namibia 0.2 Kenya 0.92 - Figure 39: Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Africa (estimates for 2012) South Africa 0.1 Senegal 0.1 Chad 0.1 Algeria 0.2 Botswana 0.1 Libya 0.2 Madagascar 0.1 Mali 0. Please refer to original source for methods.000 per year. Data accessed on 08 May 2017.2 Rwanda 0.5 Age−standardised incidence rate per 100.1 Djibouti 0.1 Comoros 0.

Togo. Somalia. Eritrea. Central African Republic. GLOBOCAN quality index for availability of incidence data: . Mozambique. Morocco.93 - ( Figure 43 – continued from previous page) Head and neck cancer cases (oropharynx. Rwanda: The rates are those of neighbouring countries or registries in the same area . Guinea. Sierra Leone. Liberia. Egypt. Eritrea. Cameroon: One cancer registry covering part of a country is used as representative of the country profile . Ethiopia. Namibia: Most recent rates applied to 2012 population .For Gambia. Int J Cancer. South Sudan. Chad.For Malawi. Sierra Leone. Tanzania: Estimated as the weighted average of the local rates . Mali. Lesotho. Algeria. Mauritania. Angola. Djibouti. Morocco.For Congo. Algeria. Guinea-Bissau.3 BURDEN OF HPV RELATED CANCERS . Zimbabwe. Sudan. Vignat J. Burundi.For Congo.For South Africa: Rates projected to 2012 Data sources: de Martel C. Lesotho. Gabon: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Senegal. Plummer M.For Gambia.For Nigeria. Zimbabwe: High quality regional (coverage lower than 10%). Malawi. Worldwide burden of cancer attributable to HPV by site. Guinea. Nigeria. 2017 ICO HPV Information Centre . . Cameroon. Senegal. Burkina Faso. Tunisia. Niger. Swaziland. Equatorial Guinea. Djibouti. Western Sahara. Comoros. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Togo. Kenya. Madagascar: No data. Niger. Ethiopia. Equatorial Guinea. Franceschi S. Egypt. Sudan. Central African Republic. Namibia. Mali. Ghana. Ghana. Zambia. Mozambique. . South Africa: National data (rates). Madagascar. Western Sahara.For Cape Verde. Libya. Liberia. Kenya. Uganda. Benin. Gabon. Libya. Comoros. . Zambia. .For Cape Verde. Benin. Burundi. South Sudan. Chad. Burkina Faso. Uganda. Mauritania. Tunisia. oral cavity and larynx). Rwanda: Frequency data.For Côte d’Ivoire. Tanzania: Regional data (rates). DR Congo. DR Congo.and age-specific incidence rates of cancer for a specific country: . Botswana. Botswana. Somalia. Angola. Swaziland. Mauritius. country and HPV type.For Côte d’Ivoire. Guinea-Bissau. Mauritius.

** 0 0.1 St Vincent** St Lucia** St Kitts & Nev.2 Panama 0.1 El Salvador 0.3 BURDEN OF HPV RELATED CANCERS .3 Venezuela 0.4 Barbados 0.2 Suriname 0. ASR: Age-standardized rate.7 Canada 1.1 Haiti 0.5 Age−standardised incidence rate per 100. (Continued on next page) ICO HPV Information Centre . 0.2 Guatemala 0.1 Chile 0.5 2 2.1 Bolivia 0.1 Honduras 0.2 Guyana 0.3 Dominican Rep.1 Ecuador 0.2 Trinidad & Tob.1 Costa Rica 0.1 Argentina 0.1 Mexico 0. Data accessed on 08 May 2017. 0.1 Peru 0.5 1 1.3 Cuba 0.** Grenada** Dominica** Antigua & Bar.4 Uruguay 0.2 Bahamas 0.1 Jamaica 0. rates per 100.0000 women World Standard ** No rates are available. Please refer to original source for methods.1 Nicaragua 0.3 Brazil 0.1 Belize 0.1 Colombia 0.2 Paraguay 0.94 - Figure 40: Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in the Americas (estimates for 2012) USA 1.000 per year.

Paraguay. Franceschi S. Canada. Chile. Panama. Peru: Regional data (rates). USA: Rates projected to 2012 . Guyana.and age-specific incidence rates of cancer for a specific country: . Suriname. Plummer M. . Colombia. Barbados.For Belize. . Guatemala. Honduras. Ecuador. USA: High quality national data or high quality regional (coverage greater than 50%). Jamaica. Panama. Trinidad & Tobago. Nicaragua. Bahamas.For Argentina. Jamaica.For Belize.3 BURDEN OF HPV RELATED CANCERS . Guyana. Nicaragua.For Chile. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. El Salvador. Suriname.For Costa Rica. oral cavity and larynx). . El Salvador. Uruguay. Guatemala. Paraguay. Honduras. Cuba: High quality regional (coverage lower than 10%).For Bolivia: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Peru. Colombia. Venezuela. Haiti. Mexico.95 - ( Figure 43 – continued from previous page) Head and neck cancer cases (oropharynx.For Costa Rica. Canada.For Mexico. Worldwide burden of cancer attributable to HPV by site. 2017 ICO HPV Information Centre . Bahamas. . Vignat J. Dominican Republic: No data.For Argentina. Cuba: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Bolivia. Brazil: High quality regional (coverage between 10% and 50%). Int J Cancer. Ecuador. Dominican Republic: Estimated from national mortality estimates using modelled survival . Barbados.For Uruguay: Most recent rates applied to 2012 population Data sources: de Martel C. GLOBOCAN quality index for availability of incidence data: .For Trinidad & Tobago: National data (rates). Haiti. country and HPV type. Venezuela. . Brazil.

000 per year.1 Brunei 0. ASR: Age-standardized rate.2 Philippines 0.5 1 Age−standardised incidence rate per 100.1 Oman 0.2 Kazakhstan 0.4 Bangladesh 0.1 Tajikistan 0.2 Nepal 0.1 Iran 0.1 Palestine 0.1 Bhutan 0. Please refer to original source for methods.1 Iraq 0.2 Malaysia 0.1 UAE 0.2 Armenia 0.2 Afghanistan 0.2 Mongolia 0.1 Lebanon 0.4 Maldives 0.1 Qatar 0.96 - Figure 41: Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Asia (estimates for 2012) Rep.2 Yemen 0. rates per 100.1 Israel 0.2 Georgia 0.1 Saudi Arabia 0.2 Thailand 0.2 Pakistan 0. Data accessed on 08 May 2017.5 Japan 0.2 Turkmenistan 0.6 India 0.1 Bahrain 0. (Continued on next page) ICO HPV Information Centre .6 Myanmar 0.1 Taiwan** Kuwait** 0 0.3 Sri Lanka 0.1 Uzbekistan 0.1 Azerbaijan 0.3 Cambodia 0. Korea 0.1 Syria 0.1 Turkey 0.1 Singapore 0.1 Kyrgyzstan 0.3 Viet Nam 0.0000 women World Standard ** No rates are available.1 DPR Korea 0.1 Jordan 0.3 BURDEN OF HPV RELATED CANCERS .5 Timor−Leste 0.1 Indonesia 0.1 China 0.1 Laos 0.

Kazakhstan. Turkmenistan. Turkey. country and HPV type. Bhutan. India: High quality regional (coverage lower than 10%). Malaysia. Tajikistan. .3 BURDEN OF HPV RELATED CANCERS . Palestine.97 - ( Figure 43 – continued from previous page) Head and neck cancer cases (oropharynx. Turkmenistan. Republic of Korea: Rates projected to 2012 . Bangladesh: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) . Israel. Timor-Leste. . Singapore. Nepal. Lebanon. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Sri Lanka: National data (rates). Saudi Arabia. Syria.For Iraq. Iraq. Afghanistan. Philippines. Saudi Arabia. Japan: High quality regional (coverage between 10% and 50%). Japan: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Cambodia.For Indonesia. Bahrain. Uzbekistan. Malaysia.For Azerbaijan. Thailand.For Azerbaijan. Timor-Leste. Afghanistan. Bhutan. Armenia. Armenia. Oman. Plummer M. Oman. Pakistan. Viet Nam: Estimated from national mortality estimates using modelled survival . Sri Lanka: Most recent rates applied to 2012 population . Kyrgyzstan.For China. Bangladesh: Frequency data.and age-specific incidence rates of cancer for a specific country: . DPR Korea. Kazakhstan. Israel. Thailand. Indonesia. Vignat J. . . Lebanon. Laos. Nepal. Brunei.For United Arab Emirates. . Pakistan. Kyrgyzstan. Jordan. 2017 ICO HPV Information Centre .For Kuwait. Franceschi S. Myanmar: No data. Iran. . Maldives. Cambodia.For United Arab Emirates. India: Estimated as the weighted average of the local rates . GLOBOCAN quality index for availability of incidence data: . Maldives.For Kuwait. Iran. Viet Nam: Regional data (rates). Bahrain. Myanmar: The rates are those of neighbouring countries or registries in the same area . Worldwide burden of cancer attributable to HPV by site. Uzbekistan. Mongolia. Turkey. Qatar. Int J Cancer. DPR Korea.For China. Palestine. Qatar. Singapore.For Laos. Jordan. Tajikistan. Georgia. oral cavity and larynx). Republic of Korea: High quality national data or high quality regional (coverage greater than 50%).For Brunei. Mongolia.For Yemen. Syria. Georgia.For Yemen: One cancer registry covering part of a country is used as representative of the country profile Data sources: de Martel C.For Philippines.

0000 women World Standard ** No rates are available.5 Denmark 1.6 Malta 0.5 Czech Rep.5 Italy 0.5 Iceland 0.9 Ireland 0.4 Belarus 1.1 Romania 2.2 Lithuania 1.98 - Figure 42: Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Europe (estimates for 2012) Hungary 3.7 Moldova 1.8 Croatia 0.4 Albania 0. 0.7 Montenegro 0.2 San Marino** Monaco** Liechtenstein** Andorra** 0 2.4 Greece 0.0 Netherlands 0.9 Germany 1.3 Ukraine 1.3 Luxembourg 1.2 Russia 1.8 Sweden 0. rates per 100.8 Belgium 1.7 Finland 0.0 Slovakia 2.5 Macedonia 0.4 Poland 1. ASR: Age-standardized rate. 1.5 Bosnia & H.6 Spain 0.8 Serbia 0.3 Cyprus 0. Data accessed on 08 May 2017. (Continued on next page) ICO HPV Information Centre .3 BURDEN OF HPV RELATED CANCERS .0 France 1.0 Bulgaria 1.3 Austria 1.5 5 Age−standardised incidence rate per 100.000 per year.9 Estonia 0.0 Portugal 1.8 Norway 0.9 Slovenia 0.3 Switzerland 1.9 Latvia 0. Please refer to original source for methods.0 UK 1.

Spain. Bulgaria. Worldwide burden of cancer attributable to HPV by site. Finland. Germany. Austria.For Greece. Norway.For Montenegro: The rates are those of neighbouring countries or registries in the same area Data sources: de Martel C. Croatia. Iceland. Plummer M.For Italy. France: High quality regional (coverage between 10% and 50%).3 BURDEN OF HPV RELATED CANCERS . Poland. Lithuania. . Franceschi S. Serbia.For Romania: Regional data (rates). Serbia. Albania. Republic of Moldova. Ireland. Luxembourg. Czech Republic. Ireland. Switzerland.and age-specific incidence rates of cancer for a specific country: . 2017 ICO HPV Information Centre . Belgium.99 - ( Figure 43 – continued from previous page) Head and neck cancer cases (oropharynx. Sweden. Russian Federation. Poland: High quality regional (coverage lower than 10%). country and HPV type. Netherlands. . Norway. Switzerland. Denmark. Albania. Estonia. Czech Republic.For Italy. Latvia. Macedonia. Ukraine. Hungary: No data.For Iceland. United Kingdom.For Greece. France: Estimated from national mortality by modelling using incidence mortality ratios derived from recorded data in country-specific cancer registries . Montenegro. Estonia. Republic of Moldova. Latvia.For Portugal. Malta. Denmark. Netherlands. Int J Cancer. United Kingdom. . Luxembourg: National data (rates). Macedonia. Bulgaria. Malta. Belgium: Most recent rates applied to 2012 population . Spain. Portugal. Austria. Bosnia & Herzegovina. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex. Romania. GLOBOCAN quality index for availability of incidence data: .For Cyprus. oral cavity and larynx). Belarus.For Cyprus. Ukraine. Vignat J. Russian Federation. Germany. Croatia. Slovakia: Rates projected to 2012 . Hungary: Estimated from national mortality estimates by modelling using incidence mortality ratios derived from recorded data in local cancer registries in neighbouring countries . . Slovenia. Slovakia: High quality national data or high quality regional (coverage greater than 50%). Sweden. Finland. . Lithuania. Slovenia.For Bosnia & Herzegovina. Belarus.

100 - Figure 43: Age-standardised incidence rate of head and neck cancer cases attributable to HPV by country in Oceania (estimates for 2012) Australia 0.5 1 Age−standardised incidence rate per 100.3 BURDEN OF HPV RELATED CANCERS .2 Solomon Is.0000 women World Standard ** No rates are available.9 Papua N.8 New Zealand 0. Guinea 0. Data accessed on 08 May 2017. Please refer to original source for methods. rates per 100.1 Samoa** Tuvalu** Tonga** Palau** Nauru** Marshall Is. 0.1 Fiji 0. ASR: Age-standardized rate. (Continued on next page) ICO HPV Information Centre .** Kiribati** FS Micronesia** 0 0.000 per year.6 Vanuatu 0.

in the World and its regions.6 0.3 7. 9 0.1 (Continued on next page) ICO HPV Information Centre . 9 0.4 0. 0 1.6 1401 0.2 0.2 3.and age-specific incidence rates of cancer for a specific country: .0 Europe 28394 7.2 3. Lyon.3 18505 0.6 0.3 BURDEN OF HPV RELATED CANCERS .For New Zealand. 11 [Internet].3.1 Asia 65016 3.000 women per year.1 Eastern Europe 10187 7.8 10454 1.7 0.0 Micronesia 0 0.0 0.7 0. Includes ICD-10 codes: C09-10.0 0. Includes ICD-10 codes: C09-10.4 4471 0. Dikshit R.5 3. Worldwide burden of cancer attributable to HPV by site.7 0. it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.4 844 1.3 1270 0.1 0.4 0.0 0 0.3 0. Vanuatu: National data (rates). Forman D.3 4. 6 0. country and HPV type.0 0.0 Data accessed on 15 Nov 2015.2 208 0.1 More developed regions 44400 7.2 South-Eastern Asia 6933 2. 6 0. France: International Agency for Research on Cancer.1 567 0.6 1.9 0.5 392 1. C12-14 (estimates for 2012). 1 0. Australia: High quality national data or high quality regional (coverage greater than 50%). GLOBOCAN 2012 v1. 0 0.3 0.For Solomon Islands: The rates are those of neighbouring countries or registries in the same area .5 0. 3 0.5 0. Franceschi S. 6 0.8 0. Mathers C.4 14997 0.3 1965 0.1 0.6 0. MALE FEMALE Area N cases Crudea ASRa Cum riskb N cases Crudea ASRa Cum riskb rate (%) ages rate (%) ages 0-74 0-74 World 77585 2.8 0.7 0.7 3.3 0. For cancer. 8 0.0 Southern Asia 43190 4.6 5700 1. 2 1. C12-14 (estimates for 2012). 3 1. 9 0.1 611 0.For Samoa.2 0.8 6.8 3. 1 0.1 0.5 0. Plummer M.1 373 0.1 Caribbean 815 3.3 3. 8 0.1 4.000 men per year. 5 0.6 0. a Male: Rates per 100. 8 1.1 Southern Europe 4137 5.5 0.3 3.8 3. 6 1.2 0.9 5. Bray F.2 0.For Papua New Guinea: Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) Data sources: de Martel C. Vanuatu: Estimated from national mortality estimates using modelled survival .8 0.0 0.0 Americas 17637 3.1 Africa 3369 0.2 0.1 150 0.4 0.0 0.3 0. 7 1. Eser S. in the World and its regions. Int J Cancer.1 Central America 694 0.6 3. 5 0. Soerjomataram I. 0 0.1 1928 0.4 160 0.9 0.2 Western Africa 473 0. 3 0.5 0.7 0. GLOBOCAN quality index for availability of incidence data: . oral cavity and larynx). Table 12: Cancer mortality of pharynx (excluding nasopharynx) by sex.4 321 1. .1 Melanesia 71 1.101 - ( Figure 43 – continued from previous page) Head and neck cancer cases (oropharynx.1 Western Asia 735 0.For Solomon Islands.6 1.6 0.5 0 0.For New Zealand.8 0. 3 0.2.1 Eastern Africa 906 0.0 0.4 0.0 3.6 0.6 0.1 Pharyngeal cancer (excluding nasopharynx) Table 11: Cancer incidence of pharynx (excluding nasopharynx) by sex. GLOBOCAN quality index of methods for calculating incidence: Methods to estimate the sex.9 1. 2 0.0 Northern America 10493 6.6 14 0.1 Western Europe 11476 12.3 18059 0. Papua New Guinea: No data. Ervik M.1 Northern Europe 2594 5.0 0. Australia: Rates projected to 2012 .1 South America 5635 2.fr. 4 0.5 1.4 227 1.1 Eastern Asia 13441 1.9 0.5 0.3 0. Fiji. Parkin DM.6 0.7 3.8 0.1 Less developed regions 70731 2. . 7 0.3 3.2 0.1 1884 0. Vignat J. 3 0.5 2756 1. 1 0.7 0.6 9197 1.9 3.3 2.6 0.1 Central Asia 717 2.2 0.6 0. 3 0. Female: Rates per 100.For Samoa: Most recent rates applied to 2012 population . 4 0.4 731 0. 6 0.4 2.7 0.1 0.1 218 0.0 0.0 Polynesia 11 3. MALE FEMALE Area N cases Crudea ASRa Cum riskb N cases Crudea ASRa Cum riskb rate (%) ages rate (%) ages 0-74 0-74 World 115131 3.iarc.4 27256 0.1 Middle Africa 585 0. 2013. b Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. 2017 3.4 146 1. Rebelo M.For Fiji. Data sources: Ferlay J.2 2.0 0.7 0.0 0.9 1.9 2724 2.1 Australia & New Zealand 633 4.5 0.2 Oceania 715 3. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.4 5.7 0.4 0.3 0. Available from: http://globocan.1 Southern Africa 784 2.1 Northern Africa 621 0.

3 0.1 Central America 482 0. a Male: Rates per 100.1 Central Asia 516 1. 11 [Internet].4 0.3 0.8 0.3 0.1 More developed regions 21420 3.5 0.3 BURDEN OF HPV RELATED CANCERS .iarc.1 Northern Africa 483 0.9 2.6 0. Data sources: Ferlay J.8 0.1 0. 2 0. Rebelo M. it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.0 Asia 51005 2. Eser S.3 2.3 891 0. 2013.1 Middle Africa 518 0.2 430 0.7 2.102 - ( Table 12 – continued from previous page) MALE FEMALE Area N cases Crudea ASRa Cum riskb N cases Crudea ASRa Cum riskb rate (%) ages rate (%) ages 0-74 0-74 Less developed regions 56165 1.7 2.8 2.4 0.7 0. 0 1.2 0. GLOBOCAN 2012 v1.0 0. 5 0.0 Polynesia 6 1.3 0. For cancer.3 231 0. Forman D.2 0.9 1.0 South America 4186 2.8 1.3 0.0 0.2 0.4 0.0 Africa 2631 0.0 Northern America 3145 1.8 1.5 0.0 Australia & New Zealand 261 1.6 0.6 0. Soerjomataram I.4 0. 5 0.8 0. Lyon.9 2.1 288 0.4 0.6 0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.3 12126 0.6 0.2 1545 0.0 0.5 14 0.6 0. 5 0.2 0.6 8710 1.4 0.0 0 0.3 0.1 Eastern Africa 786 0. b Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years.0 1.5 0.5 0.5 0. 3 0.7 0.0 Western Europe 4508 4.5 2.2.7 2.0 Data accessed on 15 Nov 2015.3 0.3 0.3 995 1.2 0.4 0. 3 0.0 Melanesia 56 1.2 191 0. 5 0. Female: Rates per 100. 0 0.3 0.0 0. 7 0.1 Eastern Asia 7867 1. 1 0.0 Southern Asia 36667 4.2 0.4 0.2 2.1 1459 0. 0 0. 5 0.2 1 0. 5 0.5 0.0 Caribbean 568 2.3 0. Mathers C.1 0.3 145 0. Available from: http://globocan.3 14440 0.2 2173 0.000 women per year. Dikshit R.7 1.3 4065 0.0 Americas 8381 1. France: International Agency for Research on Cancer.4 0.9 0. 2 0.3 3.5 0.1 Western Africa 418 0.0 Southern Europe 2342 3. 6 0.0 Europe 15245 4.5 0.8 1.3 0.1 494 0.3 0.1 Southern Africa 426 1.2 0. 3 0. 5 0.3 159 0.1 153 0.3 1.0 0.9 0.2 352 0.1 5. 7 0.7 0. 7 0.fr.7 0.1 70 0. 3 0.8 0.3 2662 0. 5 0. 3 0. 7 0.2 85 0.0 Northern Europe 1118 2.1 2.0 Eastern Europe 7277 5.1 0.6 0. 4 0. ICO HPV Information Centre . 6 0.5 885 0.3 2.1 1352 0.2 0.1 Oceania 323 1. Bray F.1 133 0.5 0.5 2.6 0. Ervik M. 6 0. 2 0.1 970 0.000 men per year. Parkin DM.1 Western Asia 541 0.1 South-Eastern Asia 5414 1.0 Micronesia 0 0.4 0.4 0.1 496 0. 5 0.

Rebelo M. 11 [Internet]. 2013. Soerjomataram I.C12-14 (estimates for 2012) MALE 25 World 25 Less developed regions 25 More developed regions 20 20 20 pharyngeal cancer (excluding nasopharynx) per 100. Available from: http://globocan. ICO HPV Information Centre . Lyon.000 men per year.3 BURDEN OF HPV RELATED CANCERS . Bray F. Mathers C. Includes ICD-10 codes: C09-10.000 15 15 15 10 10 10 5 5 5 Age−specific rates of 0 0 0 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 FEMALE 25 World 25 Less developed regions 25 More developed regions 20 20 20 15 15 15 10 10 10 5 5 5 0 0 0 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 0−14 15−39 40−44 45−49 50−54 55−59 60−64 65−69 70−74 >=75 Incidence Mortality Data accessed on 15 Nov 2015.103 - Figure 44: Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) by sex and age group in the World. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. France: International Agency for Research on Cancer.iarc.2. Ervik M. GLOBOCAN 2012 v1. Parkin DM. Eser S. Female: Rates per 100.fr.000 women per year. Forman D. Data sources: Ferlay J. Dikshit R. Male: Rates per 100.

fr. Rebelo M.000 women per year. Parkin DM.000 men per year.000 30 Africa 30 Europe 25 25 20 20 Age−specific rates of 15 15 10 10 5 5 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= 30 Americas 30 Oceania 25 25 20 20 15 15 10 10 5 5 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= Age group (years) Incidence Mortality Data accessed on 15 Nov 2015. Bray F. Ervik M. Dikshit R.iarc.104 - Figure 45: Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) in males by age group in the World and its regions. Includes ICD-10 codes: C09-10. Data sources: Ferlay J. Mathers C. 11 [Internet]. Female: Rates per 100. Soerjomataram I. GLOBOCAN 2012 v1.2. (Continued on next page) ICO HPV Information Centre .C12-14 (estimates for 2012) 30 World 30 Asia 25 25 20 20 15 15 10 10 5 5 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= pharyngeal cancer (excluding nasopharynx) per 100. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.3 BURDEN OF HPV RELATED CANCERS . Lyon. Available from: http://globocan. France: International Agency for Research on Cancer. Forman D. Male: Rates per 100. Eser S. . 2013.

000 5 Africa 5 Europe 4 4 3 3 Age−specific rates of 2 2 1 1 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= 5 Americas 5 Oceania 4 4 3 3 2 2 1 1 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= Age group (years) Incidence Mortality ICO HPV Information Centre .3 BURDEN OF HPV RELATED CANCERS . .C12-14 (estimates for 2012) 5 World 5 Asia 4 4 3 3 2 2 1 1 0 0 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 15 4 40 9 45 4 50 9 55 4 60 9 65 4 70 9 4 75 −7 −7 1 1 −3 −4 −5 −6 −3 −4 −5 −6 −5 −5 −6 −6 −4 −4 0− 0− >= >= pharyngeal cancer (excluding nasopharynx) per 100.105 - ( Figure 45 – continued from previous page) Figure 46: Comparison of cancer incidence and mortality of pharynx (excluding nasopharynx) in females by age group in the World and its regions. Includes ICD-10 codes: C09-10.

GLOBOCAN 2012 v1. Available from: http://globocan.000 women per year. Soerjomataram I.106 - Data accessed on 15 Nov 2015. Rebelo M. Lyon. ICO HPV Information Centre . Mathers C.iarc. Ervik M. Data sources: Ferlay J. Parkin DM. Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No.3 BURDEN OF HPV RELATED CANCERS . Dikshit R.fr. France: International Agency for Research on Cancer. 11 [Internet].2.000 men per year. Male: Rates per 100. Female: Rates per 100. Forman D. Eser S. 2013.

CIN-3/CIS) and invasive cervical cancer. Vaccine 2012. low-grade cervical lesions. these account for an additional 20% of cervical cancers worldwide (Clifford G et al. Inclusion criteria were: HPV DNA detection by means of PCR or HC2. Vaccine 2006. namely 31. 45. 26. 24. CIN-2.1 HPV burden in women with normal cervical cytology. cervical precancerous lesions or invasive cervical cancer The statistics shown in this section focus on HPV infection in the cervix uteri. HPV causes virtually 100% of cases of cervical cancer. paraffin embedded or exfo- liated cells).24(S3):26-34). 35. (Vaccine 2006. high-grade cervical lesions and normal cytology: systematic re- view and meta-analysis A systematic review of the literature was conducted regarding the worldwide HPV-prevalence and type distribution for cervical carcinoma. Vol. Suppl 3. Vol. and an underestimation of HPV prevalence in cervical cancer is most likely due to the limitations of study methodologies. The prevalence of HPV increases with severity of the lesion. 52 and 58.4 HPV RELATED STATISTICS . the two vaccine-preventable types. HPV-16 and 18. and there is growing evidence of its central role in other anogenital sites. HPV infection is measured by means of HPV DNA detection in cervical cells (fresh tissue. these data should be interpreted with caution and used only as a guide to assess the burden of HPV infection in the population. high-grade cervical lesions and normal cytology from 1990 to ’data as of ’ indicated in each section. Worldwide. The search terms for the review were ’HPV’ AND cerv* using Pubmed. 24(S3):35). The number of cases tested and HPV positive extracted for each study were pooled to estimate the prevalence of HPV DNA and the HPV type distribution globally and by geographical region. After HPV-16/18. low-grade cervical lesions. 4. The aetiological role of HPV infection among women with cervical cancer is well-established. IARC Monographs 2007. For more details refer to the methods document. Binomial 95% confidence intervals were calculated for each HPV prevalence. 90). Suppl 10. a minimum of 20 cases for cervical carcinoma. Vaccine 2008. Vol. For this section. Suppl 5. con- tribute to over 70% of all cervical cancer cases. between 41%-67% of high-grade cervical lesions and 16-32% of low-grade cervical lesions. 33. References cited in selected articles were also investigated. HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts. ICO HPV Information Centre . Vaccine 2006.107 - 4 HPV related statistics HPV infection is commonly found in the anogenital tract of men and women with and without clinical lesions. 20 cases for low-grade cervical lesions. There were no limits in publication language. Due to the limitations of HPV DNA detection methods and study designs used. the six most common HPV types are the same in all world regions. Methods: Prevalence and type distribution of human papillomavirus in cervical carcinoma. both mainly caused by HPV types 6 and 11(Lacey CJ. 30. Vol. 20 cases for high- grade cervical lesions and 100 cases for normal cytology and a detailed description of HPV DNA detec- tion and genotyping techniques used. HPV cervical infection re- sults in cervical morphological lesions ranging from normalcy (cytologically normal women) to different stages of precancerous lesions (CIN-1. the methodologies used to compile the information on HPV burden are derived from systematic reviews and meta-analyses of the literature.

ICO HPV Information Centre .4 HPV RELATED STATISTICS .1 HPV prevalence in women with normal cervical cytology Figure 47: Prevalence of HPV among women with normal cervical cytology in the World Data updated on 15 Dec 2016 (data as of 30 Jun 2015).1.108 - 4. Data sources: See references in Section 9. The samples for HPV testing come from cervical specimens (fresh / fixed biopsies or exfoliated cells).

109 - Figure 48: Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in the World and its regions HPV prevalence (%) 50 Europe 50 Oceania 45 45 40 40 35 35 30 30 25 25 20 20 15 15 10 10 5 5 0 0 <25 25−34 35−44 45−54 55−64 65+ <25 25−34 35−44 45−54 55−64 65+ HPV prevalence (%) 50 Africa 50 Asia 45 45 40 40 35 35 30 30 25 25 20 20 15 15 10 10 5 5 0 0 <25 25−34 35−44 45−54 55−64 65+ <25 25−34 35−44 45−54 55−64 65+ HPV prevalence (%) 50 Americas 50 World 45 45 40 40 35 35 30 30 25 25 20 20 15 15 10 10 5 5 0 0 <25 25−34 35−44 45−54 55−64 65+ <25 25−34 35−44 45−54 55−64 65+ Age group (years) Data updated on 15 Dec 2016 (data as of 30 Jun 2015). Data sources: See references in Section 9. ICO HPV Information Centre .4 HPV RELATED STATISTICS .

5 (9.3) Manga 2015c − 108 43.2−65.5 (16.3−51.5 (34.1) Belglaiaa 2015 18−76 190 17.7) c Tebeu 2015 (Tiko and Yaoundé) 30−65 540 27.0 (35.2) Hammouda 2005 (Algiers) 31−80 133 10.9−38.3) Guinea Keita 2009 (Conakry) 15−64 752 47.1 (17.9) Côte d'Ivoire La Ruche 1998 (Abidjan)d 20−50 194 16.0) Ethiopia Leyh−Bannurah 2014 (Gurage)c 15−64 537 17. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).4 (12.6) Gambia Wall 2005 (Farafenni) 15−54 576 11.1) Morocco Alhamany 2010 (Rabat) 17−80 785 15.9−7.7−32.0) Naucler 2011 (Maputo) 25−88 183 31.5−20.2) Mozambique Castellsagué 2001 (Manhiça) 14−61 196 32.5) Thomas 2004 (Idikan (Ibadan)) 15−98 844 24.9 (10.5) Bennani 2012 (Fez) 17−81 751 42.8 (33.3−18.2) Nigeria Gage 2012 (Irun) >=15 1.3 (3.0 (46.9 (44.9−13.8−17.2−10.8 (13.0−46.2) c Tracy 2011 (Bamako) 15−65 202 11.0−28.8) g Pimentel 2013 19−85 374 12.9) De Vuyst 2003 (Nairobi) 25−55 369 38.9−43.9 (8.4) Egypt Shaltout 2014c 18−99 443 10.9−29.8 (13.9−48.5) Hovland 2010 (Bukavu) − 287 13. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.3) Mali Schluterman 2013 (Naréna)c 15−65 212 23.5 (11.7 (14. 95% CI: 95% Confidence Interval.5 (20.1) Adjorlolo−Johnson 2010 (Abidjan) 23−69 110 29.5 (14.8 (22.0) c Akarolo−Anthony 2013 (Abuja) − 108 10.3 (6.3−16.5−30.5 (39.9) Benin Piras 2011b 18−63 258 26.5 (8.6 (32.3) c Ghana Yar 2016 18−59 100 56. N: number of women tested.1−19.9) 0% 10% 20% 30% 40% 50% 60% 70% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).3 (9.5−42.4−38.1 (24.4−18.9 (11.6) Untiet 2014 (Yaoundé)c 20−89 694 16.6) Abdel Aziz 2006 (Cairo) 20−60 156 10.9) Ruland 2006 (Gurage)c 18−65 189 15.4) Chaouki 1998 (Rabat) 18−70 172 21.5 (6.0 (23.1−17.5−51.7 (21.4) c Cameroon Catarino 2016 25−65 731 39.8) Yamada 2008 (Nairobi)c 16−61 333 16.4−21.6−23.9−44.2−21.2 (2.1−14.6−52.5) Burkina Faso Ouédraogo 2015c 15−19 200 41.4) c Kenya Temmerman 1999 (Nairobi) 19−54 513 17.9−22.075 10.1 (21.2 (5.4) e La Ruche 1998 (Abidjan) 20−50 120 27.0 (14.4−16.9−48.138 8.4) De Vuyst 2010 (Mombasa) >=15 454 40.2) Maranga 2013 (Nairobi) 21−50 101 41.5 (34.4 HPV RELATED STATISTICS .4−16.0) Dareng 2016c >=18 111 10.8 (6.8−12. a Zeralda (Algiers) (Continued on next page) ICO HPV Information Centre .5 (34.5−7.0−27.8) Gabon Si−Mohamed 2005 (Libreville)c 18−44 195 41.4 (7.4−18.0−20.2) DR Congo Sangwa−Lugoma 2011f >=30 1.0) Amrani 2003 (Rabat) 25−54 306 4.7 (7.0−39.110 - Figure 49: Prevalence of HPV among women with normal cervical cytology in Africa by country and study Country Study Age N % (95% CI) a Algeria Hammouda 2011 18−65 732 5.3 (35.3−36.1 (26.

Lokossa. Djougou. Cotonou.4 HPV RELATED STATISTICS . Kinshasa g Okene. Lagune. Parakou. Abuja and Katari Data sources: See references in Section 9. ICO HPV Information Centre .111 - ( Figure 49 – continued from previous page) b Abomey. Porto-Novo and Tanguetà c Women from the general population. including some with cytological cervical abnormalities d HIV negative women (controls of women with HSIL) e HIV negative women (controls of women with LSIL) f Mbuku. Atakora.

including some with cytological cervical abnormalities b Tshwane District.7 (19.987 24.5) Tanzania Dartell 2014c 15−82 2.112 - Figure 50: Prevalence of HPV among women with normal cervical cytology in Africa by country and study (continued) Country Study Age N % (95% CI) Rwanda Sinayobye 2014a 30−60 1.4) a Baay 2004 (Mupfure) 15−49 174 27.4−20.9−20.633 25.7−19.1) a Asiimwe 2008 (Bushenyi District) 25−37 305 15.0 (14.1−20.311 8.5 (8.9−16.2) Odida 2011 (Kampala) 18−74 251 26.7 (11.9−80.6 (72.1 (25.5 (11.e Nowak 2011 18−35 478 47.2 (13.6−14.7 (12.2) Zimbabwe a.0) Womack 2000e 25−55 186 24.8) Denny 2005 (Khayelitsha)a 35−65 6.5 (13.0−14.2−32.1−37.5 (43.6) Allan 2008 (Cape Town) 21−59 848 20.7) Tunisia Guettiti 2014 18−69 573 3.6) Senegal Hawes 2003 (Dakar)a >=15 3.2 (70.d 18−49 1. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.7) Hassen 2003 (Sousse) 20−45 96 14.0) Xi 2003 (Dakar) 35−80 1.7 (30.8) a Singh 2009 >=25 188 14.4) a.1) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Data updated on 15 Dec 2016 (data as of 30 Jun 2015).8−23.2−29.4 (17.b 16−83 1.3−76.9−23.1−52.4) Fukuchi 2009 a. Epworth (Harare) e Chitungwiza and Harare Data sources: See references in Section 9.8 (2. Pwani.0) Uganda Jeronimo 2014 (Kampala) 25−60 2.0−34.3 (23.5−23.6−26.1−31.8 (11.6 (12.4 (24.2) Mbaye 2014 (Saint−Louis)a 18−80 145 20.2) Astori 1999 (Dakar) 20−75 158 13. Mwanza d Chitungwiza.9−26.9 (16.2) a Giuliano 2015 16−24 391 71.3 (24.2 (6.1−46. 95% CI: 95% Confidence Interval.0 (21.6−17.555 21. Gauteng province c Dar es Salaam.2) Mbaye 2014 (Louga) 18−80 108 23.4−22.9) South Africa McDonald 2012 (Khayelitsha) 17−65 7.7) Banura 2008 (Kampala)a 12−24 868 73.445 74.1 (16.7) Hanisch 2013 (Dakar)a 15−84 2.4 (66. ICO HPV Information Centre .0) Safaeian 2007 (Rakai)a 15−49 505 15.269 15.0) Watson−Jones 2013 (Mwanza) 10−25 117 73.1−76.4 (10.4−43.8−9.1−35.676 15.7−75.1) a Moses 2015 30−65 248 29.1) Veldhuijzen 2012 (Kigali)a − 144 16.5 (22.569 16.1) a Mbulawa 2015 18−66 207 36.5−24.6 (8. N: number of women tested.1−20.9 (17.7) Mbaye 2014 (Thiès) 18−80 185 30.7 (48.8) Richter 2013 Wright 2000 (Cape Town) 35−65 1.3−27.139 27.9 (9.5−5.1−17.5 (64.4) Taube 2010 (Kampala) 18−30 157 56.9−64. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).3 (21.6) Jones 2007 (Cape Town) >=18 368 41.4 (20.737 12.0 (36.2) Mbaye 2014 (Dakar) 18−80 498 20.1) Vidal 2011 (Kilimanjaro) >=18 148 13.2−31.639 12.4 HPV RELATED STATISTICS . a Women from the general population.

1−19.5) Chagas 2015 − 390 55.4) f 15−83 418 6.9−9.9 (28.8) Vieira 2015 18−55 227 23.9−42.1−18.5−11.3−10.509 29.6) Franco 1995 (Paraiba)c 15−65 525 18.0 (22.2−11. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).7) Augusto 2014 (Niterói City) 14−79 338 8.4) Coser 2013 (Cruz Alta) 13−82 327 32.0 (5.9) 0% 10% 20% 30% 40% 50% 60% 70% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).5) da Silva 2012 Miranda 2012g 18−65 399 11.2) Caixeta 2015 15−25 227 42.4−14.0) Badano 2011 (Posadas City) 18−62 139 33.4−30.800 12.9 (44.7 (9.8) Noronha 2005 (Para) 30−45 433 6.9 (21.988 15.8) Tomita 2010 21−65 453 28. N: number of women tested.9) c Campos 2014 (Campo Grande) 18−65 169 23.0 (12.3) Belize Cathro 2009 (Belize City) − 426 10.6) Silva 2009 (Itaboraí) 14−79 128 21.3−14.6−29.7 (27.921 10.0−48.7 (23.0 (24.8) Tamegão−Lopes 2014k − 120 35.113 - Figure 51: Prevalence of HPV among women with normal cervical cytology in the Americas by country and study Country Study Age N % (95% CI) Argentina Matos 2003 (Entre Ríos) 13−78 843 15.3) Pinto 2011 (Tucuruí) >=13 211 14.8−41.6−13.1 (13.0 (11.4) Rocha 2013i 18−78 314 29.7) Cassel 2014 (Porto Alegre) − 158 12.2) Pinto 2011 (Pará)c >=13 233 15.9 (15.5 (9.3 (36.006 25.9) e Girianelli 2010 25−59 1.7−9.7) c Figueiredo Alves 2013 (Goiana) 15−19 432 28.1 (25.6 (5.3−29.4 (13.4−22.5−32.0) de Oliveira 2013 (Rio Grande)c >=14 162 13.2) de Abreu 2012h 15−83 370 7.3 (18.7 (8.1 (17.6 (9.3 (15.9) Abba 2003 (La Plata) 15−70 152 46.8−54.6) Muñoz 1996 (Sao Paulo) 26−77 194 17. 95% CI: 95% Confidence Interval.1−28.0) Silva 2009 (Maricá) 14−79 130 2.9 (3.3 (10.0 (27.3) Cervantes 2003 Brazil Trottier 2006 (Sao Paulo) 18−59 1.6) Lippman 2010 (Sao Pulo) 18−40 209 34.1 (38.1 (7.3−54.3−18.0−20.c 16−71 135 5.5 (24.4 HPV RELATED STATISTICS .0 (8.0−11.3) Chouhy 2013 (Buenos Aires) 15−69 371 49.2−21.0) Chouhy 2013a 14−77 403 37.0−32.5 (32.2 (10.9−13.1 (27.8−6.3−37.4−32.1−36.7) Entiauspe 2014 (Pelotas) 18−45 136 27.6−16.5) Carestiato 2006 (Rio de Janeiro) 11−70 672 12.9) Roteli−Martins 2011c 15−25 1.4 (50.3) Bolivia b.1−35. a Granadero Baigorria City (Santa Fe Province) (Continued on next page) ICO HPV Information Centre .3 (0.8−41.7 (4.8−25.7) Lorenzi 2013d 18−77 1. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4−60.9 (4.3) Oliveira 2010j 14−26 225 28.6 (10.5 (14.1−43.0) Magalhães 2015 14−64 1.9 (25.4) c Oliveira 2007 (Pacoti.5−34. Ceara) 13−49 579 11.1−19.2) Lorenzato 2000 (Recife) 13−84 215 19.3−15.

including some with cytological cervical abnormalities d Barretos (Sao Paulo) e Duque de Caxias and Nova Iguaçu (State of Rio de Janeiro) f Paiçandú (Paraná) g Ouro Preto city (Minas Gerais) h Maringá.114 - ( Figure 51 – continued from previous page) b Amazonian lowland c Women from the general population. Paiçandú and Uniao da Vitoria (Paraná State) i Coari (Amazonas State) j Niterói City (Rio de Janeiro) k Juruti (Pará) Data sources: See references in Section 9.4 HPV RELATED STATISTICS . ICO HPV Information Centre .

6) Costa Rica Herrero 2005 (Guanacaste) 18−94 7.e 25−60 9.2−52.3) Safaeian 2007 (Guanacaste) 18−25 4.9−22.8 (7.9−49.7) Tábora 2005 (Tegucigalpa) 18−35 100 28.7−29.245 5.6) Cuba Soto 2014 (La Havana) 30−69 111 41.4) Watt 2009 (Western Jamaica)a − 99 83.2−42.0 (20.4−12.7) Ferreccio 2004 (Santiago) 15−86 913 11.2−20.459 22. 95% CI: 95% Confidence Interval.2 (40.6 (1.7 (47.8 (47. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.9−4.6−30.5 (17.7−50.340 12.4 HPV RELATED STATISTICS .8 (11.127 9.2) Camargo 2014 (Bogotá)a 14−76 1.2) Honduras Tábora 2009 (Tegucigalpa) 18−65 562 51.2−8.3−19.0−33.0 (25.4) Haiti Walmer 2013a.168 11.5) Ferrera 1999 (Tegucigalpa) 15−65 438 38.8 (9.3) b Jiang 2013 14−69 13.6 (20.769 19.9 (17.6) a Ogilvie 2013 (British Columbia) − 4.3−13.2 (27.053 8.6−7.545 7.8) Cecchini 2009 21−72 249 2.8) Mandigo 2015 30−50 426 12.6 (28.3) Lazcano−Ponce 2010 Salmerón 2003 (Morelos) 15−85 7.8−16. N: number of women tested.0 (0.6) Lazcano−Ponce 2001 (Morelos) 18−82 1.9) Colombia Molano 2002 (Bogota) 13−85 1.8−8.564 49.3) Moore 2009 (British Columbia) >=15 4.3−89. including some with cytological cervical abnormalities (Continued on next page) ICO HPV Information Centre .2−22.7−5.4) Montalvo 2011 (Arica) 18−25 195 2.9) Muñoz 1996 (Cali) 19−74 307 13.3) Young 1997 (Winnipeg) − 1.2 (14.9−39.2 (17.4−47.8 (34.4 (10.1) Leon 2009 (Girardot) 14−80 744 19.7) Kapala 2007 (Ontario) − 222 15.8−13.4 (21.330 12.5−33.1−16.831 14.4) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).1) Roteli−Martins 2011 15−25 185 23.3) Sellors 2000 (Ontario) 15−49 878 10.3−55.5) Jamaica Lewis−Bell 2013 16−49 765 50.3 (8.9−14.4) g Illades−Aguiar 2010 15−97 3.3) Soto−De Leon 2011d 14−77 1.857 42.159 44.5) Ferrera 2011 (Tegucigalpa)a 18−35 393 44.1−5.6) Guatemala Vallès 2009 (Escuintla) 18−49 274 33.8 (75.9 (39.7) Ecuador Brown 2009 (Guayas) 18−78 285 20.2 (4.4 (32.7 (9.1−37.4 (47.4) Richardson 2003 (Montreal) 17−42 568 27.3) Mayrand 2006c 30−69 9.6 (13.8) Chile Ferreccio 2013 (Santiago) 16−78 8.117 40.9) Demers 2012 (Manitoba) >=18 517 17.5 (9.132 30.0 (18.3−54.003 12.4−43.5 (10.115 - Figure 52: Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued) Country Study Age N % (95% CI) Brazil Fernandes 2009 (Natal) 15−65 110 24.4) a Ferreccio 2008 16−97 1.4−30.8 (39.9−43.100 28.2 (9.1 (23. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).1−10.3 (11.0−17.0 (7.4) Canada Louvanto 2014 (Montreal)a 30−65 23.3 (41.379 21.6−21.4−25.8) Mexico f 20−70 49.739 6.7 (16.3−13.4−23.2 (11. a Women from the general population.0) Guyana Kightlinger 2010 13−80 1.9 (6.3−13.

Labrador. c Montreal and Newfoundland d Bogotá. State of Mexico. Nuevo León. Querétaro. Veracruz and Yucatán g Acapulco. Yukon. Giradot and Tumaco e Port-au-Prince. ICO HPV Information Centre . Leticia. Leogane f Northern and Southern Mexico City.4 HPV RELATED STATISTICS . Chilpancingo and Iguala (State of Guerrero) Data sources: See references in Section 9. Michoacán.Oaxaca.Guerrero. Jalisco.116 - ( Figure 52 – continued from previous page) b Northwest Territories. Morelos. Chaparral. Nunavut.

6 (23.2) Dunne 2013 Zhao 2007 (Pittsburgh) 11−90 8.1) Parada 2010 (State of Mexico)b 18−75 504 13.6−42.289 4.8 (13.0) c Sánchez−Anguiano 2006 20−69 487 4.0−17.7 (12.9−41.3−16. a Cuernavaca (Continued on next page) ICO HPV Information Centre .8−17.9 (6.1−32.8 (8.2 (13.0 (4.0) b Suriname Geraets 2014 (Paramaribo) >=18 813 54.3−18.4−55.340 9.7) Schiffman 2011 (Portland) 16−94 18.8) Martorell 2012 Santos 2001 (Lima) 21−82 175 17.7−14.231 30.2 (19.8−57.4) 0% 10% 20% 30% 40% 50% 60% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015). 95% CI: 95% Confidence Interval.5−40.0 (8.4 (29.8 (2. N: number of women tested.1 (8.060 14.020 33.5 (32.7 (30. Andall−Brereton 2011 (North) 18−65 310 40.9 (27.9−11.4 HPV RELATED STATISTICS .e 25−75 204 13.2) h − 203 36.4) b.070 2.8) Torres 2009 (Asunción) 17−65 159 25.3) Aguilar−Lemarroy 2015 18−87 356 12.6 (15.7 (12.7) Paraguay Mendoza 2011 (Asunción) 16−77 207 20.8) Silva−Caso 2014 (Cajamarca) 18−65 241 17.7−9.2 (12.450 9.8) Sherman 2003 (Portland) 16−94 20.d 18−81 336 49.9−36.0 (29.8−42.3−13.3−46.5 (6.8−57.3 (23.4) Datta 2008 Goodman 2008 (Hawaii) 18−85 2.6 (32.g 17−79 2.8) López Rivera 2012 (Mexico City) 18−76 916 7.5) Iwasaki 2014 García 2004 18−65 501 3.6) j 11−29 9.117 - Figure 53: Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued) Country Study Age N % (95% CI) Mexico a.0) Monsonego 2015 (23 states) >=25 38.8−26.0) Orozco−Colín 2010 (Acapulco) 18−81 335 37.5−3.7−6.7 (44.4) Giuliano 2005 (Sonora) 40−82 258 7.8 (7.9−29.3−31.7 (11.2 (50.9 (9. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).6) Hernández−Avila 1997b.9−27.4−17.0 (3.356 25.6) Rojo Contreras 2008f 18−55 189 33.7−42.512 14.2) Orozco−Colín 2010b.2−10.8 (12.247 34.5) Hernández−Girón 2005 Salcedo 2014 18−70 1.9 (10.0) Castle 2009i 30−90 580.9) Monroy 2010 (Mexico City) 17−51 272 12.9) Nicaragua Jeronimo 2014 (Masaya Province) 30−49 4.156 12.450 10.5−10.2 (9.1) Peru Almonte 2007 (San Martin) 25−49 4.7−9.5−23.8 (15.2 (29.2) Ragin 2007 (Tobago) 18−65 212 35.055 16.4−5.9 (2.145.4) Rolón 2000 (Asunción) 25−73 91 19.2) b Castle 2012 (Portland) 16−94 19.6−36.9−4.1 (2.5 (29.7) Giuliano 2001 (Sonora) 15−79 995 8.6 (35.3−9.614 24.0) USA Cuzick 2015 15−65 1.284 9.b 17−39 1.4 (9.8−24.8 (33.9−10.3−42.2) k 18−65 8.8) Carrillo−García 2014 17−74 518 37.218 7.6) Geraets 2014 25−37 813 54.2 (50.3−16. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.8−8.8−24.8) Illades−Aguiar 2009 (Acapulco) − 256 35.3) Wheeler 2013 (New Mexico) − 33.6) b Trinidad & Tob.

Sacramento. Piura. Cajamarca.118 - ( Figure 53 – continued from previous page) b Women from the general population. including some with cytological cervical abnormalities c Durango City d Lázaro Cárdenas e Mexico City f Guadalajara g Iquitos. Arequipa. Chiclayo. ICO HPV Information Centre . Baltimore. New Orleans. Central Valley. Northwest Oregon and Southwest Washington Areas k Boston. Cuzco and Juliana h Iquitos and Loretos i Northern California j San Francisco Bay. Los Angeles Data sources: See references in Section 9. Lima. Denver.4 HPV RELATED STATISTICS . Seattle.

2 (24.3 (17.0 (17.9) Khanna 2007 (Baltimore) 18−69 418 10.3−15.3 (22. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4−14.6−24.2) Moscicki 2001 (San Francisco) 13−24 547 80.3−12.1 (10.1) Kahn 2008 (Cincinnati)a 13−26 409 68.4 (45.2 (63.8 (6.0) Chaturvedi 2005 (New Orleans) 18−70 173 19. N: number of women tested.8) Insinga 2007 16−23 1.8 (77.4 (32.2) Smith 2003 (Iowa) 42−85 223 11.8 (8.9) Evans 2006 (Vermont) 16−69 300 27. a Women from the general population. 95% CI: 95% Confidence Interval.9−42.8 (10.0) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Data updated on 15 Dec 2016 (data as of 30 Jun 2015).4) Hernandez 2004 (Hawaii) >=18 183 9.3−83.1−16. ICO HPV Information Centre .1 (11.8−28.6) Swan 1999 (Texas) 18−45 270 20. including some with cytological cervical abnormalities Data sources: See references in Section 9.1 (14.7−25.6−72.9 (2.1−25.6−23. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).8−15.6) Venezuela Téllez 2015 15−69 409 37.3) Giuliano 1999 (Tucson) 18−47 911 10.7 (8.6−32.203 12.1 (13.9−5.4−28.1 (8.921 26.8 (24.1) Cibas 2007 (Boston) 30−45 1.9−33.5−22.119 - Figure 54: Prevalence of HPV among women with normal cervical cytology in the Americas by country and study (continued) Country Study Age N % (95% CI) a USA Dunne 2007 14−59 1.4 HPV RELATED STATISTICS .2) Giuliano 2001 (Arizona) 15−79 881 12.000 3.6) Smith 2004 (Iowa) 45−64 105 17.2) Michelli 2013 15−69 238 22.5) Kotloff 1998 (Maryland) 17−44 390 29.5) Tarkowski 2004 (Atlanta) 12−20 189 52.5) Uruguay Berois 2014 (Montevideo) 21−76 883 20.3−59.7 (16.0 (15.8) Ramas 2013 18−62 236 19.2) Winer 2003 (Seattle)a 18−20 553 19.1−14.9−25.

115 14.4 (9.8−6.6−10.3−24.559 7.4) Yeoh 2006 (Hong Kong) − 1.0 (21.5) a Yip 2010 (Macao) 20−60 1.7) China Wei 2014b 18−81 67.5) 0% 10% 20% 30% 40% 50% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).1−10.114 19.7−8.9 (10.269 20.4−14.8−14.6 (8.2−28.b Wang 2012 18−60 24.4 (6.2) Wu 2007 (Shenzhen) 15−59 942 11.8−10.6 (6.0−7.7) Belinson 2003g 27−56 6.0−30.5 (37.4) Bangladesh Nahar 2014 (Dhaka and Mirzapur)a 13−64 1.6) Dai 2006 (Shanxi) 19−59 601 10.9−13.7 (23.0) Qiao 2008k 30−55 2.6) Chen 2013 (Urumqi)a 18−69 2.2) c Mai 2014 >=18 22.112 9.2) Zhao 2013f 25−65 7.017 16.4) a Wang 2014 (Luoyang (Henan)) 17−79 578 44.3) Zhao 2014 (Jiangsi Province) 18−25 5.5−8.4) Jin 2010 Chan 2009 (Hong Kong) 15−83 2.737 8.600 8.3 (12.643 14.3 (18.2) Belinson 2011d 25−59 7.160 40.987 13.9−10.120 - Figure 55: Prevalence of HPV among women with normal cervical cytology in Asia by country and study Country Study Age N % (95% CI) Bahrain Hajjaj 2006 20−60 91 12.9 (7.l 25−59 2.090 25.n 16−59 883 8.1 (6. N: number of women tested.6−6.5) e Moy 2010 30−54 7.2 (12.8 (12.4−13.8) i 17−54 3.000 12.3 (15.h 18−65 5.9) Ye 2010o 25−65 734 20.902 7.9) Belinson 2001 Lin 2008 (Guandong)a 20−68 1.1) a.4−13.571 5.0 (7. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.6 (6.962 5.936 8.7−43.032 11.8 (7.3 (12.172 1.5 (14.000 16. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).1) Sun 2012 Li 2010 (Beijing) 25−54 5.5−8.5−19.9−20.7) h 35−45 1.6 (45.3) Ye 2010 (Zhejiang Province)a 20−79 4.7−22.9−18.367 9.6 (11.4) Zhang 2012a.0−46.9 (8.9) Wu 2013 Li 2013 (Hunan Province) 17−74 3.7 (11.0) Zhang 2013 (Shangai)a 17−89 10.8 (7.041 45.8) a.2−11.6−9.5−48.6 (4.8) Chen 2012 (Chaozhou)a 35−60 48.6−15.5 (8.5 (40.3−8.0 (18.847 7.1 (28.2) Wu 2010 Chan 2002 (Hong Kong) 19−83 1.1) Sui 2013a.8) Yuan 2011 (Shandong Province) 20−61 3.089 10.5 (13.6−1.5−10.416 13.7 (4.168 10.0−14.m 20−64 1.272 23.6−15.2 (17.1 (9.3−15.413 13.7) j 19−65 2.525 7.2−11.7 (1.3 (7.3) Wang 2013 (Shenzhen)a >=15 4.9 (7.2) Lu 2015 (Beijing)a − 1. including some with cytological cervical abnormalities b Shenyang (Liaoning Province) c Shantou City (Guandong Province) (Continued on next page) ICO HPV Information Centre .5) a DU 2012 (Shenzhen) 20−59 10. a Women from the general population. 95% CI: 95% Confidence Interval.2) Li 2006 (Shenyang) 17−59 663 13.4 (13.4−23.2) a.5−14.530 6.3) Zhang 2008 (Shangai)a 18−78 6.9 (10.6−17.4 HPV RELATED STATISTICS .705 9.784 14.3−16.405 29.6 (8.9) Bhutan Tshomo 2014 (Thimphu) 16−73 2.0−9.

Xinjiang j Tibetan Autonomous Region k Wuxiang and Xiangyuan (Shanxi Province) l Shenzhen (Guangdong Province) m Wufeng County (Hubei Province) n Uyghur (Yutian County.121 - ( Figure 55 – continued from previous page) d Guangdong Province e Shanxi. ICO HPV Information Centre . Jiangxi and Gansu Provinces f Yangcheng. Xinmi and Tonggu g Yangcheng and Xiangyuan (Shanxi) h Qujing (Yunnan Province) i Beijing. Henan. Xingjian Province) o Lishui County (Zhejiang Province) Data sources: See references in Section 9.4 HPV RELATED STATISTICS . Shanghai. Shanxi.

1) Hu 2011 (Jaingsu Province) 18−25 257 10.4) India Basu 2013 (West Bengal)a 30−65 28.2) Indonesia Vet 2008 (Tasikmalaya) 12−70 919 8.385 4.0−8.8−13.5) g Sankaranarayanan 2004 25−65 3.7−16.9−5.2 (4.6−34.365 6.247 11.8 (4.0 (12.301 10.7−17.1−24.7) Jeronimo 2014e 30−60 4.4) Laikangbam 2007 (Manipur) 20−80 672 6.6 (4.4 (3.2) Yu 2013a.1−10.9) Ding 2014 (Beijing) 18−68 165 9.331 10.3−14.4 HPV RELATED STATISTICS .9 (11.4−24.7 (6.7) Chui 2012 (Macau)a 20−66 402 29.8) Aggarwal 2006 (Chandigarh) 19−75 472 36.6) Dutta 2012 (Eastern India) 25−65 2.1−10.7) a.6−5.039 5.1−15.2−19.0) d Sankaranarayanan 2004 25−65 6.7 (8.6−41.2−15.1−36.0) Gupta 2009 (New Delhi) 18−45 769 16.9−2.1−25.2) Wang 2013 (Huzhou)a 20−35 292 19.480 9.630 4.3) Kerkar 2011 (Mumbai) − 470 8.4) Laikangbam 2007 (Sikkim) 19−75 359 11.8) Vinodhini 2012 (Tamil Nadu) − 257 30.3−9.2 (12.300 11.547 2.390 7.1 (7.9) Arora 2005 (New Delhi) 20−60 160 10.6 (14.3 (9. N: number of women tested.h >=25 2.0 (6.2 (8.9−8.6−13.7) Georgia Alibegashvili 2011 (Tbilisi) 15−59 1.8−13.8 (6.0) Datta 2010 j Sarkar 2011 (West Bengal) >=15 1.2−5.7 (9.5−7.5 (9.1) Sankaranarayanan 2004f 25−65 4.2 (15.4 (15.106 9.3 (5.2) Sun 2010 (Liaoning Province) − 165 21.c Sankaranarayanan 2005 30−59 27.8) Vet 2008 (Bali) 12−70 887 11.3−14.b 20−60 373 12.4) Franceschi 2005 (Tamil Nadu) 17−59 1.4) Wu 2010 (Fujian Province) 20−70 314 19.8 (16.313 9.1) a.7) Sankaranarayanan 2004 (Mumbai) 25−65 3.2 (9.5 (9.007 11.5 (7. including some with cytological cervical abnormalities (Continued on next page) ICO HPV Information Centre .6−10.8) Vet 2008 (Jakarta)a 12−70 880 13.8 (7.7) Pandey 2012 (Lucknow)a 20−70 890 11.3 (9.3) 0% 10% 20% 30% 40% 50% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).5−6.0) Laikangbam 2007 (West Bengal) 14−80 1. a Women from the general population.3 (1.122 - Figure 56: Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) Country Study Age N % (95% CI) China He 2008 (Hangzhou) − 480 15.8 (3.6) Singh 2009 (North India) − 109 10.1−11.5−15.7) Mittal 2014 (Kolkata)a 30−60 9.9−10.6 (9.6−13.6−11.2−5. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).5) Bian 2013 (Beijing) 20−55 379 20.9−10.3−18.1 (5.6 (9.i 16−24 1.2−28.8 (5.8 (17.799 14. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.6 (5.4 (25.1) Srivastava 2012 (Varanasi)a 17−80 2.9) Bhatla 2008 (New Delhi) 30−65 458 7.6−16.8) Jeronimo 2014 (Hyderabad) 30−49 4.332 4.9 (32.1 (8.1 (5. 95% CI: 95% Confidence Interval.278 5.9) Gravitt 2010a.9 (25.5−10.7−14.7 (5.2) k Kashyap 2013 46−58 207 5.

18 only k Few HPV types tested: 16 only Data sources: See references in Section 9.123 - ( Figure 56 – continued from previous page) b Shiquan County (Shaanxi Province) c Osnamabad d Kolkata (2) e Rural Uttar Pradesh f Trivandrum g Kolkata (1) h Medchal Mandal (Andhra Pradesh) i Govindpuri (New Delhi) j Few HPV types tested: 16. ICO HPV Information Centre .4 HPV RELATED STATISTICS .

95% CI: 95% Confidence Interval.3−6.1) Johnson 2014j 16−60 211 2.1) Pakistan Raza 2010 (Karachi) 15−59 877 2.249 10.2−25.0−8.5−33.8) b Chong 2010 (Southern Selangor) 19−69 180 46.8−32.775 34.1−38.6−21.1 (1.0−20.6) Lee 2012 (Suwon) − 26.6 (6.6) Masumoto 2004 (Tokyo) 20−89 414 16. N: number of women tested.0 (0.8 (10. a Jakarta. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).2−5.4−3.6 (5.1−8.7−11.6) Asato 2004 (Okinawa) 18−85 3.7) Rachmadi 2012a 18−60 101 16.1) Othman 2014g 19−83 588 3.9 (16.4 HPV RELATED STATISTICS .6 (0.1−7.8) Safaei 2010 (Shiraz) 20−72 400 5.2 (1.2) Maehama 2005 (Okinawa) 20−89 4.4−15.0−7.124 - Figure 57: Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) Country Study Age N % (95% CI) Indonesia de Boer 2006 (Jakarta) 21−75 200 31.6 (9.4) i Nepal Sherpa 2010 16−59 898 8.8 (14.7) b Kazakhstan Buleshov 2011 (South) 35−60 17.8−34.2−10. Tasikmalaya and Bali (Continued on next page) ICO HPV Information Centre .4 (8.3) b Iran Eghbali 2012 (Bushehr Port) 17−50 799 0.3−29.111 18.026 4.6) Rep.3) Moradi 2011 (Gorgan) 15−75 226 18.5) Kuwait Al−Awadhi 2011 18−81 3.9−4.7) Chen 2013 (Nagasaki)b − 1.5−11.1−19.7−6.5−10.2 (9.1−19.517 22.6 (5.5 (3.564 6.068 9.9 (13.1−9.7 (39.1 (9.1 (23.7) h Chimeddorj 2008 − 100 1.5 (3.6) e Konno 2011 19−25 908 26.9−3.8−25.8) 0% 10% 20% 30% 40% 50% 60% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).562 9.1 (6.2) Sasagawa 2005 (Hokuriku) 15−59 637 16.9 (3.7) b Zandi 2010 (Bushehr) − 200 5.0−37.000 11.3−1.5 (3.3 (6.078 10.4) Philippines Ngelangel 1998 (Manila) 21−72 377 9.7−23.2 (33.4) Karam 2005 20−67 246 10.2) b Shahramian 2011 (Zabol) − 265 32.9) Ishi 2004 (Chiba) 17−73 420 12.5) Khodakarami 2012 (Tehran) 18−59 791 6.5 (20. Tokyo) 19−88 109 23.5 (27.0 (10.980 20.3 (19.8 (1.5) Zavarei 2008 (Tehran) 15−55 600 5.7 (8.8−12.0 (19.3−6.0 (25.011 2.2 (7.5 (27.7 (4.9) Mongolia Dondog 2008 (Ulaanbaatar) 15−59 842 30.6−20. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4 (1.7) Satoh 2013 (Tsukuba.0−14.2 (16.9−20.5−24.1) Saito 1995 (Osaka) 18−72 800 6.7 (11.1 (13.6) Japan Inoue 2006 (Ishikawa) 14−94 7.8) Nishiwaki 2008 19−70 292 14.3−11.6 (9.2) Yoshikawa 1999 <=55 130 14.0) b Lebanon Mroueh 2002 (Beirut) 18−70 1.3−11.6) f Sasagawa 1997 16−82 778 4.7) d Sasagawa 2001 16−72 1.6) Malaysia Tay 2009 (Johor and Singapore) 18−77 745 22. Korea Lee 2012b 18−79 60.7−8.5−53.3) Takehara 2011c 15−98 2.2) Onuki 2009 (Ibaraki) 15−78 1.

18. Osaka. 58 only d Hokuriku(Fukui. Miyazaki and Kagoshima f Ishikawa and Toyama g North-Eastern region os West Malaysia h Few HPV types tested: 16 only i Bharatpur (Chitawan Province) j Sanphebagar Village (Achham District) Data sources: See references in Section 9. Hiroshima. Fukui. Ishikawa and Toyama) e Aomori. ICO HPV Information Centre . Tokyo. including some with cytological cervical abnormalities c Few HPV types tested: 16. 52.125 - ( Figure 57 – continued from previous page) b Women from the general population.4 HPV RELATED STATISTICS .

3−13.2 (5.9 (27.4−31.5) Chen 2011 Lin 2006 (South Taiwan)a 16−78 4.6−11. a Women from the general population.7) d 30−65 10.2 (6.143 35.6) Kim 2013 (Seoul) − 6.3) Shin 2004 (Busan)a 16−29 672 15.7−28.3−7.6−15.0 (6.7) Saudi Arabia Al−Ahdal 2014 (Riyadh) 20−74 455 28.5) Kim 2012 Shin 2003 (Busan) 20−74 821 8.2) Bae 2014 (Seoul) 18−85 471 21.7−18.2 (12.7−6.8−22.6) Kim 2014 (Gangnam (Seoul))a 25−81 799 12.4 (18.7 (0.7−16.5 (6.6) Wang 2010a. Seoul) 30−84 4.279 17.2 (5.6−19.8−6.7) 0% 10% 20% 30% 40% 50% 60% 70% 80% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).8 (47.7 (5.750 27.1 (10.126 - Figure 58: Prevalence of HPV among women with normal cervical cytology in Asia by country and study (continued) Country Study Age N % (95% CI) Rep. 95% CI: 95% Confidence Interval.4−1.5−15.8−7.9 (15.0 (25.9) Lee 2014 (Seoul.9) Taiwan Lai 2012 (Taoyuan) 30−94 14.2 (5.2 (11. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).8−14.9 (3.5 (5.6) Laowahutanont 2014 (Bangkok) >=20 2.8−22.3−9.6) Huang 2008 23−80 1.9−20.2 (64.4 (35.383 19. including some with cytological cervical abnormalities (Continued on next page) ICO HPV Information Centre .0−29.903 13.0) Um 2011 − 122 23.4−37.5) a Kim 2014 (Busan) 22−83 315 70. Korea Kim 2012 (Seoul) − 11.2) Thailand Swangvaree 2010 (Bangkok) 20−77 14.8−6.7) Kim 2012 25−75 1.310 8.8) Park 2014 28−83 1.111 6.146 18.0 (17.1) Liaw 1995 30−64 260 9.1) Cho 2011a − 624 47.8 (14.144 0.9) Shim 2010 (Seoul) 21−48 235 22.1 (32.6−36.9) Cho 2003 (Kyonggi−do) 22−70 414 31.c 14−87 10. Busan.0 (10.681 17.0−29.8) Hwang 2012a 21−77 177 54.214 14.6−32.0−39.190 13.3) Kim 2013 (Gwangju) − 206 8.6) Lee 2003 (Seoul) − 746 7.2−14.8 (13.3 (16.3 (43.6−24.4) Tsai 2005 (Kaohsiung County) >=20 175 16.3) Kim 2013 (Seoul) 21−76 2.9 (6.0) b 20−59 902 4.1−14.8−7.2) Hwang 2004 18−62 1.6 (10.4−51.543 15.3 (5.735 6.8) a Kim 2010 20−59 902 12.9−74.800 6.4−62.4) An 2003 (Kyonggi−do) − 1.6−9. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.609 37.2−12.9) Jeng 2005 (Taipei) 21−65 1.4 HPV RELATED STATISTICS .205 6.2) Lee 2011 − 101 20.9−9.6 (17.6 (11.8) Bae 2009a 15−75 1.1 (16.8−10.2−20.6 (12. Cheonan)a 25−79 912 7.494 14.8) Bae 2009 (Gyeonggi.0 (16.0 (14.8) Lin 2005 (Kaohsiung) − 127 15. N: number of women tested.3−15.2 (6.4 (13.3) Oh 2009 (Busan and Suwon) 20−69 4.724 11.0 (9.2) Kim 2014 (Cheonan)a 19−78 5.467 7.6 (24.7) Oh 2001 (Seoul) 23−72 1.4−18.

Taoyuan. ICO HPV Information Centre .4 HPV RELATED STATISTICS . Makung. Keelung) d Sanchi. Hsinchu. Paihsa and Huhsi Data sources: See references in Section 9. 11. 42. 44 only c Taipei.Kaoshu. 43.127 - ( Figure 58 – continued from previous page) b Few HPV types tested: 6. Chungli. Chutung. Potzu.

4 HPV RELATED STATISTICS - 128 -

Figure 59: Prevalence of HPV among women with normal cervical cytology in Asia by country and study
(continued)

Country Study Age N % (95% CI)
Thailand Siriaunkgul 2014 (Chiang Mai) 30−60 2,633 4.3 (3.5−5.1)
Paengchit 2014a 30−70 1,961 4.0 (3.2−5.0)
Chansaenroj 2010 (Bangkok) − 1,622 7.8 (6.6−9.2)
Marks 2011b,c 20−37 1,070 19.8 (17.5−22.3)
Sukvirach 2003 (Lampang) 15−76 972 5.9 (4.6−7.5)
Sukvirach 2003 (Songkla) 15−85 687 3.3 (2.2−5.0)
c
Wongworapat 2008 (Chiang−Mai) 20−65 531 11.5 (9.0−14.5)
Chandeying 2006c,d 15−47 430 4.7 (3.0−7.1)
c
Thomas 2001 (Bangkok) 24−60 291 6.9 (4.5−10.4)
Chichareon 1998 (Songkla) 19−78 261 15.7 (11.8−20.6)
Suwannarurk 2009 (Pathumthani)e − 225 28.9 (23.4−35.1)
Natphopsuk 2013 (Khon Kaen) 26−81 198 14.1 (10.0−19.7)
Chopjitt 2009 (Khon Kaen) − 160 33.8 (26.9−41.4)
Ekalaksananan 2010 (Khon Kaen) 18−54 155 40.6 (33.2−48.5)
Chaiwongkot 2007 (Khon Kaen) − 140 38.6 (30.9−46.8)
Sriamporn 2006 (Khon Kaen) >=35 113 10.6 (6.2−17.6)
Siritantikorn 1997 (Bangkok) 16−77 102 4.9 (2.1−11.0)
f 25−70 100 13.0 (7.8−21.0)
Settheetham−Ishida 2005
Turkey Inal 2007 (Izmir) 15−45 1,344 1.5 (1.0−2.3)
Yuce 2012 (Ankara) 30−70 640 21.4 (18.4−24.7)
Ozalp 2012 (Eskisehir region) − 564 3.4 (2.2−5.2)
Kasap 2011 (Izmir) 15−65 546 32.1 (28.3−36.1)
Demir 2012g 15−68 530 17.9 (14.9−21.4)
Sahiner 2014 17−81 517 22.4 (19.1−26.2)
Bayram 2011 (Gaziantep) 18−56 502 15.1 (12.3−18.5)
Özcan 2011 16−64 480 3.5 (2.2−5.6)
Eren 2010 (Istanbul) 19−85 469 13.6 (10.8−17.0)
c
Altun 2011 (Adana) 20−68 460 5.2 (3.5−7.6)
Akcali 2013 (Manisa)c − 410 8.5 (6.2−11.6)
Tezcan 2014 (Mersin Province) 18−76 380 18.9 (15.3−23.2)
Sahiner 2014 (Ankara)c 17−74 315 19.7 (15.7−24.4)
Dursun 2009 20−67 310 19.7 (15.6−24.5)
Oztürk 2004 18−62 192 2.1 (0.8−5.2)
Uzbekistan Inamova 2009 (Tashkent) 18−40 2,295 37.9 (35.9−39.9)
Viet Nam Vu 2012 (Can Tho)c 18−65 1,000 10.2 (8.5−12.2)
Vu 2012 (Hue)c 18−69 1,000 8.6 (7.0−10.5)
Vu 2012 (Thai Nguyen) 18−69 1,000 9.2 (7.6−11.2)
Pham 2003 (Hanoi) 15−69 983 1.5 (0.9−2.5)
Pham 2003 (Ho Chi Minh City) 15−69 914 9.6 (7.9−11.7)
Vu 2011 (Ho Chi Minh)c 18−69 750 8.3 (6.5−10.5)

0% 10% 20% 30% 40% 50%

(Continued on next page)
Data updated on 15 Dec 2016 (data as of 30 Jun 2015).
95% CI: 95% Confidence Interval; N: number of women tested;
The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells). The line represents the 95% confidence interval and the shadowed square is proportional
to the sample size.
a Lampang Province

(Continued on next page)

ICO HPV Information Centre

4 HPV RELATED STATISTICS - 129 -

( Figure 59 – continued from previous page)
b Chiang Mai, Khon Kaen, Bangkok, Songkla and Hat Yai
c Women from the general population, including some with cytological cervical abnormalities
d Hat Yai (South Thailand)
e Few HPV types tested: 16, 18, 31, 33 only
f Khon Kaen
g Istanbul, Ankara, Antalya, Nigde and Elazig
Data sources: See references in Section 9.

ICO HPV Information Centre

4 HPV RELATED STATISTICS - 130 -

Figure 60: Prevalence of HPV among women with normal cervical cytology in Asia by country and study
(continued)

Country Study Age N % (95% CI)

Viet Nam Vu 2011 (Hanoi) 18−69 750 6.1 (4.6−8.1)

0% 10%

Data updated on 15 Dec 2016 (data as of 30 Jun 2015).
95% CI: 95% Confidence Interval; N: number of women tested;
The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells). The line represents the 95% confidence interval and the shadowed square is proportional
to the sample size.
Data sources: See references in Section 9.

ICO HPV Information Centre

4 HPV RELATED STATISTICS - 131 -

Figure 61: Prevalence of HPV among women with normal cervical cytology in Europe by country and
study

Country Study Age N % (95% CI)
Belarus Rogovskaya 2013 (Minsk) 15−63 322 23.6 (19.3−28.5)
Belgium Depuydt 2010 (Flanders)a 14−97 57,876 14.8 (14.5−15.1)
Arbyn 2009 (Antwerp) 15−85 8,729 11.9 (11.3−12.6)
Merckx 2014a,b 4−18 4,180 15.7 (14.6−16.8)
Baay 2005 (Antwerp) 20−50 2,293 6.9 (5.9−8.0)
Depuydt 2012 30−70 1,142 8.4 (6.9−10.2)
Schmitt 2013 (Flanders) 15−86 913 33.3 (30.3−36.4)
Weyn 2013 (Brussels) >=20 906 10.8 (9.0−13.0)
Depuydt 2003 (Flanders) 17−85 287 24.0 (19.5−29.3)
Baay 2001 (Antwerp) 17−78 286 10.8 (7.7−15.0)
Bulgaria Kovachev 2013a,c 15−55 1,120 38.8 (36.0−41.7)
Croatia Kaliterna 2013 (Dalmatia County)a 17−58 1,160 35.0 (32.3−37.8)
Kaliterna 2007a,d 18−62 570 35.1 (31.3−39.1)
Grahovac 2007 (Zagreb,Rijeka) − 205 35.6 (29.4−42.4)
Czech Rep. Tachezy 2013 14−79 1,302 25.6 (23.3−28.0)
Denmark Kjær 2014 (Copenhagen)e 14−95 37,958 20.4 (20.0−20.8)
Nielsen 2008 (Copenhagen) 20−29 10,220 15.9 (15.2−16.6)
f 16−88 4,642 33.3 (32.0−34.7)
Bonde 2014
Nielsen 2008 (Copenhagen) 40−50 1,443 4.4 (3.4−5.5)
Svare 1998 20−39 119 21.8 (15.4−30.1)
Estonia Uusküla 2010 (Tartu)a 18−35 326 36.8 (31.8−42.2)
Europe Joura 2015 16−26 13,862 27.5 (26.7−28.2)
Paavonen 2008g 16−24 9,162 15.9 (15.2−16.7)
Finland Malila 2013a 25−65 66,457 7.9 (7.7−8.1)
a
Auvinen 2005 (Helsinki) 19−47 1,469 33.0 (30.7−35.5)
France Clavel 2001 (Reims) 15−76 7,339 10.5 (9.9−11.3)
Monsonego 2011 (Paris) 20−65 4,004 12.6 (11.6−13.7)
Boulanger 2004 (Amiens) 20−62 3,617 12.6 (11.6−13.7)
Heard 2013h 16−88 3,023 18.1 (16.8−19.5)
Vaucel 2011 (Nantes) 17−86 980 13.1 (11.1−15.3)
Baudu 2014 (Franche−Comté) 15−23 948 24.1 (21.4−26.9)
Dalstein 2003 (Besançon) 16−76 652 27.0 (23.7−30.5)
Haguenoer 2014 20−65 634 15.6 (13.0−18.6)
Beby−Defaux 2004 (Poitiers) 17−77 613 5.2 (3.7−7.3)
i 16−76 426 25.1 (21.2−29.4)
Riethmuller 1999
Casalegno 2011 (Lyon) 15−88 302 48.3 (42.8−54.0)
Pannier−Stockman 2008 (Amiens) 18−78 289 28.7 (23.8−34.2)
Monsonego 2005 (Paris) 19−79 221 28.5 (23.0−34.8)
Germany Luyten 2014 (Wolfsburg) − 23,093 6.8 (6.5−7.2)
Petry 2003j 30−85 7,832 5.9 (5.4−6.4)

0% 10% 20% 30% 40% 50% 60%

(Continued on next page)
Data updated on 15 Dec 2016 (data as of 30 Jun 2015).
95% CI: 95% Confidence Interval; N: number of women tested;
The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells). The line represents the 95% confidence interval and the shadowed square is proportional
to the sample size.
a Women from the general population, including some with cytological cervical abnormalities

(Continued on next page)

ICO HPV Information Centre

4 HPV RELATED STATISTICS - 132 -

( Figure 61 – continued from previous page)
b Flanders and Brussels
c Sofia, Plovdiv, Varna, Burgas, Pleven and Vidin
d Split and Dalmatian County
e HPV prevalence for high-risk HPV types
f Copenhagen and Frederiksberg
g Czech Republic, Denmark, England, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, and Sweden
h Alsace, Auvergne, Centre - Pays de Loire, Ile-de-France and Vaucluse
i Besançon, Belfort
j Hannover and Tuebingen
Data sources: See references in Section 9.

ICO HPV Information Centre

4 HPV RELATED STATISTICS - 133 -

Figure 62: Prevalence of HPV among women with normal cervical cytology in Europe by country and
study (continued)

Country Study Age N % (95% CI)
Germany Schneider 2000 (East Thuringia) 18−70 4,604 7.1 (6.4−7.9)
Iftner 2010 10−30 1,692 22.3 (20.4−24.3)
de Jonge 2013a >=20 1,463 29.8 (27.5−32.2)
Petry 2013 (Wolfsburg) 25−27 659 25.5 (22.3−29.0)
b
Petry 2013 (Wolfsburg) 20−22 599 27.5 (24.1−31.3)
Greece Agorastos 2014b − 5,107 5.8 (5.2−6.5)
c
Agorastos 2015 25−55 3,783 10.4 (9.5−11.4)
Argyri 2013 (Athens) 14−70 2,218 15.7 (14.2−17.3)
Tsiodras 2011 − 1,348 39.5 (36.9−42.1)
d
Agorastos 2004 17−69 1,272 2.0 (1.4−3.0)
Tsiodras 2010 (Athens) 21−45 1,029 10.2 (8.5−12.2)
Paraskevaidis 2001 (Ioannina) 17−79 738 6.4 (4.8−8.4)
Panotopoulou 2007 (Athens) 18−48 639 26.4 (23.2−30.0)
Hungary Nyári 2006 20−60 491 5.5 (3.8−7.9)
Ireland Anderson 2013 (Northern Ireland) 20−64 5,068 13.2 (12.3−14.2)
Keegan 2007 (Dublin) 16−72 886 11.4 (9.5−13.7)
b
Italy Del Mistro 2014 (Veneto) 25−64 46,694 6.9 (6.7−7.1)
e
Carozzi 2014 25−60 13,660 4.5 (4.2−4.9)
Agarossi 2009 15−73 9,148 11.3 (10.7−12.0)
Giorgi Rossi 2011f 25−64 3,151 9.7 (8.8−10.8)
Tenti 1997 (Pavia) 16−47 1,064 12.3 (10.5−14.4)
Ronco 2005 (Turin) 25−70 997 7.8 (6.3−9.7)
g
Giambi 2013 18−26 907 13.6 (11.5−15.9)
Ammatuna 2008 (Sicily) 18−24 894 22.4 (19.8−25.2)
b
Del Prete 2008 (Apulia) >=20 871 23.2 (20.5−26.1)
Verteramo 2009 (Rome) 17−57 737 21.7 (18.9−24.8)
h 16−26 566 18.2 (15.2−21.6)
Panatto 2013
Centurioni 2005 (Genova) 20−81 500 15.4 (12.5−18.8)
Salfa 2011 (Asti) 25−65 452 9.5 (7.1−12.6)
Sammarco 2013 (Molise) 18−63 398 32.4 (28.0−37.2)
Barzon 2010 (Padova) 17−74 333 40.8 (35.7−46.2)
Carozzi 2000 (Florence) 25−64 332 5.1 (3.2−8.0)
Masia 2009 (Sardinia) 18−46 309 17.8 (13.9−22.5)
Bellaminutti 2014b − 305 40.0 (34.7−45.6)
Piana 2011 (North Sardinia) 15−54 242 32.2 (26.7−38.4)
Zappacosta 2009 (Molise) 21−64 220 6.4 (3.8−10.4)
Astori 1997 (Udine) 18−67 197 20.3 (15.3−26.5)
Tornesello 2006 (Milan, Naples) 18−63 183 19.7 (14.6−26.0)
Tornesello 2008 (Naples) − 107 11.2 (6.5−18.6)
Latvia b 18−89 237 8.0 (5.2−12.2)
Silins 2004

0% 10% 20% 30% 40% 50%

(Continued on next page)
Data updated on 15 Dec 2016 (data as of 30 Jun 2015).
95% CI: 95% Confidence Interval; N: number of women tested;
The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells). The line represents the 95% confidence interval and the shadowed square is proportional
to the sample size.
a Nordrhein-Westfalen, Niedersachsen, Schleswig-Holstein, Bremen and Hamburg

(Continued on next page)

ICO HPV Information Centre

Mihaniona. Tuscany. Milan and Genoa Data sources: See references in Section 9. ICO HPV Information Centre . Emilia-Romagna and Piedmont h Turin.134 - ( Figure 62 – continued from previous page) b Women from the general population. Patrasand Alexandroupolis d Thessaloniki. Trento and Florence f Abruzzo. Thermi. Lazio. Campania. Larissa. including some with cytological cervical abnormalities c Athens. Corfu.4 HPV RELATED STATISTICS . Thessaloniki. Veria and Serres e Turin. Lazio. Sardinia and Sicily g Abruzzo. Campania. Padua.

1 (3.1) Kubanov 2005 (Moscow) − 8.7) Ursu 2011 (Northeast) 20−61 164 25.9 (23.199 10.065 19.8−9.001 25.4 (4.0 (17.0 (11.8−29.4 (3.8) Goncharevskaya 2011 (Moscow) 15−77 5.9) Shipulina 2011 (Moscow) 13−19 177 40.6) Gjøoen 1996 (Oslo) 20−44 222 15.2−26.0−26.2 (6.0) Shipitsyna 2011 (St Petersburg) 30−65 741 9.1 (33.8) a Dutra 2008 (Açores) 16−81 286 10.0) Portugal Pista 2011 18−64 2.0 (14.1 (24.0) Simanaviciene 2014 (Vilnius) 18−81 277 24.1 (3.4 HPV RELATED STATISTICS .8) Russia Bdaizieva 2010 (Moscow)a 15−69 33. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).250 5.2 (23.970 9.182 13.7−4.172 16.2) 0% 10% 20% 30% 40% 50% 60% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).6) Romania Moga 2014 (Brasov County) 17−57 801 34.1−33.8) Boers 2014 30−60 900 3.5 (15.2) Komarova 2010 (Moscow) 16−76 352 48.2) a.6 (3.4) Netherlands Rijkaart 2012 (Utrecht) 29−61 25.2) Rozendaal 2000 (Amsterdam) 34−54 2.4−10.b 18−29 2.4 (21.5) Slovenia Ucakar 2012 20−64 4.4−14.4−30.533 15.3 (43.6 (19.9) Molden 2006 (Oslo) <=30 275 30.1 (15. a Women from the general population.7−5.245 3.7 (9.2) Martorell 2010 (Valencia)a 18−64 1.9 (7.7) Ucakar 2014 20−64 944 8.1−53.9−14.956 13.5−14.8) Dillner 2008 (Maresme) 14−82 939 7.5−29.2) Hesselink 2013 (Utrecht region) 31−60 858 8.0−12.3 (8.9) Gudleviciene 2005 (Vilnius) 16−64 332 24. 95% CI: 95% Confidence Interval.8−5.112 25.8) Pista 2011d 18−67 425 25.9 (25.135 - Figure 63: Prevalence of HPV among women with normal cervical cytology in Europe by country and study (continued) Country Study Age N % (95% CI) a Lithuania Kliucinskas 2006 18−50 1.1−17.200 17.2−47.5−19.1 (13.1−37.c Skjeldestad 2008 16−24 896 25.5−32.5−27.059 13.9) Rijkaart 2012 30−56 19.2 (19.3 (31.2) Jacobs 2000 (Amsterdam) 16−68 3.5) Bernal 2008 (Zaragoza) − 1.4−20.1) Norway Molden 2005 (Oslo) 30−69 3.1 (22. N: number of women tested.1 (17.0 (3.1−29.9−20.7−36.6) Poland Bardin 2008 (Warsaw) 18−59 799 14.1) Vieira 2013 18−76 463 17.8−11. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4 (12.3 (11.1−10.0) a Montenegro Vujosevic 2012 (Podgorica) 23−68 189 20.4 (12.196 4.7 (25.2) Zielinski 2001 (Zeeland) 34−54 114 6.5 (15.1 (19.9 (23.0−18.9−12.8−4. including some with cytological cervical abnormalities (Continued on next page) ICO HPV Information Centre .2−20.373 4.8) Spain Castellsagué 2012 18−65 3.1−28.5−29.5−10.3 (5.299 4.6−14.4) Lenselink 2008a.6) Bumbuliene 2012 (Vilnius)a 15−22 169 23.3−15.4) Rogovskaya 2013e 16−76 833 25.3−34.3) Bulkmans 2004 (Amsterdam) 30−60 21.5) Alexandrova 1999f 15−45 309 29.4) Shargorodskaya 2011 (Moscow) 18−30 266 28.3−3.8 (7.0 (11.5−6.5 (7.8 (2.

Petersburg Data sources: See references in Section 9. and Den Bosch c Oslo. ICO HPV Information Centre .136 - ( Figure 63 – continued from previous page) b Arnhem. Nijmegen.4 HPV RELATED STATISTICS . Trondheim. and Levanger d Lisbon area and southern region e Moscow and Novgorod f St.

349 6.7−2.8−13.8 (4. 95% CI: 95% Confidence Interval.5) Cuzick 1995 (London) 17−59 1. Uppsala.1) Muñoz 1996 Sweden Naucler 2007c 29−46 5. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.9−6.679 58.4−8.8 (6. Navarra. ICO HPV Information Centre .9 (14.0) Cuzick 2003 Hibbitts 2008 (South Wales) 20−65 8. Girona.2) Switzerland Bigras 2005e 17−93 13.8−15.1) González 2006 (Alicante) − 703 7. Birmingham.9−21.8 (8. Guipuzcoa.4) Herbert 2007 (London) 20−49 813 12.0) b 18−75 329 5.106 6. London.0−10.584 8. Murcia.3 (2.5 (2.2 (3.6 (19.4) Grainge 2005 (Nottingham) 21−51 656 13.0) d Kjellberg 1998 20−63 295 4.4 (10. Neuchatel. Fribourg.2) de Sanjose 2003 (Barcelona) 14−75 847 1.7 (12.7−4.2 (9.4 HPV RELATED STATISTICS .8−4.7 (11.890 20. Edinburg.5) Geraets 2014 (Scotland)a 20−68 998 16.818 3.0−11.9 (10.6−13.6−34.8) Gyllensten 2012 (Uppsala County)a 55−76 2.7) Cuschieri 2004 (Edinburgh) 16−78 3. Umeå.3 (5.855 3.3) Ylitalo 2000 (Uppsala) 15−49 617 5.5−7.3) Ortiz 2006 (Madrid and Alicante)a 14−67 818 10. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells). N: number of women tested. Valais and Tessin f Birmingham.404 10.8) Hibbitts 2014 (Wales) 20−22 10.5 (5.709 5.3−8.2 (5.1−6.3 (0.2−8.0) Howell−Jones 2010g 25−64 2.9) Cuzick 1999 (London) 34−70 2.6 (11.1−10.877 5. Malmö. Zaragoza c Gothenburg.4) f 30−60 9. Salamanca.3−7. London.1 (7.5−17.7−19.0 (6.4) 0% 10% 20% 30% 40% 50% 60% Data updated on 15 Dec 2016 (data as of 30 Jun 2015). Sevilla.089 12. including some with cytological cervical abnormalities b Alava.9) Kavanagh 2014 (Scotland)a 20−21 4.9−6.128 7.2−16.6−7.5 (4.380 10.0) Stenvall 2007 (Uppsala)a 35−50 117 25.2 (6.137 - Figure 64: Prevalence of HPV among women with normal cervical cytology in Europe by country and study (continued) Country Study Age N % (95% CI) Spain Lloveras 2013 (Barcelona) 23−89 898 14. a Women from the general population. and Stockholm d Västerbotten County e Geneve.3 (56.2−7.7) UK Kitchener 2006 (Manchester) 20−64 21.1) c Elfström 2014 23−40 5.6 (18.6) Peto 2004 (Manchester) 15−64 6. Gloucestershire and Norfolk Data sources: See references in Section 9.1 (2. Vizcaya. Manchester and Mansfield g Gateshead.434 7. Vaud.9−59.

c 18−24 149 55. ICO HPV Information Centre .271 33.7 (19.9) a.0) Bowden 2005 b.7 (47.0 (31. Melbourne. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size. Perth d Santo Urban (Espiritu Santo Island) and Porto Vila (Efate Island) e Port Vila (Efate Island) Data sources: See references in Section 9.9) e McAdam 2010 30−50 379 5. a Australian Capital Territory b Women from the general population.b 16−19 161 11.7−63.2−17.4 HPV RELATED STATISTICS .7−26.244 24. N: number of women tested.0) 0% 10% 20% 30% 40% 50% 60% 70% Data updated on 15 Dec 2016 (data as of 30 Jun 2015). 95% CI: 95% Confidence Interval.138 - Figure 65: Prevalence of HPV among women with normal cervical cytology in Oceania by country and study Country Study Age N % (95% CI) Australia Tabrizi 2014 15−66 2.2 (7.3 (3.4−8. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).4) Tabrizi 2014 Fiji Foliaki 2014 (Suva)b 16−63 1. including some with cytological cervical abnormalities c Sydney.0 (21.1−34.4) Vanuatu Aruhuri 2012d 18−65 726 22.8−25.

520 4. .652 54.2) 50.3-31.5-52.5-4.2) 38. .401 27.8) 138 45.6) 661 60.0 (73.9 (51.9 (56.0-28.022 3.3) 133 60.4 HPV RELATED STATISTICS . 24 12.1 (11.4 (4.8 (29.9 (65.8) Southern Africa 8.7 (2. .4-89.4-58.6-37.3) 10.664 3.928 4.2-26.4-4.6-59.8 (36.1 (53.516 56.2-3. .447 46.3 (2.0 (75.536 4.8 (12. -.9 (75.5 (56.6) 57 21.0 (64.8) South America 13. 653 78.8 (4.0-30.350 70.1) More developed regions 334.766 68.0 (19. -- Polynesia .5) Central Asia .2-40.3-64.2 (2.1) 399 38.818 9.1 (4. -. CIS or HSIL.2-29.0 (23.7 (6.9) 785 76.139 - 4.3 (7.6-36. HPV Prev No. .2-65.7-26.7-68.9-47.2) 926 55.7-3.0) 28.9) 15.9) 2.4) 474 27.0) 1. -- Northern Africa 2.1) Southern Europe 50.5) 285 32.7) 225 30.6-43.7-61.424 15.755 3.7) Eastern Africa 4.4) Western Europe 57.4 (23.329 67.5) .3) 58.0 (13.8) South-Eastern Asia 8.0 (66.4) 24 20.271 8.2) 5.8-4.1) 3. .4) 33.4-5.7) 2. Low-grade lesions: LSIL or CIN-1.191 25.4 (5.058 31.028 78.0) 559 40.4 (4.5) 6.298 4.1) Caribbean 323 15.3) 98 33.1-3.4-74.4-9.7) 10.3-3.3-4.6 (27.216 2.3-4. -- Eastern Asia 116.4 (69.987 2.1-43.268 5.4) 10.3-31.866 53.8) 3.5 (53.6-54.6 (29.5 (68.7-68.5-27.4 (57.5 (59.1 (56. -.4-63.6-26.949 30. .897 63.959 21. CIN-3. . -- Data updated on 19 May 2017 (data as of 30 Jun 2015 / 30 Jun 2015).7) 2.0-43. HPV Prev No.2 (51.8-71.629 59.652 4.7-64.0) 13.9-54. -. HPV Prev No.893 26.123 69.672 3. -.8 (71.037 68.6 (5.7) 279 24.2) 1.1) 13.7 (45.6) 4.4 (68.1 (26.9-70.4-26. ICO HPV Information Centre .5) 9.421 4.5 (4.8 (25.2) 1.0) 465 24.1-10.9 (53.2-20.3-17.6 (52.8) Less developed regions 177.2 (67.8-81.7-79.875 25.0-9.6) 2.239 62.6 (2.6) 1.8 (59.8-54.059 3.796 69.517 58.2) 10.2) 18.202 51.5 (4.9 (68.015 27.2-5.2 HPV type distribution among women with normal cervical cytology.4-21.367 2.1 (23.9 (25.0-2.8) Americas 110. High-grade lesions: CIN-2.5-38.7) 473 27.3-5.2 (3.2 (3.4 (69.3 (54.0-34.2 (24.1 (26. -.4 (30.5) 150 30.9 (72.291 3.2 (51. 112 68.952 4.9-60.8-55.2) 1.3 (49.0-65.6) 3.707 71.9) .3-31.4 (69.8) Northern America 77.2-72.0-11.3-42. 95% CI: 95% Confidence Interval.6 (61.3-31.9) 8. -.726 4.448 54.4-9. -.5 (7.757 80.921 77.5) 7.8-3.2-80.3-69.590 56.236 65.3-70.6-54.3) 3.8-27.5) 4.3 (19.6) Eastern Europe 7.7 (37.140 54.9-78.3) Middle Africa .4) 1.8 (3.0) .1 (72.0) 1.3 (3.2-37.4 (3.5) 791 62.6 (34. -.0-4.4 (24.5) 3. precancerous cervical le- sions and invasive cervical cancer by World region and sub-regions Normal cytology Low-grade lesions High-grade lesions Cervical cancer Country /Region No. .1 (12.8-56.9) Melanesia 726 7.8) 929 72.7 (4.062 59.5-69.7-3.9) 20.5-2.0 (2.6 (33.2 (23.444 42.6-12.4-26. -. Data sources: See references in Section 9.0) 5.230 58.2 (20.4) 1. -.4) 473 27.9 (3.4 (4.5-33.4) Africa 20.1-4.4-29. -.3) 6.1. -.7-76.2 (65.9) Southern Asia 14.1) Central America 18.7-61. precancerous cer- vical lesions and cervical cancer Table 13: Prevalence of HPV 16/18 in women with normal cervical cytology.4-58.6 (73.1 (24.551 41.7 (9.9) Micronesia .6) 25.495 25.0-69.7 (82.3 (78.7 (25.7) 21.5) 855 76.0-3.9-72.8 (9.6 (57.1 (23.9) 210 24.1 (41.7 (77.105 71.3) Northern Europe 119.9-78.2) 263 7.4 (57.8) 2.7 (3.5) 9.562 52.1-57.3) Australia & New Zealand 2. .022 68.1 (61.3 (19.6-36.4 (55.5-75.814 67.5) 163 35. HPV Prev tested (95% CI) tested (95% CI) tested (95% CI) tested (95% CI) World 514.9 (21.7) Western Asia 6.6) 13.8) Western Africa 4.3-22.406 74.3-69.6-81.997 8.771 12.1) Oceania 2.5) 287 63.5) 25.2) Europe 232.8-44.0 (40.6 (28.6) 70 82.9-86.9) 19.7-68.519 25.6-31.044 33.1-41.677 84.2) 6.7 (25.696 25.8-4.8) Asia 145.356 3.981 20.661 3.191 35.

1 (0. Data sources: See references in Section 9.1−5.639 1.3) Allan 2008 848 2.2) Jones 2007 368 1.9) Morocco Alhamany 2010 785 2. 95% CI: 95% Confidence Interval.3) Senegal Xi 2003 1.4) Hammouda 2005 133 6.6 (5.1−8.6) 0% 10% 20% 30% Data updated on 15 Dec 2016 (data as of 30 Jun 2015).9−20. ICO HPV Information Centre .0−10.3) De Vuyst 2003 369 3.7) Astori 1999 158 5.6) Uganda Odida 2011 251 2.0 (1.3) Watson−Jones 2013 117 12.1) Tunisia Guettiti 2014 573 1.6−8.3−3.7−3.3) Chaouki 1998 172 4.737 1.8 (2.5 (0.8−11.4 HPV RELATED STATISTICS .4−7.7 (3.5 (5.0 (2.445 2.0) Hassen 2003 96 5.5) South Africa McDonald 2012 7.6−12.8 (3.2−1.5−3.2 (1.1) Nigeria Gage 2012 1.8 (1.2−11.9−2.6−1.140 - Figure 66: Prevalence of HPV 16 among women with normal cervical cytology in Africa by country and study Country Study N % (95% CI) Algeria Hammouda 2011 732 0.3−2.4) Thomas 2004 844 3.9) Naucler 2011 183 6.2 (2.6 (0.0−4. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.075 1. N: number of women tested.6 (0.8 (1.3 (2.6 (3.4−5.8−3.3) Belglaiaa 2015 190 2.4) Benin Piras 2011 258 4.5) Tanzania Dartell 2014 2.3 (0.4−3.0 (1.5 (2.7−2.5) Guinea Keita 2009 752 6.8 (7.7) Kenya De Vuyst 2010 454 7.0−8.0 (0.2) Mozambique Castellsagué 2001 187 4.4−10.4) Amrani 2003 306 1.8−5.5 (0. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).1 (2.

Ragin 2007 212 2.1 (1.7) Badano 2011 139 6.3 (8.0−8.0 (2.8 (1.1−11.3−7.5−17.459 2.020 6.2−39.5−2.1 (26.8) Aguilar−Lemarroy 2015 356 3.4−4.3 (1.2 (14.5 (2.0) Moore 2009 4.3 (1.5 (3.3) Soto−De Leon 2011 1.2 (4.9) Paraguay Mendoza 2011 202 4.2) Tábora 2005 100 6.8−14.2 (1.2 (2.0) Noronha 2005 433 0.9 (1.2 (0.1) Martorell 2012 203 12.9 (5.8 (2.3) Oliveira 2010 225 4.6 (6.7−13.5 (0.117 2.1) Rocha 2013 314 9.7 (1.2) Sánchez−Anguiano 2006 487 2.4−6.0) Trinidad & Tob.5) Chile Ferreccio 2004 913 2.2 (2.1−1.2) Peru García 2004 501 2.1) López Rivera 2012 916 1.3) Tamegão−Lopes 2014 120 9.6−3.1) Augusto 2014 338 1.4 HPV RELATED STATISTICS .1 (0.4 (2.3−4.5−1.6) Cuba Soto 2014 111 35.9−44.0) Muñoz 1996 307 5.6) Demers 2012 517 1.4−3.9 (1.0 (8.6 (34.2 (8.4) Guatemala Vallès 2009 274 3.8−9.5) Mexico Illades−Aguiar 2010 3.8) Miranda 2012 399 5.9) Lazcano−Ponce 2001 1.1−2.7−5.0−15.7) Canada Jiang 2013 13.4 (1.8 (0.4−8.6−4.003 8.4) Coser 2013 327 2.8) Illades−Aguiar 2009 256 11.2 (0. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).1 (1.9−2.6) Chagas 2015 390 8.4−14.8−29.5−10.5 (2.0) Lorenzato 2000 215 7.9−7.8−13.4) Monroy 2010 272 1.8−12.1−3.6 (3.5) Santos 2001 175 4.2) Cassel 2014 158 8.2) Muñoz 1996 194 5.0 (2. ICO HPV Information Centre .1 (10.0 (0.3 (6.9−2.5 (0.3−3.0 (5.2−15.3 (2.0 (3.379 3.4) 0% 10% 20% 30% 40% 50% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).7) Brazil 448 3.3−21.564 36.2−4.5 (6.6−3.8) Rojo Contreras 2008 189 9.5−5.1) Honduras Ferrera 1999 438 11.7 (7.2) Rolón 2000 91 5.3−11.6) de Abreu 2012 370 1.5−2.4−11.0−5.4) Abba 2003 152 15.340 1.2−2.5−8.7−2.4−14. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.5 (3.4) Greenland Svare 1998 118 21.7−6.3 (8.7) Costa Rica Herrero 2005 7. 95% CI: 95% Confidence Interval.4−12. N: number of women tested.7−4.831 3.2) Giuliano 2005 258 0.8) Belize Cathro 2009 426 1.2 (0.7) da Silva 2012 418 1.9−9.6) Salcedo 2014 1.141 - Figure 67: Prevalence of HPV 16 among women with normal cervical cytology in the Americas by country and study Country Study N % (95% CI) Argentina Matos 2003 843 3.4 (1.2 (5.6) Chouhy 2013 774 8.2) Colombia Molano 2002 1.8) Giuliano 2001 995 1. Data sources: See references in Section 9.9) Carrillo−García 2014 518 11.4−8.4 (0.0 (4.

2) Wideroff 1998 958 2.8) Ramas 2013 236 2.2−1.203 6.7 (23.614 2.356 4.6 (1.5 (0.8−13.4 (2.142 - Figure 68: Prevalence of HPV 16 among women with normal cervical cytology in the Americas by country and study (continued) Country Study N % (95% CI) USA Wheeler 2013 33.1 (0.6 (2.7) Chaturvedi 2005 173 1. N: number of women tested.5−5.4−2.6) Evans 2006 300 9.4) Cibas 2007 1.6 (0.7 (6.7) Hernandez 2004 183 1.1) Uruguay Berois 2014 883 3. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).7) 0% 10% 20% 30% 40% Data updated on 15 Dec 2016 (data as of 30 Jun 2015).9) Moscicki 2001 547 26. 95% CI: 95% Confidence Interval. ICO HPV Information Centre .8−18.9−5. Data sources: See references in Section 9.9−3.450 2.5) Swan 1999 270 3.0−2.8 (5.2 (2.4) Goodman 2008 2.8) Schiffman 2011 18.9) Venezuela Téllez 2015 409 14.9 (11. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4−4.7 (1.7 (3.4 HPV RELATED STATISTICS .7−3.2−30.9) Giuliano 2001 881 2.6−4.9−4.2 (0.000 0.5−8.0 (1.6) Insinga 2007 1.3−4.

7) Franceschi 2005 1.5−1.3−0.3−5.1 (3.9) Moradi 2011 226 4.038 4.5 (0.1) Sasagawa 2001 1.3−5.7−1.7 (1.249 0.9−5.4 (20.7−1.0) Wu 2013 3.247 0.847 1.5 (1.9) Singh 2009 109 8.903 0.0) Bhatla 2008 458 2.1) Arora 2005 160 9.0−7.4 (2.6 (1.7) Kerkar 2011 470 1.5 (2.3 (3.2 (1.0) Nishiwaki 2008 292 4.2−12.799 2.2−6.9) Safaei 2010 400 2.0 (1.9) Park 2014 1.6 (1.9 (8.5) Aggarwal 2006 472 3.4) Wu 2010 314 3.1−2.5) Yoshikawa 1999 130 0.5−2.8−2.8−2.5) Zhao 2009 5.0) India Dutta 2012 2.9 (0.114 3.3 (0.1 (1.8−14.6) Georgia Alibegashvili 2011 1.0 (0.3−1.2) Sun 2010 165 10.2−27.6) Lee 2003 746 4.143 22.1−7.2−4.9 (19.9) Laikangbam 2007 2.7 (3.6 (3.7) Oh 2001 1.609 6.3) Wu 2007 942 1.1−4.9 (6.7) Gupta 2009 769 10.143 - Figure 69: Prevalence of HPV 16 among women with normal cervical cytology in Asia by country and study Country Study N % (95% CI) Bahrain Hajjaj 2006 91 1.8) Takehara 2011 2.0 (0.3−0.2) Korea.4 (5.0 (0.9) Zhao 2014 5.5 (0.1−6.3 (4.144 0.0) Bhutan Tshomo 2014 2.5 (2.1 (0.6 (2.115 2.2−0.284 1.7−2.0) Vinodhini 2012 257 8.9) Shin 2003 821 0.562 1.4−15.3−1.1−24.681 1.9−3.3) China Mai 2014 22.7 (3.8 (0.0 (0.5) Dai 2006 601 3.068 1.5 (2.9 (1. Kim 2013 6.1 (1.7 (0.4) Chan 2009 2. N: number of women tested.8 (2.2−7.0) Iran Khodakarami 2012 791 1.6) Sasagawa 1997 778 1.3−3.0 (2.3 (1.3 (0.5) Maehama 2005 4. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).2) 0% 10% 20% 30% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015). ICO HPV Information Centre .214 9.2−3.260 1.8 (1.6) Kim 2012 1.6 (0.3−11.0−6.0) Li 2006 663 2.6−1.9 (2.4) Japan Inoue 2006 7. 95% CI: 95% Confidence Interval.0) Onuki 2009 1.272 3.416 2. Data sources: See references in Section 9.112 2.0−16.313 0.4 HPV RELATED STATISTICS .5) Asato 2004 3.571 0.6−7.4) Li 2013 3.3) An 2003 1.0) Indonesia de Boer 2006 200 2.8−5.2 (1.6) Konno 2011 908 4.5 (0.737 1.0−3.3 (5.5) Yuan 2011 3. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.0−2.0−1.2−1.8 (0.3−1.3) Bian 2013 379 4.4−3.9) Jin 2010 2.4−2.3) Hwang 2004 1.1 (8.3−3.0−5.7−3.5 (0.2−3.9 (7. Rep.0−13.8−4.517 2.078 0.0) Cho 2003 414 22.

735 1.1 (1. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.5−6.1−0.6−1.9−1.1−15.9) Suwannarurk 2009 225 4.4) Pakistan Raza 2010 877 0.0 (2.5) Viet Nam Pham 2003 1.2−5.4 (0.9 (8.724 0.2 (0. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).6 (1.4 (1.7) Dursun 2009 310 7.6) Huang 2008 1.5) Tezcan 2014 380 4.4) Siritantikorn 1997 102 1. 95% CI: 95% Confidence Interval.2 (0. Data sources: See references in Section 9.5) Johnson 2014 211 0.8) Thailand Laowahutanont 2014 2.6 (3.3 (0.1 (0.8) Tsai 2005 175 2.0−2.1) 0% 10% 20% Data updated on 15 Dec 2016 (data as of 30 Jun 2015). N: number of women tested.3) Chichareon 1998 261 4.4 (0.5) Malaysia Othman 2014 588 0.6−7.3−5.2−7.897 1.5 (1.144 - Figure 70: Prevalence of HPV 16 among women with normal cervical cytology in Asia by country and study (continued) Country Study N % (95% CI) Kuwait Al−Awadhi 2011 3.7−2.7−10.7) Sukvirach 2003 1.6 (2.0 (4.067 1.2−1.4) Sriamporn 2006 113 7.5) Lin 2005 127 3.4) Nepal Sherpa 2010 898 1.8−2.1−7.3−19.2 (2.6−3.2) Philippines Ngelangel 1998 377 1.6−13.1 (3.6−6.5) Bayram 2011 234 2.8) Demir 2012 530 3.4) Natphopsuk 2013 198 5.7 (0.9 (0.1 (4.4−2.0) Mongolia Dondog 2008 842 4.1−9.9 (0.3) Chaiwongkot 2007 140 12.2−0.5 (0.6 (2.1) Taiwan Lai 2012 14.2 (0. ICO HPV Information Centre .0 (0.2−1.3−3.659 0.6 (3.9 (1.8 (3.7) Chopjitt 2009 160 5.4−1.011 0.0) Turkey Ozalp 2012 564 1.3) Settheetham−Ishida 2005 100 8.2−5.0−10.3) Chen 2011 10.310 1.2−6.4 HPV RELATED STATISTICS .

0 (3.8 (0.2) Czech Rep.833 1.029 0.5−7.3) Schmitt 2013 913 5.8 (1.8 (1.1 (1.0−7.9−3.6 (2.6 (5.8 (0.7 (5.4−5.6−2. 95% CI: 95% Confidence Interval.1) Svare 1998 119 8.8 (3. ICO HPV Information Centre .5 (0.7) Vaucel 2011 980 3.1) Sammarco 2013 244 6.6−11.6 (4.4 (0.7−2.2) Simanaviciene 2014 277 4.0−3.463 4.0 (0.6) Salfa 2011 452 0.1−2.4 (4.7 (0.8 (1.023 3.8 (6.5−3.142 1.0−1.4) Nielsen 2008 11.3 (1.2) Norway Molden 2005 3.6−5.642 5.3−3.8−10.3 (2.9 (4.3) 0% 10% 20% 30% (Continued on next page) Data updated on 15 Dec 2016 (data as of 30 Jun 2015).4 HPV RELATED STATISTICS .8) de Jonge 2013 1.6−14.660 1.9) Casalegno 2011 302 10.9−1.1) Denmark Kjær 2014 37.4) Panotopoulou 2007 639 0.2) Baay 2001 286 2. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).145 - Figure 71: Prevalence of HPV 16 among women with normal cervical cytology in Europe by country and study Country Study N % (95% CI) Belarus Rogovskaya 2013 322 7.6−2.729 2.7−1. Data sources: See references in Section 9.2−1.148 3.5−6.068 3.250 2.692 6.9−6.4) Iftner 2010 1.958 4.4 (0.1 (1.1 (1.0−4.6−4.4) Giorgi Rossi 2011 3.4) Netherlands Bulkmans 2007 21.8−6.1 (1.1−10.0 (3.218 2.302 4.2 (2.5−13.4) Tsiodras 2011 1.245 1. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.5) Centurioni 2005 500 8.2) Agorastos 2004 1.9) Tsiodras 2010 1.9−3.5) Belgium Arbyn 2009 8.9−1.0 (2.3 (3.7−3.299 0.1) Jacobs 2000 3.2 (4.6−14.9) Panatto 2013 566 2.970 1.8) France Heard 2013 3.7−10.8−6.3) Depuydt 2003 287 4.348 4.272 0.0 (3.8−9.6 (7.3−2.7−2.1−3.9) Lithuania Gudleviciene 2005 332 6. Tachezy 2013 1.7 (2.6 (4.1 (2.9 (0.2−0.3 (2.6 (2.7−3.1 (0.9 (0.8 (1.293 2.9−2.7) Gjøoen 1996 222 6.1) Tornesello 2006 183 8.3−21.783 2.4) Zielinski 2001 114 1.1) Agarossi 2009 9.6 (11.3) Rozendaal 2000 2.3) Bonde 2014 4.0−0.151 2.7) Ronco 2005 997 2.2 (2.0 (0.4−7.7) Tornesello 2008 107 2.3) Beby−Defaux 2004 170 1.5−13.9 (3.7) Baay 2005 2.3−7.1) Italy Carozzi 2014 13.4) Croatia Grahovac 2007 205 15.0 (2. N: number of women tested.7) Keegan 2007 579 1.7−4.6) Pannier−Stockman 2008 289 9.1 (4.4) Astori 1997 197 5.2) Greece Agorastos 2015 3.7 (1.4) Ireland Anderson 2013 5.663 4.5−7.6−4.1) Germany Klug 2007 7.1−5.3) Barzon 2010 333 6.9−9.6) Argyri 2013 2.8) Depuydt 2012 1.3 (6.8−10.3) Weyn 2013 906 2.4 (4.

4 (0.0) Dillner 2008 721 3.4 (0.7−5.3 (0.0−3.1−3.5 (5.8 (1. 95% CI: 95% Confidence Interval.8 (4.9−4.8 (0.4−7.6) 0% 10% 20% 30% Data updated on 15 Dec 2016 (data as of 30 Jun 2015).146 - Figure 72: Prevalence of HPV 16 among women with normal cervical cytology in Europe by country and study (continued) Country Study N % (95% CI) Poland Bardin 2008 799 2.0) Kjellberg 1998 295 1.4 HPV RELATED STATISTICS .7) Romania Moga 2014 801 7.9−2.7 (1.8−4.1−1.7−2.8−4.199 2.7 (1.4 (5.6−2.6) González 2006 447 1. ICO HPV Information Centre .2) Cuzick 1999 2.5 (2.7) Slovenia Ucakar 2012 4.3) Cuzick 1995 1.584 2. N: number of women tested.7) Hibbitts 2014 10.9) UK Sargent 2008 21.0) Grainge 2005 656 1.5 (1. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).3 (0.1) Portugal Pista 2011 425 5.0−4.089 4.5−9.0) Hibbitts 2006 1.7) Cuschieri 2004 3.1 (5.0−10.3 (3.3−1.3−2.6−2.9) Sweden Naucler 2007 5.1 (19.5) Russia Rogovskaya 2013 833 7.877 1.1 (0.2 (3.5 (2. Data sources: See references in Section 9.0 (1.3−29.4−2.0) Elfström 2014 5.777 1.9) Muñoz 1996 329 1.818 1.890 4.059 2.1) Alexandrova 1999 309 7.0) Spain Castellsagué 2012 3.2−8.9−2.0) Shipitsyna 2011 741 2. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.3) Ylitalo 2000 617 5.9) Komarova 2010 257 24.0 (0.1 (2.4 (3.855 0.364 1.4 (0.8−3.1) de Sanjose 2003 847 0.9−9.0−0.

9−6.4 HPV RELATED STATISTICS .271 5. Data sources: See references in Section 9.5) 0% 10% Data updated on 15 Dec 2016 (data as of 30 Jun 2015). ICO HPV Information Centre . 95% CI: 95% Confidence Interval. N: number of women tested.147 - Figure 73: Prevalence of HPV 16 among women with normal cervical cytology in Oceania by country and study Country Study N % (95% CI) Australia Tabrizi 2014 2.8) Vanuatu Aruhuri 2012 726 6. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).5 (4.8 (4.9−8. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.

8 (6.3 (6.3 (5. Low-grade lesions: LSIL or CIN-1.7−35.3−29. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.1) Senegal Xi 2003 86 8.0 (0. N: number of women tested.7 (6. 95% CI: 95% Confidence Interval.6−19.1−100.9) Chabaud 1996 42 40.7) De Vuyst 2010 12 8.0−15.0−27.3 (1.1−23. Data sources: See references in Section 9.7−20.0) Kenya De Vuyst 2003 30 13.1 (4.0−55.5 (27.6) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Data updated on 28 Jun 2017 (data as of 30 Jun 2015).4 HPV RELATED STATISTICS .9−28.5) South Africa Allan 2008 57 12.3 (1.6−43.0) Guinea Keita 2009 16 18.5−35.6 (12. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).0 (74.8) Ethiopia Abate 2013 11 100.2) Zimbabwe Sawaya 2008 97 19.4) Morocco Alhamany 2010 24 16.1) Gage 2012 32 6.9) Nigeria Thomas 2004 34 5.9 (1. ICO HPV Information Centre .148 - Figure 74: Prevalence of HPV 16 among women with low-grade cervical lesions in Africa by country and study Country Study N % (95% CI) DR Congo Hovland 2010 10 0.

2) Deluca 2004 36 8.3 (11.4 (11.8) Chouhy 2006 22 18.6−34.0−39.3 (19.6) Moore 2009 505 35.149 - Figure 75: Prevalence of HPV 16 among women with low-grade cervical lesions in the Americas by country and study Country Study N % (95% CI) Argentina Abba 2003 279 26.8 (2.5 (61.4 HPV RELATED STATISTICS .9) Tran−Thanh 2003 80 15.2−39.2) Peru Martorell 2012 22 22.2−57.9) Carrillo 2004 21 19.1−23.5−15.0 (4.8) Ili 2011 90 55.3) Rattray 1996 62 6.8−24.2 (9.2 (15.3 (3.7) Vidal 2014 239 10.2 (10.1−27.5) Belize Cathro 2009 10 10.7−69.4 (5.1) Franco 1999 27 25.5−34.7−84.7−30.5 (21.5 (61.0−45.0 (7.6−12.7 (10.3) Chile López M 2010 116 22.5 (19.8) Ecuador Tornesello 2008 29 34.8−14.4) Koushik 2005 53 26.4) Brazil Tomita 2010 143 28.7 (1.4 (30.5 (14.8−22.0) Jamaica Strickler 1999 186 4.8−42.4−39.4−30.6) Fernandes 2009 82 18.0) Piña−Sánchez 2006 95 25.4) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% (Continued on next page) Data updated on 28 Jun 2017 (data as of 30 Jun 2015).2 (9.4−33.3−38.273 21.0) Sellors 2000 24 37. Low-grade lesions: LSIL or CIN-1.7−84.6 (3.3 (17.0 (0.7−32. N: number of women tested.4 (68.6) Richardson 2003 44 18.8−40.9−19.4 (13. 95% CI: 95% Confidence Interval.2−26.8−26.0) Lorenzato 2000 62 19. ICO HPV Information Centre .9−52.9−21. Data sources: See references in Section 9.0−21.9) Freitas 2007 15 20.0) Torroella−Kouri 1998 21 4.4 (16.0 (8.0 (30.5 (18.7 (21.2−44.4) USA Wheeler 2006 1.5 (2.3−65.6 (8.2−8.2−88.2 (6.4−28.2−29.0) Venezuela 2012 120 14. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).2) Del Río−Ospina 2015 59 42.0 (1.3) Sellors 2000 22 50.9 (9.4) Ribeiro 2011 66 27.4) Mexico Illades−Aguiar 2010 784 10.9 (9.8 (0.6 (23.7) Cuba Soto 2007 15 6. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.5) Einstein 2007 207 6.9) Velázquez−Márquez 2009 233 12.2 (31.9−36.7) Pitta 2010 22 0.5−15.1−43.2) Eiguchi 2008 37 18.7−10.4 (15.8) Giuliano 2001 33 15.1 (18.2) Canada Coutlée 2011 508 27.2−17.6) Paraguay Mendoza 2011 164 19.6−55.5) Tonon 1999 55 74.5−32.7) Honduras Ferreira 2008 44 11.0−24.0 (6.7) Nicaragua Hindryckx 2006 79 7.8−30.9) Carestiato 2006 55 29.2 (7.3 (2.9−31.7−12.8) González−Losa 2004 104 5.3 (18.3 (2.3) Jiang 2011 108 19.1) García 2011 56 80.7−40.9 (13.0−14.0) Resende 2014 82 23.6) Wentzensen 2009 431 22.9−18.5) Antonishyn 2008 344 14.6 (45.2) Tonon 1999 55 74.5 (21.4) Colombia Molano 2002 70 10.0 (7.

6) Uruguay Ramas 2013 227 23.8−53.0−12. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.2) Schiff 2000 190 5.7−56.0) Adam 2000 161 45. ICO HPV Information Centre .6 (10.1 (6.150 - Figure 76: Prevalence of HPV 16 among women with low-grade cervical lesions in the Americas by country and study (continued) Country Study N % (95% CI) USA Evans 2006 200 15.3) Liaw 1999 173 7.7 (10.3−33.4 HPV RELATED STATISTICS .0 (0.9−27.7) Venezuela Correnti 2011 200 21.3−10.9 (17.7 (7. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).6) Guo 2007 27 0.4−12.4) Kulasingam 2002 166 15.3 (9.1−21.6) Moscicki 2008 157 19.9) Castle 2011 106 8.4) Lee 2009 76 3.7) Swan 1999 149 10.3 (1.5 (4.4) Jarboe 2004 95 7.3−25.6) Evans 2002 28 7.0 (23.7−30.8 (3.3−26.9−22.7−29.7) Park 2007 30 16.9 (1. 95% CI: 95% Confidence Interval.4−59. Low-grade lesions: LSIL or CIN-1.5−18.5−35.8−16.5 (11.4) Hu 2005 45 8.8 (18.0) Wheeler 2009 67 26.2) 0% 10% 20% 30% 40% 50% 60% Data updated on 28 Jun 2017 (data as of 30 Jun 2015).9 (8.7 (14.5−15.5) Zuna 2007 67 14.1 (2. N: number of women tested.3 (37.8 (6. Data sources: See references in Section 9.2−15.6 (8.4 (3.1) Stoler 2011 158 10.1) Tortolero−Luna 1998 175 12.6−14.5−20.7−38.4) Kong 2007 11 27.3) Bell 2007 12 8.0 (15.5 (4.3) Voss 2009 59 18.5) Brown 2002 25 40.0−22.4−11.9 (3.

9 (12.9−12.1 (4.5−34.1 (12. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).0−28.6 (12.0−6.2) Zhao 2008 56 12.7) Inoue 2006 128 17.0−16.9) Liu 2008 90 5.8 (11.7 (19.0−28.3−14.5−18.2 (13.5) Myanmar Mu−Mu−Shwe 2014 15 60.4) Sun 2014 81 21.2−18.6) Konno 2011 75 20.4 (8.0 (11.0 (12.3−27.3) Li 2012 143 16.0−22.2) Iran Esmaeili 2008 23 39.7) Yuan 2011 302 15.6) Chan 1999 51 21.8−14.3 (8.6) Jin 2010 44 9.6) Li 2013 165 12.2) Rep.7) Chan 2012 769 14.2−34. Low-grade lesions: LSIL or CIN-1. Data sources: See references in Section 9.8 (15.3 (11.2) India Singh 2009 80 23.4 (4. N: number of women tested.3) Hong 2008 105 13.6 (1.8) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% (Continued on next page) Data updated on 28 Jun 2017 (data as of 30 Jun 2015).6−13.7) Onuki 2009 318 8.1−21.0 (0.4) Kuwait Al−Awadhi 2011 71 18.2) China Chan 2006 769 14.8−26.9) Taiwan Ding 2008 542 6. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.0 (11.5 (6. 95% CI: 95% Confidence Interval.2 (11.7−80.4) Lee 2007 167 19.2) Huang 2008 13 0.1) Nagpal 2002 14 35.2−23.8−16.4−26.1 (3.1−43.7 (6.8) Guo 2010 201 20.8−34.8−25.9−35.9 (1.9 (4.8−30.8−16.5−30.3−42.3−61.9−25.1) Nair 1999 37 18.2−28.9−12.1 (11.1) Takehara 2011 447 11.7 (16.2−59.3 (1.0 (0.7) Yamasaki 2011 125 19.0 (10.5−50.0) Nishiwaki 2008 120 13.8 (14.3) Kang 2009 90 17.4 HPV RELATED STATISTICS .4 (15.0) Japan Matsumoto 2011 479 9.5−35.8 (16.0) Wu 2010 129 11.5−31.0) Berlin Grace 2009 20 0.0 (35.6 (7.1) Saito 2001 151 2.2) Franceschi 2005 26 30.0−23. Korea An 2003 200 36. ICO HPV Information Centre .0 (5.4 (27.6−21.151 - Figure 77: Prevalence of HPV 16 among women with low-grade cervical lesions in Asia by country and study Country Study N % (95% CI) Bangladesh Banik 2013 13 15.3 (8.6−24.8) Al−Awadhi 2013 71 18.9 (7.9 (9.2−20.1) Tao 2006 101 21.8) Zhang 2013 94 17.4) Chao 2008 51 3.9−41.1) Wu 2013 77 18.8) Malaysia Sharifah 2009 23 26.4−20.3 (11.5−46.4−12.6) Hwang 2003 24 16.2) Ghaffari 2006 12 41.7 (8.3−68.0 (13.8 (15.4) Yoshida 2004 12 8.6 (2.8) Cho 2003 150 26.7 (20.9) Oh 2001 28 17.2 (11.7−35.5−34.6) Sasagawa 2001 145 9.2−26.2 (6.7) Ding 2014 152 7.5 (30.1−13.2 (13.5) Liu 2010 180 34.5 (5.4) Zhao 2014 207 20.1 (22.4−8.

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).5) Chansaenroj 2010 12 0.9−53. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.5) Chaiwongkot 2007 140 14.4−21.7−54.1 (1.0) Ekalaksananan 2001 45 4. Data sources: See references in Section 9.6 (11.4 HPV RELATED STATISTICS .0 (0.3 (9.8) Bhattarakosol 2002 27 0.0 (21.0−24.3−31. N: number of women tested. ICO HPV Information Centre .4 (4.3−42.5−36.0 (8.2−14. 95% CI: 95% Confidence Interval.0 (0.2) 0% 10% 20% 30% 40% 50% 60% Data updated on 28 Jun 2017 (data as of 30 Jun 2015).0−12.6 (11.0−32.2 (12.5) Ozgul 2008 13 15.6) Tezcan 2014 14 7.3) Ergünay 2008 14 28.5) Sahiner 2012 45 22.152 - Figure 78: Prevalence of HPV 16 among women with low-grade cervical lesions in Asia by country and study (continued) Country Study N % (95% CI) Thailand Chansaenroj 2014 200 27.4 (1.2) Turkey Yuce 2012 51 19.3−33. Low-grade lesions: LSIL or CIN-1.2) Suwannarurk 2009 12 25.

4−85.1) Czech Rep.0) Giorgi Rossi 2010 76 21.6−29.4 (25.0) Latvia Kulmala 2007 94 35.4 (7.2−45.7 (31.8 (5.6−14.4−29.6−27.1) Panotopoulou 2007 516 6.4 HPV RELATED STATISTICS .1 (15.1) Arbyn 2009 243 23.4 (54.0−22.4 (18.2) Weyn 2013 211 10.5−24.6 (27.4) Monsonego 2008 37 5.3−85.0−34.8) Venturoli 2008 10 20. Low-grade lesions: LSIL or CIN-1.7 (12.9) Denmark Kjær 2014 287 17.2) Labropoulou 1997 51 11.3) Butler 2000 26 0.8) Greece Argyri 2013 821 14.5−23.2) Gargiulo 2007 83 15.0) France Prétet 2008 397 21.2 (5.2) Belgium Depuydt 2003 369 20.8 (11.5 (18.3 (23.4) Grce 2004 60 8.0 (6.0 (5.1) Tornesello 2006 101 36.5 (9.9) Zerbini 2001 43 14.8 (16.0) Nindl 1999 49 12.8 (28. Data sources: See references in Section 9.5 (14.8−42.7 (9. 95% CI: 95% Confidence Interval.4 (1.4) Kroupis 2007 235 23.8 (7.9−46. Tachezy 2011 676 28.2) Merkelbach−Bruse 1999 16 68.4 (17.3) Meyer 2001 130 13.0 (18.6−18.9) Kjaer 2008 86 12.8 (14.2−28.9) Italy Voglino 2000 1.1 (13.8) Murphy 2003 29 72.5 (14.499 24.5−51.7) Germany de Jonge 2013 441 17.0 (3.8−42.3) Venturoli 2002 40 7.2−21.2) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% (Continued on next page) Data updated on 28 Jun 2017 (data as of 30 Jun 2015).3−35.7−51.1 (26.7−25.2−17.4−31.5 (2.1 (8.1 (13.2−21.4) Agodi 2009 96 32.6) Ireland Keegan 2014 49 40.7−44.7 (19.0 (6.5) Croatia Grce 2001 1.6−47.4−25.3 (16.1 (26.0−16.7 (22.3−33.153 - Figure 79: Prevalence of HPV 16 among women with low-grade cervical lesions in Europe by country and study Country Study N % (95% CI) Belarus Kulmala 2007 94 35.1) Chironna 2010 385 13.240 25.0) Capra 2008 149 11.8 (4.0−36.0) Spinillo 2014 1.1−45.2−24.5) Sandri 2009 47 21. ICO HPV Information Centre .7) Beerens 2005 324 18.7) Grce 1997 183 6.4) Mammas 2008 46 21.6 (23.3−21.7) Vaucel 2011 117 14. N: number of women tested.0 (14.6−19.0 (0.3 (17.2−54.5−17.2−45.9) Menegazzi 2009 12 16.5) Hording 1995 41 31.9) Laconi 2000 20 30.7 (4.7−24.0−12.4−10.3−19.9−9.7−34.8−13.3 (12.7) Baay 2001 58 24.0 (10.5 (12.7−23.3) Tsiodras 2011 314 17.9) Klug 2007 52 11.7) Agarossi 2009 383 19.6−27.3) Humbey 2002 40 30.1) Spinillo 2009 343 36.5 (5.028 11.3 (3.6 (9.4−23.3−17. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).0) Bergeron 1992 48 20.8 (44.1−31.5) Astori 1997 111 24.3−22.

3−24.6−26.6−11.9 (2. ICO HPV Information Centre . Data sources: See references in Section 9.0 (1.1−19.5−32.7 (7.2−50.1 (8.3 (20.3) Cuschieri 2004 243 28.1−28.7−23.0 (11.0 (27.7 (3.2) García−Sierra 2009 108 17.5) Switzerland Dobec 2011 136 25.8) Netherlands Bollen 1997 134 12.356 12.3) 0% 10% 20% 30% 40% 50% 60% Data updated on 28 Jun 2017 (data as of 30 Jun 2015).4−16.035 24.3) Cuzick 1999 50 12. Low-grade lesions: LSIL or CIN-1.8 (20.8 (19.9) Jamison 2009 97 27.0 (22.7 (12.5) Molden 2005 20 25.2−40.9−19.8−29.4) Doménech−Peris 2010 21 23.1) Martín 2011 387 24.0 (18.7 (1.9−37.1 (26.7−36.2) Romania Ursu 2011 107 5.2 (4.0 (5.9) Hibbitts 2008 126 27.7) Anton 2011 87 11.0−20.7−33.0) Cuzick 1994 13 23.6 (15.0 (5.7−20.5 (6.0) Howell−Jones 2010 697 20.1−54.8) Arends 1993 20 15.8) Reesink−Peters 2001 35 28.6−45.2−36.4 HPV RELATED STATISTICS .0−54.6−14.5) Woo 2010 60 41.5 (17.9) Brismar−Wendel 2009 223 20. The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).8−46.1) Sweden Söderlund−Strand 2011 1.6 (2.7 (8.7 (30.4−19.6−25.8−26.4) Prinsen 2007 38 7.9) Andersson 2005 50 20.4) Kalantari 1997 141 17.2) Spain de Oña 2010 1.2 (21.5−49.8 (10.154 - Figure 80: Prevalence of HPV 16 among women with low-grade cervical lesions in Europe by country and study (continued) Country Study N % (95% CI) Lithuania Gudleviciene 2005 15 6.2−33.8) Southern 2001 49 10. N: number of women tested.2−29.1) Norway Roberts 2006 40 5.0 (20.6−23.2 (10.2−46. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.3 (15.3−45.4−21.9) Russia Kulmala 2007 94 35.6 (16.3) Herraez−Hernandez 2013 236 39.6 (11.8 (20.2) Giannoudis 1999 118 12.0) Nobre 2010 28 10.8) Conesa−Zamora 2009 75 29.0) Zehbe 1996 45 40.0 (11.7−27.9) UK Sargent 2008 878 17.7) Anderson 2013 417 24.8 (33. 95% CI: 95% Confidence Interval.2−45.2 (39.9) Portugal Medeiros 2005 416 44.

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).3 (19.2−18. The line represents the 95% confidence interval and the shadowed square is proportional to the sample size.4 HPV RELATED STATISTICS . N: number of women tested. Low-grade lesions: LSIL or CIN-1.0−44.3 (9.9 (17.8) 0% 10% 20% 30% 40% 50% Data updated on 28 Jun 2017 (data as of 30 Jun 2015).3−30. Data sources: See references in Section 9. 95% CI: 95% Confidence Interval.7)